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This book is in essence a collection of essays which are state of the art in their 
respective areas of knowledge. They inform  the reader of all sorts of mechanistic 
considerations when developing understanding of  issues  surrounding the origins 
of congenital abnormalities. These chapters are written by world renown authorities 
in this area of science and represent a wide range of expertise from a clinician 
perspective, through to genetic mechanisms. Unlike some books which take a formal 
textual, somewhat plodding way through pathophysiology here instead we have cut 
through chapters in which the student , or scientist or medic is lead to understand just 
how complex the origins can be via examples from different parts of the body. With 
the erudite chapters are relevant tables and other diagrams to help clarify the text . 
These chapters represent a starter text for the stimulus for further knowledge of what 
is an increasingly important area of human health.
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devastating effects of congenital anomalies on the health 
of children and the burden they can put on their parents 
and health services.
He qualified from the University of Manchester and has 
spent the last 15 years in academic posts in University 
College London. As an internationally regarded expert on the health of 
children conceived from assisted reproductive technologies , since his 
first seminal studies of children born afer embryo freeze thawing, he has 
watched the proportion of IVF births rise from 0.5% to the present 2% in 
the UK, with some coutries double that. Some of his studies have focussed 
on congenital anomalies. Professor Sutcliffe also  has expertise in paedi-
atric therapeutics and is presently conducting studies looking at pharma-
covigillance of medicines given to both Mothers in pregnancy and chil-
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Preface 
Congenital Anomalies – Case Studies and Mechanisms 
An introductory text for the student
Chapter 1 
- Hox Genes and Teratogenic Factors 
Within this state of the art book is a series of exemplary chapters which illustrate the
shear complexity of understanding of factors which need to be anticipated when 
considering, mechanisms, aetiology, investigation, epidemiology, and other 
considerations in human malformations. 
Starting with a Chapter 1 on Hox genes and their importance in teratology, the reader 
is given an in depth understanding as to how these now well understood basic 
building block control genes are intimately involved in potential structural
malformations. Introducing the reader to the idea that genetic errors from simple 
deletions, missense and other mutations in Hox can have profound implications for
the human being in development. From this the student is encouraged to read further 
regarding potential other genetic bases for malformations and how subtle these 
changes can be in the fully formed individual. They are reminded and indeed this is a 
recurrent theme of this excellent ‘sampler’ book of what a fascinating but highly
complicated area of medical science this is.
Chapter 2 
- Signalling Mechanisms Underlying Congenital Malformation: The Gatekeepers,
Glypicans
Moving to another key concept in malformation aetiology…glypicans I immensely 
enjoyed this erudite chapter (2) written by one of the world’s experts on this topic. The
title for the non-expert is quite scary! But enjoy the chapter is it is an excellent example 
of a way to illustrate a theoretically complex concept ‘signalling’ via our old friends
the glypicans and their key role as gatekeepers of the ‘fort.’ The reader is encouraged
via this exemplary chapter to consider how complex malformations may develop from 
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Moving to another key concept in malformation aetiology…glypicans I immensely 
enjoyed this erudite chapter (2) written by one of the world’s experts on this topic. The 
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XII Preface
Chapter 3 
- Central nervous system vascular malformations
This Chapter logically leads the student to a broader understanding of how gene 
malfunction, signalling and other mechanisms start to broaden into gross anatomical 
malformations and the human being then becomes diseased being. An understanding 
of the body needs to focus on individual parts which can be affected. In terms of sheer 
complexity the order of body systems is in order the central nervous system, then the 
heart and cardio vascular system, then the genito urinary system and so forth. 
So it unsurprising that due to its sheer complexity the CNS is most prone to 
malformations. This is both challenging and has profound implications for the patient. 
Thus again in this demonstration chapter one is drawn to the malformations as erudite 
examples of the theme that underpinning complex mechanisms result in gross 
anatomical problems. 
Chapter 4 
- Ultrasound Diagnosis of Congenital Brain Anomalies
Continuing the CNS theme here is the only truly clinical chapter in this book. Day to 
day millions of ultrasound investigations are done worldwide. A major area of their 
usage is in clinical medicine. When the patient is suspected of a congenital 
malformation which can present at any age, they present to doctor and are then 
investigated. Advances in ultrasound scanning which have occurred in my 25 years in 
clinical practice are used in the diagnoses of anomalies of the CNS more and more 
especially in the neonate. Herein the student in science of teratology is brought as it 
were to the bedside with a practical example of how the patient is investigated at the 
bedside. 
Chapter 5 
- An Autopsy Case of Congenital Pulmonary Lymphangiectasis Masquerading as
Pulmonary Interstitial Emphysema
It is said that most patients who end up in the morgue are found to have incorrect in 
vivo diagnoses. The historical approach to determining cause of death was via morbid 
anatomy. In this short chapter this principle is beautifully exemplified with a case 
incorrectly diagnosed in vivo in which the irreplaceable skill of the gross pathologist, 
histologist and related are demonstrated reminding the student of the multiple skills 
and levels of understanding needed to become a malformation expert. 
Chapter 6 
- Assisted Reproductive Technology and Congenital Malformations
If you are looking up in the sky and you see some white lines which are clearly not 
clouds, you generally would conclude that these are vapour trails from a passenger jet 
which has passed by recently. Even if you had not seen the airplane.Welcome to the 
Preface XI 
concept of epidemiology. Possible causation of disease are imputed by evidence that 
an event has happened. Most individual congenital anomalies are fortunately rare. The 
only way one can potentially become aware of that risk factor for them is through
epidemiological studies using decent datasets with minimal missing data. In this 
chapter a discussion surrounds the up to 4% of human beings now being conceived 
with extra help via assisted conception and their much talked about increased risk of 
birth defects. The senior author is the world’s most expert person in this field and the
authors’ expertise is reflected in the thorough description of studies of congential 
anomalies after ART and their potential risks according to types of ART (assisted
reproductive technologies). This is a final chapter in this introduction to concepts in 
congenital anomalies. 
Enjoy this brief taster in what is a fascinating field.
Professor Alastair Sutcliffe
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Hox Genes and Teratogenic Factors 
Takuya Kojima and Naoki Takahashi 
Department of Applied Biological Chemistry, 
 Graduated School of Agricultural and Life Sciences,  
University of Tokyo, 
Japan 
1. Introduction 
Exposure to a variety of chemicals is a hazard of daily life. Some of these chemicals have 
teratogenic potency and may lead to social problems. As an example, thalidomide was 
prescribed as a sedative and for morning sickness in the late 1950s and caused serious 
embryonic effects worldwide. To avoid these problems, the development of efficient 
techniques for the detection of teratogenic substances contained in various chemical 
compounds is desired. Detection of teratogenic effects using various experimental animals is 
only partially effective because different phenotypes occur among species. Therefore, 
effective methods for the detection of teratogenic factors must be based on their molecular 
mechanisms. However, knowledge of the molecular mechanisms that lead to the different 
phenotypes caused by teratogenic factors is limited, and useful molecular markers for these 
factors are not known. 
Approximately 30,000 genes in higher organisms are expressed under strict control. This 
regulation of expression is mainly dependent on transcription factor networks. In higher 
organisms, there are about five hundred transcription factors that contain a DNA-binding 
domain and cooperate in the regulation of the expression of downstream genes. 
Alterations in these regulatory mechanisms result in a variety of problems. In the case of 
teratogenic factors, abnormal morphogenesis is one of the common findings in exposed 
embryos. Developmental abnormalities including skeletal malformations, cleft palates, 
neural tube defects, and cardiovascular anomalies have been found to have a  
similar causative mechanism, which was revealed in loss- or gain-of-function studies of  
the transcription factors involved in morphogenesis. The information from genetic 
analyses is important for the understanding of the molecular mechanism of teratogenic 
effects.  
The present chapter discusses the transcription factors involved in morphogenesis (Hox, T-
box family, and other homeo-box genes) and the deleterious agents that lead to congenital 
malformations, and the link between them is explored. We also present recent findings from 
our group and provide guidelines for the prevention of the risks associated with 
environmental contaminants. In addition, we speculate on the molecular mechanisms of 
congenital malformation.  
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2. Transcription factors for development  
The individual cells that make up multi cellular organisms acquire a wide variety of 
positional information cues from body axes. This local information leads to the formation of 
tissues and organs and is essential for the maintenance of homeostasis. There are three 
fundamental axes in multi cellular organisms: anterior-posterior, dorso-ventral, and 
proximal-distal. Abnormalities in body axis formation caused by genetic or external factors 
can lead to the development of lesions. Certain transcription factors play critical roles in 
body axis patterning, along with a wide variety of diffusible factors such as growth factors, 
BMPs, sonic hedgehog. 
In this section, we refer to several transcription factors involved in body axis formation. 
2.1 Hox genes 
2.1.1 Overview of Hox genes 
Hox genes encode transcription factors that play important roles in the process of 
morphogenesis along the anterior-posterior axis of the body. In the early 1900s, Morgan and 
Bridges found abnormal body plan mutants such as the replacement of antennae with legs 
in Drosophila melanogaster. These morphological abnormalities may have been caused by 
alterations in the expression of genes that contain a characteristic sequence (homeo-box), 
which were described in 1970. The homeo-box sequence encodes 61 amino acids designated 
as the homeo-domain and composed of a helix-turn-helix. Through the activity of this 
homeo-domain, Hox proteins bind a core consensus sequence (5’-TAAT-3’) in target genes 
and function as transcriptional activators or repressors. In the regulation of the expression of 
various downstream genes, Hox proteins function as monomers, homodimers, 
heterodimers, or heterotrimers with cofactors such as Meis or Pbx family proteins (Moens 
and Selleri, 2006). Hox genes are highly conserved across species. In the nematode 
Caenorhabditis elegans, there are seven Hox genes in chromosome III that are distributed in 
intervals of 3.9 Mb. In the fly Droshophila melanogaster, eight Hox genes are clustered in 
chromosome 3R, which is referred to as the homeotic complex (HOM-C), and they are 
located across long interval regions consisting of 9.5 Mb. Hox genes are also clustered 
between 100 kb regions in the mammalian genome but this cluster is tandem duplicated; 
there are four clusters in the mouse (chromosomes 7, 17, 12, and 2) and humans 
(chromosomes 6, 11, 15, and 2). These separate clusters are termed Hox A, B, C, and D, 
respectively. 
In normal vertebrate development, there are three important features of Hox gene 
expression. First, the genomic locations reflect the expression in the A-P axis. Generally, 3’ 
genes are expressed in anterior tissues and 5’ genes in posterior tissues. This phenomenon is 
termed “spatial colinearity”. Second, 5’ located Hox genes will have a dominant phenotype 
to more 3’ located Hox genes. This is referred to as “posterior prevalence”. The third feature 
is “temporal colinearity”; 3’ located Hox genes in the cluster are expressed earlier than 5’ 
located Hox genes (Mallo et al., 2010). These properties are under strict expressional control; 
actually a wide range of factors are involved in the control of Hox gene expression. A 
common mechanism of regulation of Hox expression is epigenetic control. In general, the 
silencing of genes is mediated by histone modifications such as the methylation of the 
promoter region. Polycomb and trithorax group proteins are important modulators of 
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histone trimethylation. The polycomb group and trithorax complexes trimethylate lysine 27 
of histone H3 (H3K27) and lysine 4 of histone H3 (H3K4), respectively (Mendenhall and 
Bernstein, 2008). These histone modifications can be reflected in gene expression states such 
as inactive in H3K27m3 or active in H3K4m3. In undifferentiated pluripotent cells, two 
modifications are found in some local regions and are described as a bivalent chromatin 
domain (Bernstein et al., 2006). These chromatin modifications lead to changes in the 
accessibility of trans-acting factors that bind to cis-elements. The expression of Hox genes is 
regulated by a wide variety of trans-acting factors: Hox (self-, palalogus-, and another 
family gene) and other types of transcription factors (Cdx, Rar/Rxr, etc: see below). 
Second, small or large RNAs that are independent of protein synthesis regulate Hox gene 
expression. In the Hox cluster, there are three miRNA families, namely mir-10, mir-196, and 
mir-615. These miRNAs are conserved between the fly and humans. Generally, miRNAs 
have been thought to influence the target mRNA stability and translation. In mammalians, 
at least 30 of the 39 Hox 3’ UTRs have one or more conserved matches to miRNAs like mir-
196. The expression of these mir-10 and mir-196 families is complementary to Hox gene 
expression (Mansfield et al., 2004) and is closely linked to posterior prevalence (Hornstein et 
al., 2005; Yekta et al., 2004). The number of registered miRNAs has recently reached more 
than 16,000 (miRBase, release 17), suggesting that other miRNAs from outside the Hox 
cluster may contribute to the regulation of Hox gene expression. LncRNAs (long noncoding 
RNAs), which range from several hundred bases to dozens of kilobases, are another type of 
RNA polymerase II transcribed RNA with a different function from a template for protein 
synthesis. Xist, known as a regulator of parental-specific expression of imprinting genes, is 
cited as one example (Augui et al., 2011). There are two lncRNAs transcribed from both 
sides of the HoxA cluster. Hottip, transcribed from the 5’ site of HoxA13, and Hotairm1, 
transcribed from between HoxA1 and HoxA2, are the recently reported lncRNAs that lead to 
conformational changes in chromatin together with the transcribed Hox gene RNA (Rinn et 
al., 2007; Wang et al., 2011).  
The regulation of the expression of the Hox cluster genes occurs through a wide variety of 
mechanisms, and irregularities in this regulation can result in several abnormalities as 
described in the following sections.  
2.1.2 Phenotypes of Hox mutants 
Loss or gain of function Hox mutants show homeotic transformations across species. The 
identity of body segments is determined by specific combinations of Hox gene expression 
known as the “Hox-code”. Alterations in the Hox-code result in abnormalities in 
morphogenesis along the longitudinal (A-P) axis of the body, termed homeotic 
transformation. For example, loss of function of the labial gene in the fly, which is located in 
the 3’ region of the cluster, results in the disorganization of cranial structure, which is seen 
in the formation of the salivary glands. The antennapedia mutant is characterized by the 
replacement of antennae by legs (Hughes and Kaufman, 2002). The HOM-C complex is 
formed by two gene clusters, the antennapedia complex (ANT-C) and the bithorax complex 
(BX-C). These two complexes are encoded in the same chromosome but are separated by 9.5 
Mb. Genetic analyses have shown that ANT-C determines the specificity of the anterior 
thoracic and head regions, and BX-C determines the posterior thoracic segments and the 
abdomen. 
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In higher organisms, there are 39 known Hox genes and the analysis of their function has 
become increasingly more complex. The analysis of the function of mammalian Hox genes in 
vivo has been carried out through the generation of a large number of Hox gene knockout or 
knock-in mice. These mice frequently show skeletal abnormalities such as alterations in the 
number of thoracic segments. These phenotypes are explained as resulting from aberrances in 
the Hox-code (Wellik, 2009). Dramatic phenotypes, such as the replacement of antennae by 
legs in the fly mutant, are not observed in single gene mutants in mammals possibly because 
of compensatory effects between the 39 Hox genes, especially among paralogous genes.  
Individual Hox genes have specific functions in various organs. Among skeletal 
abnormalities, cleft palate phenotypes have been detected in Hoxa2-/- mice (Gendron-
Maguire et al., 1993). These phenotypes have also been observed in Hoxa7 and Hoxb7 gain of 
function mice (Balling et al., 1989; McLain et al., 1992).  
The expression of Hox genes belonging to paralog groups 9 to 13 are coordinately detected 
during limb bud development. Among these genes, Hoxa13 and Hoxd13 in the paralog 
group 13 are specifically expressed in the developing distal region (the autopod). Human 
synpolydactyly (SPD) is a rare dominantly inherited limb malformation characterized by 
syndactyly between the third and fourth fingers and between the fourth and fifth toes. 
Typical SPD is caused by mutations of the Hoxd13 gene such as expansions, frame-shift 
deletions, and functional mutations (Malik and Grzeschik, 2008). Another human 
malformation, the hand-foot-genital syndrome (HFGS), is associated with mutations in the 
Hoxa13 gene (Goodman, 2002).  
In addition, aberrant limb formation has been observed in Hoxa13+/- and Hoxd13-/- mutant 
mice (Dolle et al., 1993; Fromental-Ramain et al., 1996). The greater severity of the 
phenotypes of Hoxa13+/-/Hoxd13-/- mice suggested that redundancies within paralog groups 
may play a role in limb development. These redundant manners are also observed in kidney 
formation. There are three Hox11 paralogous genes in clusters A, C, and D. In triple mutants, 
metanephric induction is completely absent, and the reduction of Six2 and Gdnf expression 
is believed to be one of the causative factors for this phenotype (Wellik et al., 2002). On the 
other hand, the activities of Hox genes within a single cluster are important for kidney 
formation (Di-Poi et al., 2007).  
Hoxa13-/-and Hoxd13-/- mice exhibit a reduction of branching in prostate ducts; Hoxa13-/- 
mutants die in utero with severe urinary and genital tract malformations (Podlasek et al., 
1999; Podlasek et al., 1997; Warot et al., 1997). Hoxb13 also functions in ventral prostate 
morphogenesis. Hoxb13-/- mice exhibit transparent ducts of the ventral prostate and these 
abnormalities are more severe in Hoxb13-/-/Hoxd13-/- mice, which show a 50% reduction in 
the number of duct tips (Economides and Capecchi, 2003). 
The involvement of the Hox genes described above in various morphogenetic events 
suggests the possible existence of a close relationship between Hox gene expression and the 
effects of teratogenic factors. 
2.1.3 Function of Hox genes: Proliferation, apoptosis, and differentiation 
Hox genes have different functions associated with proliferation, apoptosis, and 
differentiation. The Hox genes of the A, B, and C but not of the D clusters are transcribed in 
specific subpopulations during normal hematopoiesis. Gain- or loss-of-function analyses of 
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expressed Hox genes showed their ability to specifically regulate different stages of 
hematopoietic development. Among them, Hoxb4 serves as a positive regulator of self-
renewal and expansion (engraftment) in hematopoietic stem cells (HSC) (Antonchuk et al., 
2002; Kyba et al., 2002). On the other hand, definitive hematopoiesis was not disrupted in 
Hoxb4-deficient mice, but Hoxb3-/-/Hoxb4-/- mice exhibited more pronounced hematopoietic 
differences (Bjornsson et al., 2003; Sauvageau et al., 1995). These results suggest that a more 
complex mechanism, such as gene redundancy, compensatory mechanisms and cross-
regulatory interactions, among Hox genes may play a significant role in vivo. 
Hox genes are involved in the regulation of cell proliferation, and their expression in tumor 
cells has therefore been studied. Certain Hox genes show aberrant expression in various 
tumor cells (Shah and Sukumar, 2010). These disruptions of normal Hox expression may 
affect various pathways linked to the promotion of tumorigenesis and metastasis. Moreover, 
some Hox genes (Hoxa9, 11, and 13) are fusion partners of the nucleoporin gene Nup98 in 
human leukemia (Moore et al., 2007). This fusion oncoprotein may play a role in modulating 
transcription and controls the nucleo-cytoplasmic transport of some mRNAs and proteins. 
Actually, the Nup98-hox fusion induces myeloproliferative disease and AML in mouse bone 
marrow transplantation models. Other fusion proteins such as Hoxc11 or 13 are also known 
to induce AML.  
Tumorigenesis is often characterized by alterations in the balance between proliferation and 
apoptosis. When viewed from this perspective, alterations in Hox gene expression can 
contribute to tumorigenesis (oncogenesis) by allowing the activation or repression of the 
apoptosis pathway. In breast cancer cell lines, Hoxa5 directly regulates p53 expression by 
binding to its promoter (Raman et al., 2000). In addition, Hoxa5 induces apoptosis by 
promoting the expression of caspase 2 and caspase 8 in breast cancer cells in a p53-
independent manner (Chen et al., 2004). In the fly, Hox genes induce the localized cell death 
that is essential for the maintenance of a morphological boundary between the two 
structures of the embryo’s head, namely the maxillary and mandibular head lobes. In this 
case, the Hox gene Deformed (Dfd) directly activates the expression of the cell death 
promoting gene reaper (rpr), thereby inducing localized cell death (Lohmann et al., 2002). 
Although it is not clear whether this apoptotic pathway is conserved in mammalian cells, 
some Hox genes show a close relationship to the apoptosis pathway. 
Hox genes play crucial roles in differentiation. In HSC, the expression of Hox genes is 
downregulated during differentiation and maturation. The gain or loss of some Hox genes 
causes alterations in hematopoietic lineage commitment (He et al., 2011). Neural crest cells 
(NCCs) are also multipotent and can differentiate into different cell types, including 
peripheral and enteric neurons, glia, melanocytes, and smooth muscle. The Hox genes 
specify the location of the NCCs and contribute to the differentiation process (Minoux and 
Rijli, 2010).  
Recent observations indicated that some Hox genes also have multiple functions in higher 
order biological mechanisms. Grooming is a stereotypic behavior in mammals and energizes 
the various regions of the brain, such the brainstem, striatum, and cortex. Excessive 
grooming manifests itself in humans as the obsessive-compulsive spectrum disorder 
trichtilomania. Hoxb8 knockout mice show the excessive grooming phenotype. This 
abnormal behavior becomes a cause of death in knockout mice (Greer and Capecchi, 2002). 
Cell lineage tracing showed that this aberrant behavior can be attributed to the lack of bone 
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marrow-derived microglia cells (Chen et al., 2010). The reduction of the total number of 
microglia cells in the adult brain of Hoxb8 mutants is clear, although it remains unknown 
why the disruption of Hoxb8 function only affects a small fraction of microglia cells and 
whether Hoxb8 promotes the proliferation, differentiation or activation of apoptosis in a 
subpopulation of microglia cells.  
These results indicate Hox genes are involved in a wide range of biological functions. 
However, the role of these genes in various processes is not entirely clear and knowledge of 
the direct targets of Hox genes is quite limited. We identified Hox protein target genes using 
chromatin immunopurification (ChIP) (Tomotsune et al., 1993). The use of modified 
methods, such as ChIP-sequence, is necessary to obtain further information on target genes 
and to understand their mechanisms of action. 
2.2 Cdx family 
The Hox cluster is believed to have arisen through the duplication of an ancestral ProtoHox 
cluster in early metazoan evolution. In this process, the ParaHox cluster genes, which show 
close evolutionary relationships, also arose (Garcia-Fernandez, 2005). Cdx (caudal-type 
homeo-box) genes are ParaHox genes, and three paralogous Cdx genes are present in the 
mouse genome and are located in different chromosomes. Cdx genes are required to 
correctly pattern the head to tail axis.  
In Cdx1-/- mutants, an anterior homeotic transformation involving the occiput and the first 
three cervical vertebrae is observed. These changes are accompanied by a posterior shift of 
Hox expression involving three different clusters (Subramanian et al., 1995).  
Cdx2-/- mutants present a much more severe phenotype and die between E3.5 and E5.5. The 
embryonic lethality of these mutants may be attributed to aberrations in the maturation of 
trophoblasts from the trophoectoderm. Cdx2+/- animals are viable but show tail 
abnormalities and growth retardation. Anterior homeotic transformation in the lower 
cervical and upper thoracic regions is also observed in skeletal analyses 
(Chawengsaksophak et al., 1997).  
Cdx4 is an X-linked gene and no significant abnormality is observed in either sex in Cdx4-/- 
embryos (van Nes et al., 2006). However, double knockout Cdx1-/-/Cdx4-/() mice were 
reported to show alterations in skeletal structure, and Cdx2+/-/Cdx4-/() embryos were lethal 
around E10.5, which was attributed to a developmental defect of the chorio-allantoic 
placenta. 
Cdx2+/-/Cdx1-/- mutants show a greater degree of posterior truncation (van den Akker et al., 
2002). These results indicate the existence of redundancy in the Hox clusters among the Cdx 
family genes. The Cdx family genes directly regulate some Hox genes, such as Hoxa5 and 
Hoxb8 (Subramanian et al., 1995; Tabaries et al., 2005), as these Hox genes were shown to 
rescue the Cdx mutant phenotypes (Young et al., 2009). 
2.3 Another ParaHox gene 
Hox and ParaHox genes belong to the ANTP class of homeobox genes. The ANTP class also 
includes two other genes, Evx (even-skipped homeotic) and Meox (mesenchyme homeobox). 
These two ParaHox genes, Evx and Meox, are located on either side of the Hox cluster in 
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vertebrates. In the mouse genome, Evx and Meox each have two paralogous genes (Evx1, 
Evx2, and Meox1, Meox2) in different chromosomes. Evx1-/- is characterized by early 
embryonic lethality as it fails to differentiate extraembryonic tissues or to form egg cylinders 
(Spyropoulos and Capecchi, 1994). Evx2-/- mutants show malformation of the autopod, and 
these results indicate that Evx2 has a genetic interaction with Hoxd13 (Herault et al., 1996). 
Meox1-/- mutants exhibit hemi-vertebrae and rib, vertebral and cranial-vertebral fusions 
(Jukkola et al., 2005). Meox2-/- mutants show mild defects of rib and vertebral development 
(Mankoo et al., 1999). 
NK (Nirenberg and Kim) homeo-box genes are evolutionary relatives of both Hox and 
ParaHox genes. In the mouse genome, there are ten Nkx family genes that are located in 
seven different chromosomes. Nkx family genes are mostly observed in mesodermal 
derivatives; in particular, Nkx2.5 is essential for cardiac muscle differentiation (Hatcher et 
al., 2003). 
2.4 T-box family 
The T-box family genes encode a common DNA-binding domain known as the T-box and 
are also evolutionarily conserved transcription factors. This family of genes is composed of 
two independent functional domains: the T-box in the large N-terminal region and a 
transcriptional activation/repression domain in the C-terminal region. The Brachyury (or T) 
mouse mutant is characterized by a truncated tail and was discovered about 80 years ago. 
Until recently, 17 genes were identified as T-box family genes in vertebrates, and genetic 
analyses of individual genes have progressed significantly. These analyses indicate that T-
box genes are widely involved in developmental processes of mesoderm specification 
(Naiche et al., 2005). In humans, mutations in T-box genes, including deletions, 
rearrangements, missense mutations, insertions, and truncation, lead to various genetic 
disorders (Packham and Brook, 2003). The phenotypes of T-box gene knockout mice can be 
compared with the phenotypes of several human genetic disorders.  
Tbx1-/- mice have a lethal phenotype in late gestation and display a wide range of 
developmental abnormalities including facial abnormalities, cleft palate, cardiac outflow 
tract defects, and hypoplasia of the thymus and parathyroid glands (Jerome and 
Papaioannou, 2001; Merscher et al., 2001). In humans, chromosome 22q11 deletion 
syndrome is known as DiGeorge and velocardiofacial syndrome (DGS/VCFS) and its 
phenotypic characters include anomalies of the cardiac outflow tract, cleft palate, facial 
dysmophogenesis, and hypoplasia of the thymus and parathyroid glands. Tbx1 is located in 
a region spanning 3 Mb, but another genes are also located in this region. Tbx1 is thought to 
be a key gene in the etiology of DES/VCFS. 
Tbx3-/- mice show a deficiency of mammary gland induction, genital abnormalities, and 
forelimb and hind limb malformations, and die during gestation(Davenport et al., 2003). 
However, Tbx3+/- mice appear fairly unaffected. Ulnar-mammary syndrome (UMS) is a 
pleiotropic disease associated with malformations of the posterior elements of the upper 
limbs, apocrine/mammary hypoplasia and/or dysfunction, dental abnormalities, and 
genital anomalies. Clinical manifestations are highly variable. Many similarities are 
exhibited in the phenotype, but gene dose sensitivities are different between humans and 
mice.  
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Tbx4+/-mice form hind limb buds; however, they fail to outgrow them. Tbx4-/- mutants have 
problems with the allantoic connection to the placenta and die early in embryogenesis 
(Naiche and Papaioannou, 2003). The mutations in the human Tbx4 gene are linked to an 
autosomal dominant disorder called small patella syndrome (SPS) (Bongers et al., 2004). 
Tbx5-/- resulted in early embryonic lethality due to severe defects in early heart formation 
(Bruneau et al., 2001). Holt-Oram syndrome is an autosomal dominant disorder that 
includes cardiac and upper limb malformations. Tbx5+/- mutants faithfully recapitulate the 
human phenotype, including cardiac defects and forelimb malformations.  
As Tbx19 (known as Tpit) expression is restricted to the pituitary gland, Tbx19-/- mutants 
show a significant reduction in the number of pituitary POMC (pro-opiomelanocortin)-
expressing cells (Pulichino et al., 2003). In humans, the absence of pituitary POMC leads to a 
lack of adrenocorticotrophin (ACTH), resulting in adrenal insufficiency. 
The Tbx22-/- mutation caused death within 24 hr after birth due to submucous cleft palate 
and ankyloglossia (Pauws et al., 2009). In humans, Tbx22 is a gene responsible for X-linked 
cleft palate and ankyloglossia (Braybrook et al., 2001). 
3. Developmental toxicants 
Teratology is the study of abnormal development and congenital malformations attributed 
to genetic factors, maternal factors, toxicants, or other factors such as environmental 
chemicals. In the early 1970s, James G. Wilson created “The Six Principles of Teratology”. 
These principles are still applied today and guide the investigation of teratogenic agents and 
their effects on the development of organisms. A wide variety of chemicals and 
environmental factors are believed to have teratogenic potential in humans and animals. In 
the USA, the Food and Drug Administration (FDA) has categorized drugs into five different 
risk categories for pregnant women. These five categories (A, B, C, D, and X) have been 
considered a therapeutic advantage but they are only based on specific criteria and are not 
universal. Therefore, the number of these factors is likely higher than one thousand and is 
increasing daily. The teratogenic potentials of various chemicals and environmental factors 
are determined using animal models (e.g., zebra fish, mouse, rat, pig, rabbit, dog, and 
monkey). In the past, observations of the characteristics of embryos from candidate-exposed 
pregnant animals were used as the main criteria, but current teratological evaluations need 
to include knowledge about the molecular mechanisms. 
In this section, six xenobiotics known to be developmental toxicants in humans were 
selected for further description. 
3.1 Endocrine disruptors 
Under normal conditions, hormones are involved in the maintenance of homeostasis, but 
endocrine disruptors, which are environmental chemicals that have a hormone action or 
inhibit the activity of an endogenous hormone, have an adverse effect on organs and 
progeny. In adults, the role of the endocrine system in the maintenance of homeostasis is 
established and adults therefore have resistance against endocrine disruptors. However, in 
the fetus, infants, and children, resistance against these agents may be weak and they 
therefore can have irreversible impact on developmental functions such as organ formation. 
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Endocrine disruptors are found in low doses in products of daily use. DTT, polychlorinated 
biphenyls (PCBs), bisphenol A (BPA), polybrominated diphenyl esters (PBDEs), and a 
variety of phthalates are chemicals used in pesticides, plastic food containers or plastic toys, 
and are currently recognized as endocrine disruptors. 
Methoxychlor (MXC) is an organochlorine DDT derivative. MXC was shown to affect 
fertility in mice and cause maternal weight gain in fetal rats. These effects are thought to be 
mediated by the inhibition of estrogen binding to the Estrogen Receptor (Esr), by MXC and 
the suppression of the expression of Hoxa10 (Fei et al., 2005).  
BPA also affects estrogen signaling. In BPA-exposed males, an increase in the size of the 
prostate gland and oligospermia are observed. BPA exposure negatively regulates the 
expression of Hoxa10 and Hoxa11 and affects estrogen signaling (Varayoud et al., 2008).  
Estrogen and androgen are sex steroids that are needed for the proper development of 
reproductive organs (Dupont et al., 2000). Each steroid binds to a specific nuclear-receptor 
and these receptors act as ligand-dependent transcription factors. Alterations in Hox gene 
expression induced by endocrine disruptors is thus considered to be a nuclear receptor-
mediated mechanism. 
3.2 Diethylstilbestrol (DES) 
DES is a synthetic nonsteroidal estrogen. This chemical was used as a pharmaceutical 
product for the prevention of miscarriage in the 1970s, but vaginal cancer occurred 
frequently in children whose mothers took DES. Exposed offspring also experienced a high 
incidence of pregnancy wastage and preterm labor. DES induced altered Hox gene 
expression in human uterine endometrial and cervical cells. In reproductive organs, Hox 
genes are also expressed along the A-P axis. Under this rule, Hoxa9 is normally expressed in 
the oviduct and Hoxa10 in the uterus. However, this linear regulation of expression is 
disrupted in DES-exposed humans or mice, and the expressional domain is shifted 
posteriorly (Block et al., 2000). DES binds the Esr, and the irregular nuclear receptor 
activation may lead to aberrant Hox gene expression. 
3.3 Anticonvulsants (VPA) 
Valoproic acid (VPA) is a chemical compound used for the treatment of epilepsy. However, 
VPA has teratogenic potential along with other anticonvulsant drugs, including 
carbamazepine and phenytoin in humans. Having weak developmental toxicant of 
carbamazepine and phenytoin, VPA exposure is more toxicant. In humans, infants exposed 
to VPA in utero show anomalies including neural, craniofacial, cardiovascular, and skeletal 
defects. A similar teratology is exhibited in rodents, rabbits, and nonhuman primates. The 
spina bifida, a neural tube defect, is also observed in VPA-exposed infants at frequencies of 
1–2%. VPA exposed human embryonic carcinoma (NTera2/D1) cells show slight alterations 
in the expression of certain Hox genes (Faiella et al., 2000). VPA is also an inhibitor of class I 
and IIa HDACs (histone deacetylases); therefore, changes in the expressions of various 
genes are thought to occur in different tissues. However, it remains largely unknown why 
phenotypes appear only in limited organs in which HDAC is the primary target of VPA, 
and the mechanisms underlying the action of VPA are not clear. 
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Thalidomide (α-phthaliidoglutarimide) was used as a sedative and for morning sickness in 
the late 1950s. However, reports of the teratogenic potency of thalidomide appeared in the 
early 1960s. In these reports, infants exposed to thalidomide during the early stages of 
pregnancy had multiple defects, such as malformations of the limbs, ears, eyes, internal 
organs and central nervous system. The most commonly observed defects were limb 
malformations including amelia (complete absence of the limb) and phocomelia (truncation 
or absence of the zeugopod). Thalidomide-induced limb defects are observed in humans, 
monkeys, rabbits and chicks, but these phenotypes are not observed in the mouse or rat 
(Vargesson, 2009). For 50 years, the mechanism of thalidomide-teratogenicity was poorly 
understood. Thalidomide is a derivative of glutamic acid and contains two imide rings: 
glutarimide and phthalimide. Thalidomide has therefore been believed to act by causing 
biochemical alterations of glutamic acid, nucleic acids and vitamin B. Recently, the primary 
target of thalidomide was identified and parts of the molecular mechanism were revealed 
(Ito et al., 2010). A thalidomide-binding protein, Cereblon (CRBN), forms an E3 ubiquitin 
ligase complex with Ddb1 and Cul4A in a thalidomide-dependent manner and modifies the 
expression of Fgf8 in the limb. Generally, the limb has three developmental axes: the 
proximal-distal axis, which runs from the base of the limb to the tip; the A-P axis, which 
runs parallel with the body axis; and the D-V axis, which runs from the back of the hand to 
the palm. Under the control of these three axes, various positional identities are specified by 
the concentration gradient of diffusible factors, such as Fgfs, Bmps, Wnt, and Sonic Hedgehog. 
The malformed fin or limb in knockdown Crbn zebrafish or the dominant negative form of 
Crbn expressing chicken, respectively, indicated the important role of the ubiquitin ligase 
pathway for morphogenesis through thalidomide, and clearly showed that the reduction of 
Fgf8 expression lead to the deformity of the limb. Although there is no information about 
the specific target molecule of Crbn, identification of this target molecule will allow a more 
effective use of thalidomide for the treatment of multiple myeloma and erythema nodosum 
leprosum and avoid its associated teratogenic risks. 
3.5 Retinoic acid 
In normal embryogenesis, a wide variety of diffusible factors act as morphogens and control 
proper morphogenesis. Retinoic acid is one of the morphogens that function during the 
formation of various organs such as the head, trunk, limbs, heart, and the central nervous 
system. Retinol and other retinoid compounds, which are precursors of retinoic acid, cannot 
be synthesized de novo and must therefore be ingested in food or supplements. After 
modification of ingested retinol by multiple enzymes, the resulting compounds bind to 
ligand-activated nuclear receptors, namely Rar (retinoic acid receptor) and Rxr (retinoid X 
receptor). Rar and Rxr are concurrently encoded by three family genes (α, β, and γ), and 
subtypes exist that are products of alternative splicing or different promoter usage. The 
activated nuclear receptors form homo- or hetero-dimers and recruit coactivators or 
corepressors to the RARE (retinoic acid response element) on the target genes. Some target 
genes have been identified and these genes function in the cell cycle, proliferation, and 
morphogenesis (Delacroix et al., 2010; Nielsen et al., 2008).  
Retinoids were found to be teratogenic in humans in the early 1980s. Infants exposed during 
gestation have teratogenic syndrome including craniofacial abnormalities and defects of the 
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thymic, cardiovascular, and central nervous system. The teratogenic effect is observed in 
other animal models, such as mouse, rat, pig, rabbit, dog, chick, and monkey. The dosage 
and timing of gestational exposure profoundly influence the form of the birth defect and the 
lethality, but differences in the genetic background in mice also have an effect. The peak 
period of sensitivity for a given tissue appears to be during the development of the 
primordial structures. 
Rar and Rxr knockout mice were produced by several methods and these mice exhibited 
various phenotypes (Mark et al., 2006). However, their abnormalities were restricted to a 
subset of tissues normally expressing these receptors, probably reflecting the existence of 
functional redundancies between nuclear receptors. The expression of certain Hox genes is 
controlled via RARE (Oosterveen et al., 2003). Although differences in the RA exposure 
dosage determine the phenotypes, aberrant Hox gene expression is thought to play a role in 
the morphological malformations. 
3.6 Dioxin 
PCDDs (polychlorinated dibenzo-p-dioxins), PCDFs (polychlorinated dibenzofurans) and 
DL-PCBs (dioxin-like polychlorinated biphenyls) are generically termed as dioxin and are 
similar toxicants. Dioxin is an environmental contaminant and is unintentionally generated as 
a by-product of industrial combustion. Among dioxins, TCDD (2, 3, 7, 8-Tetrachlorodibenzo-p-
dioxin) is the most severe toxicant and has the highest teratogenic potency in mammals. 
Differences in the exposure dosage determine the resulting phenotypes, which include cleft 
palate, hydronephrosis, and defects of sex organs. There are differences due to timing and 
dose of exposure, TCDD exposure causes a significant decrease in ventral prostate 
development, which is similar to the effect of impairment of certain Hox genes (Vezina et al., 
2009), but the correlativity between TCDD and Hox expression is not cleared. 
The molecular mechanisms of the xenobiotic dioxin pathway can be understood through the 
analyses of nuclear receptors. The toxicant and teratogenic effects of dioxin are thought to 
depend on the activation of the Ahr (aryl hydorocarbon receptor) pathway. Ahr has 
multiple functions. Ahr is a ligand-activated transcription factor that is a member of the 
bHLH/PAS (basic Helix-loop-Helix/Per-Arnt-Sim) family of genes. Ahr generally localizes 
to the cytoplasm and forms a complex with Hsp90 (heat shock protein 90), cochaperone p23, 
and the immunophilin-like protein Ara9 (Bell and Poland, 2000). Upon binding ligand, Ahr 
is released from the p23/Ara9 complex and translocates to the nucleus. In the nucleus, Ahr 
dissociates from Hsp90 and dimerizes with another bHLH-PAS family gene, Arnt (Ahr 
nuclear translocator). The Ahr/Arnt heterodimer binds to specific DNA sequences termed 
XREs (xenobiotic response elements: 5’-GCGTG-3’) and regulates target gene expression 
with transcriptional coactivators/corepressors, which are also partners of Rar/Rxr 
(Beischlag et al., 2002). Currently, various genes are reported as Ahr target genes: phase I 
drug metabolizing enzymes, such as those of the Cyp450 (Cytochorome 450) family; phase II 
enzymes, such as Ugt1a1 (Kohle and Bock, 2007); and as down stream genes of Ahr-
pathway, such as cytokines, and Tgf family which are unrelated xenobiotic metabolism 
genes (Haarmann-Stemmann et al., 2009).  
Ahr is also a modulator of estrogen receptor signaling. Ohtake et al. indicated that the 
ligand-activated Ahr/Arnt heterodimer directly associates with the Esr, recruits a 
coactivator, and regulates the expression of Esr target genes (Ohtake et al., 2003). In this 
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case, Ahr functions as activator/repressor depending on the ligand binding state of the Esr. 
Another function of ligand-activated Ahr as a substrate-specific adaptor in the Cullin 4B 
ubiquitin ligase complex was described (Ohtake et al., 2007). In this case, agonist (3MC: 3-
methylcholanthrene)-activated Ahr ubiquitinates Esr1 and androgen receptor (Ar) in vitro 
and in vivo. In Ahr-deficient mice, responses to dioxin such as the induction of Cyp1a1 
activation were not observed. However, null mutants have functional impairments of male 
and female reproductive organs, depending on the affected allele (Schmidt et al., 1996). 
Although there are other identified ligands for Ahr, including flavonoids, UV photo-
products of tryptophan and some synthetic retinoids, the above observations suggest that 
Ahr plays a role in the cross talk between the dioxin and RA pathways. 
4. Hox-RA/dioxin 
The identification of molecular markers for the variety of existing teratogenic factors is an 
urgent need in various respects. In the present report, we focused on the expressional 
changes of the Hox cluster genes in embryos exposed to teratogenic factors because their 
aberrant expression lead to various morphological defects and the affected animals have 
close similarities (Kojima and Takahashi, 2009).  
Because the different amount and timing of exposure to teratogenic factors are correlated to 
the different effects in embryos, we firstly examined the RA or dioxin effects in E10.5 
embryos for 6 hr by one-shot administration. This dose induced craniofacial and skeletal 
defects in RA-exposed embryos, and hydronephrosis in dioxin-exposed embryos. Among 39 
Hox cluster genes, 3’-located paralogs (Hox1~8) were up-regulated and some 5’-located 
genes (Hoxa11, Hoxd9, and Hoxd12) were down-regulated in the RA-exposed embryos (Fig. 
1). Meanwhile, the influence of relative position in the cluster was not observed in the 
TCDD-exposed embryos. A and D cluster genes were down-regulated and no clear 
difference was observed in the cluster B. Additionally, aberrant expression of pri-miRNAs 
(precursors of miRNAs) was detected (Fig. 2). These pri-miRNA changes were correlated 
with changes in the expression of closely located Hox genes.  
TCDD exposure causes a decrease in the levels of all-trans RA in the liver, which is the main 
RA storage location in a variety of species (Fletcher et al., 2001). There are some similarities 
in terms of morphological changes between RA- and TCDD-exposed embryos. The 
developmental effects of the replacement of RA storage by TCDD are not clear, but it is 
suggested that TCDD and related compounds have an impact on retinoid homeostasis and 
the RA signaling pathway. Our analyses indicate that alterations in the expression of Hox 
cluster genes do not show a clear correlation with these teratogenic factors. In addition, 
expressional changes of some pri-miRNAs in the Hox clusters are also different between 
these two factors. Although the involvement of Ahr in the cross talk between the RA and 
TCDD pathways is possible, there are clear differences in the downstream effects, such as 
expressional changes of Hox cluster genes. We also detected changes in the expression of 
other transcription factors, such as ParaHoxs and T-box family genes, in embryos exposed to 
these factors. Some genes show a specific response to each teratogenic factor. Based on these 
results, changes in the expression of transcription factors can be considered as potential 
molecular markers for the verification of teratogenic effects. Therefore, to better determine 
the teratogenic potential of various chemicals, further investigation of the effects of the 
timing or dosage of RA and TCDD in exposed embryos is under way. 
 




Fig. 1. Expressional changes of the Hox cluster genes in embryos treated with teratogenic 
agents. 39 Hox genes are separated on four clusters (A, B, C, and D) in four chromosomal 
loci. The box indicates each gene. Red boxes indicate up-regulated and blue boxes indicate 
down-regulated genes in response to treatment with teratogenic agents. 
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and the blue arrow indicates TCDD exposure. The upward direction of the arrow represents 
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Hox cluster genes, 3’-located paralogs (Hox1~8) were up-regulated and some 5’-located 
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developmental effects of the replacement of RA storage by TCDD are not clear, but it is 
suggested that TCDD and related compounds have an impact on retinoid homeostasis and 
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these two factors. Although the involvement of Ahr in the cross talk between the RA and 
TCDD pathways is possible, there are clear differences in the downstream effects, such as 
expressional changes of Hox cluster genes. We also detected changes in the expression of 
other transcription factors, such as ParaHoxs and T-box family genes, in embryos exposed to 
these factors. Some genes show a specific response to each teratogenic factor. Based on these 
results, changes in the expression of transcription factors can be considered as potential 
molecular markers for the verification of teratogenic effects. Therefore, to better determine 
the teratogenic potential of various chemicals, further investigation of the effects of the 
timing or dosage of RA and TCDD in exposed embryos is under way. 
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Contrasting a comprehensive analysis using DNA microarrays, our analysis is simpler and 
allows the examination of a large number of samples. Information on molecular markers 
such as the Hox genes under various conditions (exposure-time, -dosage) will allow the 
prediction of the hazardous nature of unknown factors. In addition, the understanding of 
the molecular mechanisms common to different teratogenic agents requires the 
identification of the target genes of Hox protein and each transcription factor and an 
understanding of transcription factor networks. 
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1. Introduction  
Congenital malformations contribute to a significant proportion of infant morbidity and 
remain a leading cause of death in both the neonatal and postneonatal periods (Brunner and 
van Driel, 2004). Despite the high frequency of these disorders, their underlying causes 
remain often obscure due to the complexity of human development. The human genome 
contains approximately 25,000 genes and most of them become active to build both tissue 
and body structures (Brunner and van Driel, 2004). Moreover, growth and morphogenesis 
of the human embryo relies on the precise orchestration and intercalation of multiple 
cellular functions, and the spatio/temporal control of the inherent molecular and biological 
processes. Therefore, modern human genetics regards the detailed understanding of genes 
and molecular strategies involved as "an indispensable investment" that can foster greater 
progress in the diagnosis and treatment of these human disorders.  
From the beginning of the last century, going back to the Spemann and Mangold 
experiments, cell to cell signalling has been recognized as one fundamental principle of 
animal development (Freeman and Gurdon, 2002). At almost every developmental stage 
cells communicate with each other and such processes permit the generation of cell-type 
differences during development and the coordination of cell functions during tissue/organ 
morphogenesis or tissue/organ homeostasis (Freeman and Gurdon, 2002; Pires-daSilva and 
Sommer, 2003).  
Chemical communication is by far the major form of information transfer between cells. 
Following release by instructive cells, signals move towards target cells through either direct 
contact or by short and long diffusion (Freeman and Gurdon, 2002; Papin et al., 2005). On 
target cells signals are captured by distinct cellular receptors that upon integrating and 
interpreting them activate appropriate intracellular signalling pathways and effectors to 
modify cell fate, metabolism or function (Freeman and Gurdon, 2002; Pires-daSilva and 
Sommer, 2003).  
Research in the past two decades has yielded important advances towards the identification 
of the signal proteins, receptors, and intracellular proteins involved in signalling processes. 
For example the human genome contains more than 1500 genes that encode receptor 
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1. Introduction  
Congenital malformations contribute to a significant proportion of infant morbidity and 
remain a leading cause of death in both the neonatal and postneonatal periods (Brunner and 
van Driel, 2004). Despite the high frequency of these disorders, their underlying causes 
remain often obscure due to the complexity of human development. The human genome 
contains approximately 25,000 genes and most of them become active to build both tissue 
and body structures (Brunner and van Driel, 2004). Moreover, growth and morphogenesis 
of the human embryo relies on the precise orchestration and intercalation of multiple 
cellular functions, and the spatio/temporal control of the inherent molecular and biological 
processes. Therefore, modern human genetics regards the detailed understanding of genes 
and molecular strategies involved as "an indispensable investment" that can foster greater 
progress in the diagnosis and treatment of these human disorders.  
From the beginning of the last century, going back to the Spemann and Mangold 
experiments, cell to cell signalling has been recognized as one fundamental principle of 
animal development (Freeman and Gurdon, 2002). At almost every developmental stage 
cells communicate with each other and such processes permit the generation of cell-type 
differences during development and the coordination of cell functions during tissue/organ 
morphogenesis or tissue/organ homeostasis (Freeman and Gurdon, 2002; Pires-daSilva and 
Sommer, 2003).  
Chemical communication is by far the major form of information transfer between cells. 
Following release by instructive cells, signals move towards target cells through either direct 
contact or by short and long diffusion (Freeman and Gurdon, 2002; Papin et al., 2005). On 
target cells signals are captured by distinct cellular receptors that upon integrating and 
interpreting them activate appropriate intracellular signalling pathways and effectors to 
modify cell fate, metabolism or function (Freeman and Gurdon, 2002; Pires-daSilva and 
Sommer, 2003).  
Research in the past two decades has yielded important advances towards the identification 
of the signal proteins, receptors, and intracellular proteins involved in signalling processes. 
For example the human genome contains more than 1500 genes that encode receptor 
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proteins, and the number of different receptor proteins is further increased by alternative 
RNA splicing and post-translational modifications. Surprisingly, genetic and biochemical 
studies revealed that only a few different classes of signalling pathways mediate patterning 
of a wide variety of cells, tissues and organs. For example, Fibroblast growth factors (FGF) 
Hedgehog (Hh), Wingless related (Wnt), Transforming growth factor-b (TGF-b) and Notch 
are used reiteratively during development to mediate very different biological processes in 
different animals (Freeman and Gurdon, 2002; Pires-daSilva and Sommer, 2003). In other 
words, a signal that in one instance will cause a cell to differentiate terminally will 
elsewhere lead another cell type to undergo mitosis and in a third context will trigger cell 
death.  
These findings have raised the question of how generic signals can trigger tissue-specific 
responses. As a general principle specificity relies on the repertoire of receptors and 
intracellular mediators that are active in a given cell at a given time (Freeman and Gurdon, 
2002). Nevertheless, there is now clear evidence that specificity of signal outcome is also the 
product of biological strategies ensuring signal level, strength, duration and its spatio-
temporal distribution (Freeman and Gurdon, 2002). For example, several of these signalling 
molecules function as morphogens that form concentration gradients across developmental 
fields and specify different cell fates in a concentration dependent fashion during pattern 
formation (Freeman and Gurdon, 2002). Other studies have also shown that differences in 
the kinetics of the ligand or receptor binding mode, and changes in the temporal and 
quantitative supply of active ligand can contribute to increases in the heterogeneity of 
biological responses to incoming signals, but without losing the cell specific effects that 
ensure reproducibility of developmental processes (Freeman and Gurdon, 2002).  
In the pursuit of molecular mechanisms that underlie these further layers of regulation 
attention has progressively shifted towards components of the extracellular matrix. Besides 
being structural scaffolds, these proteins are now evaluated as vital elements of the cell 
signalling machinery that provide processing and bioavalaibility of instructive signals 
(Bernfield et al., 1999; Bulow and Hobert, 2006). 
In particular, cell surface proteoglycans such as  Glypicans (Gpcs) interact with chemokines, 
growth factors/morphogens and their receptors (Bulow and Hobert, 2006; Hacker et al., 
2005; Nybakken and Perrimon, 2002). Disruption of Gpc functions in Drosophila, Zebrafish, 
Xenopus Laevis and mouse results in phenotypes reminiscent of defects in cellular responses 
to regulatory signalling molecules (Hacker et al., 2005; Lin, 2004). Yet, genetic and 
embryological studies link Gpcs to the regulation of cell signalling events during 
morphogenesis and adult physiology (Bishop et al., 2007; DeBaun et al., 2001; Hacker et al., 
2005; Lin et al., 1999). In humans, mutations in the Gpc-3 gene are associated with several 
diseases. For example, mutations in the Gpc-3 gene underlie a condition called Simpson-
Golabi-Behmel syndrome, which is characterized by overgrowth of the body and other birth 
defects (DeBaun et al., 2001). Homozygosity for null mutations in the Gpc-6 gene cause 
autosomal recessive omodysplasia, a genetic condition characterized by severe short stature 
and congenital heart defects (Campos-Xavier et al., 2009). Additionally, increased and 
decreased activity of some Gpcs (including Gpc-1, -3, -4 and -6) occurs in certain forms of 
cancer (Filmus, 2001). Here, we review our current knowledge on the implication of these 
proteoglycans in congenital malformations, and discuss our understanding of their 
mechanism of action. 
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2. Molecular design of cell surface glypicans 
The name “glypicans” identifies a family of heparan sulphate proteoglycans (HSPGs) that 
are linked to the exocytoplasmic surface of the plasma membrane through a covalent 
glycosyl-phosphatidylinositol (GPI) linkage (Bulow and Hobert, 2006). Together with 
Syndecans, gpc gene products are the major cell surface HSPGs (Bulow and Hobert, 2006). 
Gpcs have been highly conserved throughout evolution and most likely arose early during 
metazoan evolution (Filmus et al., 2008). In this section, we describe their major structural 
features that have been crucial to elucidate their in vivo roles. 
2.1 Glypican assembly 
Gpcs are proteins of around 60–70 kDa with a characteristic pattern of 14-conserved cysteine 
residues mainly located to the central domain (De Cat and David, 2001). Gpcs also share an 
N-terminal signal sequence and a hydrophobic C-terminal sequence involved in the 
formation of the GPI anchor structure (Fig. 1; De Cat and David, 2001). Heparan sulphate 
glycosaminoglycan (HSGAG) polysaccharide side chains can be attached to serine residues 
in consensus sequences, such as XGlyXGlySerX, that are located between the central domain 
and the C-terminal GPI-anchor (De Cat and David, 2001). The HSGAG of proteoglycans can 
undergo complex patterns of modification consisting of sulphations of hydroxyl groups in 
individual sugar molecules, epimerizations of specific carbon atoms and changes in length 
of the individual sugar residues (Bulow and Hobert, 2006; Nybakken and Perrimon, 2002). 
Such modifications are thought to generate a large structural diversity that might encode 
information for the selective binding of protein ligands (Bulow and Hobert, 2006; Nybakken 
and Perrimon, 2002). In general, Gpcs carry these HS chains, but Gpc5 also displays 
chondroitin sulfate modifications (Saunders et al., 1997). 
  
Fig. 1. Schematic representation of the Gpc structure.  
The glypican core protein spans the extracellular space. Disulfide bridge (S-S) are thought to 
organize the core protein as a compact globular domain. HS chains are covalently bound to 
serine residues that are part of X-Gly-X-Gly-Ser-X motifs in the polypeptide chain close to 
the plasma membrane. The carboxyterminus of Gpcs is covalently linked to the plasma 
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proteins, and the number of different receptor proteins is further increased by alternative 
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membrane via a GPI anchor. Red filled hexagon chains represent HS chains. S = serine; G = 
glycine; X = aminoacid (adapted from De Cat, B. and David, G., 2001). 
Proteolytic cleavages of the core proteins can also contribute to generate distinct Gpc forms. 
As shown for several vertebrate and invertebrate proteins, the N-terminal cysteine-rich 
domain of Gpcs can be splitted from the HS-modified and GPI-anchored C-terminal domain 
following endo-proteolytic processing (Song and Filmus, 2002). To which extent this event 
occurs in physiological condition is matter of investigation because the ratio between 
uncleaved and cleaved Gpcs varies according to the gpc family member and the tissue-
specific context. The N-terminal Gpc fragment is not membrane-associated and, once 
generated, it can remains linked to its C-terminal half through one or more disulfide bridges 
(De Cat et al., 2003; Eugster et al., 2007). Thus, proteolytic processing can provide a 
molecular strategy to rapidly make available a secreted Gpc product, if needed, as such a 
form could be released from producing cells simply following redox changes of the extra-
cellular environment. 
2.2 Evolutionary origins 
Gpcs are evolutionarily conserved proteins found in organisms as distinct as nematodes, 
fruit flies and mammals (De Cat and David, 2001; Fico et al., 2007; Filmus et al., 2008). The 
human and mouse genome contain six Gpc family members, Gpc-1 to Gpc-6 in humans and 
gpc-1 to gpc-6 in mice (De Cat and David, 2001; Fico et al., 2007; Filmus et al., 2008) whereas 
five gpc-like genes have been identified in zebrafish (Filmus et al., 2008; Topczewski et al., 
2001), two in Drosophila (dally and dally-like; Baeg et al., 2001; Nakato et al., 1995) and two in 
C. elegans (gpn-1 and lon-2; Gumienny et al., 2007; Hudson et al., 2006). The amino acid 
sequences of mammalian Gpc vary from being 17% to 63% identical. However, sequence 
relationships and exon organizations suggest that mammalian gpcs consist of two distinct 
subfamilies (De Cat and David, 2001; Fico et al., 2007; Filmus et al., 2008). The first subfamily 
includes gpc-1, -2, -4 and -6 genes with amino acid sequence homology ranging from 40–60% 
and composed of nine exons. The other subfamily incorporates gpc-3 and -5, with amino 
acid sequences 40% identical and containing eight exons. Of note, gpc-6 maps near to gpc-5 
on mouse chromosome 14 and on human chromosome 13. Gpc-4, which is most homologous 
to gpc-6 maps to chromosome Xq26 near to gpc-3, which is highly related to gpc-5 (De Cat 
and David, 2001; Fico et al., 2007; Filmus et al., 2008). Therefore, members of the different 
subfamilies are inclined to cluster on the same chromosome. Whether gpc subfamilies and 
the genomic linkage of different members have evolved from a series of gene and genome 
duplications is still a matter of debate. In support of this possibility there are studies in 
organisms such as Drosophila and zebrafish showing the existence of distinct orthologs for 
each mammalian subfamily and their genomic linkage (Filmus and Capurro, 2008). It will be 
interesting to examine to what extent the appearance of gpc subfamilies might underlie the 
evolution of functional similarities in members of the same subfamily and functional 
differences among those more divergent. In this context, studies on Dally and Dally-like 
aimed at distinguish their activity on Hh have shown that Dally-like but not Dally is required 
for Hh response in a Drosophila cultured cell assay (Williams et al., 2010). Intriguingly, Gpc-4 
and -6, which are the mammalian Gpcs most closely related to Dally-like, complement Dally-
like function in this biological system (Williams et al., 2010). In contrast, Dally and its 
ortholog Gpc-3 exhibit trans-dominant negative activities (Williams et al., 2010). These 
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studies suggest a large trend in which related Gpc members may have evolved similar 
activities in distinct cellular contexts, but further understanding will come from studies on 
other signalling activities. 
3. Glypicans: From structural compounds to signalling molecules 
Once considered as acting merely as structural components of the extra cellular matrix, Gpcs 
are now widely recognized as essential modulator of many biological processes. These include 
their role as carriers in cellular uptake of growth promoting polyamines such as spermine 
(Casero and Marton, 2007; Fransson et al., 2004). It has been proposed that the binding of Gpcs 
to polyamines is mediated by electrostatic interactions occurring between Gpc HS side chains 
and polyamine residues. After transport to endosomes, HS moieties are degraded by nitric 
oxide. This is expected to weaken HS interaction with polyamines and results in their 
unloading and possibly exit from endosomes to elicit functions. The mechanisms underlying 
polyamines uptake has been analyzed in several systems and discussed in previous reports 
(Belting, 2003; Fransson et al., 2004).  
To date, Gpcs are also considered as potential carriers of cell-penetrating peptides. Cell-
penetrating peptides are short cationic peptides extensively studied in medicine as drug 
delivery agents for the treatment of different diseases including cancer and virus infection 
(Rajendran et al. , 2010). Their entry into cells is typically initiated through interaction with 
cell-surface HS proteoglycans (HSPGs) via electrostatic interactions, followed by 
endocytosis (Poon and Gariepy, 2007). Studies on the intracellular delivery of cell-
penetrating peptides have shown that the migration of these peptides into cells as well as 
their final destination could depend on the nature of the HSPGs expressed at the cell surface 
(Poon and Gariepy, 2007). The GPI-anchor typical of Gpc proteins provides them with 
specific membrane-trafficking properties distinct from those of transmembrane HS 
molecules such as Syndencans (Chatterjee and Mayor, 2001; Payne et al., 2007). Therefore, 
Gpcs mediated uptake of cell-penetrating peptide is currently evaluated as a new strategy to 
enhance target-specific delivery of a large variety of entrapped therapeutic drugs. 
Research on Gpcs has further increased due to the discovery that they act at the interface 
between the extra cellular environment and the inner cellular domain to fine tune inputs 
triggered by key secreted regulatory proteins. Although Gpcs have important physiological 
roles (Bishop et al., 2007), we concentrate here on their developmental functions and on the 
molecular mechanisms by which Gpcs trigger cell fate and tissue pattern.  
3.1 Glypicans as modulator of regulatory extra-cellular signals 
Our knowledge of Gpc biology has significantly expanded over the past decade with the 
discovery that Gpcs are not simply structural proteins. Being mostly extracellular, Gpcs are 
involved in the regulation of various signalling pathways triggered by secreted peptides 
including that of Wnt, Fgf, Hh, bone morphogenic protein (Bmp), insulin-like growth factor 
and hepatocyte growth factor (Fico et al., 2007; Filmus and Capurro, 2008).  
The functional relevance of Gpcs as signalling modulators has come from the genetic 
analysis and embryological manipulation of Gpcs in different species and in cultured cells 
(Table 1). 
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Table 1. Glypicans function in model organisms. This table reports the major phenotypes 
observed by genetic and embryological studies on glypican genes and the main involved 
signals 
For example, in vitro studies have shown that Gpc4 positively modulated hepatocyte 
growth factor activity during renal epithelial branching morphogenesis (Karihaloo et al., 
2004). Mice lacking Gpc3 are affected by overgrowth, renal cystic dysplasia and limb 
defects. Some of these phenotypes are consistent with defects in Wnt and Bmp signalling 
pathways, respectively (Grisaru et al., 2001; Paine-Saunders et al., 2000; Song et al., 2005). 
Additional studies have also shown that the developmental overgrowth observed in gpc3-
null mice is, at least in part, a consequence of the hyperactivation of the Hh pathway 
indicating that Gpc3 inhibits Hh ( Gallet et al., 2008; Capurro et al., 2009). Interestingly, 
Gpc5 stimulates the proliferation of rhabdomyosarcoma cells by eliciting a positive action 
on Hh signalling (Li et al., 2011), in contrast to the Gpc3-mediated negative control of Hh. 
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These findings reveal that members of the Gpc family can display opposite roles in the 
regulation of a given signalling protein. The C. elegans Gpc Lon-2 also controls body size 
length (Gumienny et al., 2007). It has been proposed that Lon-2 negatively regulates Bmp 
signalling as lon-2 mutants recapitulate phenotypes caused by Bmp over-expression 
(Gumienny et al., 2007). Another example is the Zebrafish knypek, which encodes the gpc 
homolog to mammalian Gpc4/Gpc6 (Topczewski et al., 2001). knypek controls convergent-
extension movements during zebrafish gastrulation by positively modulating Wnt11 
activity (Topczewski et al., 2001).  
Modulation of extra-cellular signals by Gpcs has also been reported in Xenopus. In 
particular, reducing Gpc4 (Xgly4) disrupts cell movements during gastrularion (Ohkawara 
et al., 2003). We have also shown that loss-of Gpc4 function in Xenopus embryos impairs 
forebrain patterning and cell survival from early neural plate stages onwards, and that these 
early developmental defects result in brains affected by microcephaly at later stages (Fig. 2; 
Galli et al., 2003). Xgly4 physically interacts with Wnt11, and might enhance function in the 
Wnt/PCP pathway during gastrulation (Ohkawara et al., 2003). In addition to Wnt11, we 
have demonstrated that Xgly4 also binds Fgf2. Inhibition of Fgf signalling results in dorsal 
forebrain phenotypes similar to those of Xgly4 depleted embryos, indicating that 
establishment and patterning of the dorsal forebrain territory may require modulation of Fgf 
signalling by Xgly4 (Galli et al., 2003).  
 
Fig. 2. Forebrain defects in GPC-4 depleted embryos. Side view of Xenopus embryos at tail 
bud stage showing expression of the dorsal forebrain marker emx-2 as detected by whole 
mount in situ hybridization (arrow in all panels). Xenopus embryos were injected at 2 cell 
stage with morpholino oligos to interfere with Gpc-4 activity. Injections were done by using 
control morpholino (controlMo), or morpholino targeting gpc-4 (gpc-4Mo). Embryos were 
also co-injected with morpholino targeting gpc4 (gpc-4Mo) and mouse gpc-4 mRNA (mgpc-4 
mRNA) for rescue experiments. (A, B) emx-2 expression in the dorsal forebrain of tailbud 
embryos; note the loss of emx-2 expression and the forebrain microcephalic morphology in 
GPC-4 depleted embryos (B). (C) Rescue of emx-2 expression and forebrain morphology in a 
tail bud embryo co-injected with Gpc-4Mo and mGpc-4 mRNA. Br: brain; Ta: Tail. 
In Drosophila the Gpc Dally-like is required for Hh signalling in the embryonic ectoderm 
whereas both Gpcs Dally and Dally-like are required and redundant in Hh movement in 
developing wing imaginal discs (Han et al., 2004; Yan and Lin, 2009). Additional studies on 
the wing disc patterning have also demonstrated that in Dally and Dally-like mutants the 
distribution and signalling of Wnt and Bmp family members, Wingless (Wg) and 
Decapentaplegic (Dpp) respectively, are altered (Nybakken and Perrimon, 2002). 
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bud stage showing expression of the dorsal forebrain marker emx-2 as detected by whole 
mount in situ hybridization (arrow in all panels). Xenopus embryos were injected at 2 cell 
stage with morpholino oligos to interfere with Gpc-4 activity. Injections were done by using 
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also co-injected with morpholino targeting gpc4 (gpc-4Mo) and mouse gpc-4 mRNA (mgpc-4 
mRNA) for rescue experiments. (A, B) emx-2 expression in the dorsal forebrain of tailbud 
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In Drosophila the Gpc Dally-like is required for Hh signalling in the embryonic ectoderm 
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developing wing imaginal discs (Han et al., 2004; Yan and Lin, 2009). Additional studies on 
the wing disc patterning have also demonstrated that in Dally and Dally-like mutants the 
distribution and signalling of Wnt and Bmp family members, Wingless (Wg) and 
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Furthermore, Dally and Dally-like also act on Wg during segment polarity determination and 
on Dpp in the developing eye and antennal discs (Hacker et al., 2005; Lin, 2004). Overall, 
these and other studies reveal that different cell types can take advantage of Gpc-mediated 
regulation to control signal supply during distinct developmental processes. In addition, 
they show that vertebrate and invertebrate Gpcs have diverse and specialized functions 
towards a given signalling protein including their capability of enhancing or suppressing its 
activity in a stage- and/or tissue-specific regulated manner. 
3.2 Heparan sulphate chains and core proteins for signal control 
The findings that Gpcs enable cells controlling activity of a wide range of extracellular 
effectors with greater selectivity towards biological outcomes, suggest that Gpcs are rather 
dynamic proteins capable of employing various mechanisms to exert their regulatory effects 
in biological processes. One question that has arisen is whether these properties are 
conferred by their unique structural motifs. As discussed above, Gpcs are most likely 
globular proteins with HS chains at the carboxyl terminus. Of note, Chen and Lander have 
identified that the Gpc1 globular domain is a structural motif that potently influences HS 
substitutions (Chen and Lander, 2001). Moreover, it has been proposed that the physical 
constraint of HS attachment sites at the carboxyl terminus could result in proteins with HS 
chains in the proximity of the cell surface. These basic structural features, together with the 
known versatile conformation and orientation of HS functional groups, could prime Gpc HS 
modifications to a degree that facilitate their contacts with cell-membrane proteins (e.g. 
signalling receptors) while retaining specificity in binding modes (Tumova et al., 2000). The 
GPI-anchorage is yet another feature that makes Gpc proteins subject to distinct subcellular 
localization and intracellular trafficking processes as well as to release into the extracellular 
environment through shedding mechanisms involving distinct extracellular lipases 
(Chatterjee and Mayor, 2001; Payne et al., 2007). Gpcs trafficking and shedding can both 
lead to a gain of signal, down-regulation properties and cell non-autonomous activities (Yan 
and Lin, 2009). These issues are the subjects of intense investigation, and a growing body of 
data is being published on Gpc mechanism of action. In this paragraph we briefly 
summarize the current state of our knowledge related to HS-mediated Gpc activity. We 
focus more on studies showing that the core protein and its GPI anchor confer on Gpcs 
additional functional versatility. 
3.2.1 The heparan sulphate chains  
The hypothesis that functional Gpc properties are mediated by HS modifications was first 
evaluated for the Fgf/Fgf receptor axis as it is well established that Fgfs rely on the co-
receptor role of HSPGs for receptor binding and activation. As demonstrated by 
experiments performed mainly in cultured cells and in cell-free systems, Gpc HS 
modifications can catalyze binding of Fgfs to their receptors and boost receptor activation 
and its biological functions. For example, purified HS chains derived from Gpc-1, 
following protease-mediated digestion, augment the binding of Fgf-2 and Fgf-1 to Fgf 
receptor 1 to an extent that lower concentrations of ligands are needed for activation 
(Bonneh-Barkay et al., 1997b). Also, the Gpc-dependant Fgf binding and activation of 
receptors is nearly abolished when cells are treated with chlorate to inhibit Gpc 
sulfatation (Steinfeld et al., 1996). In this context, covalent cross-linking of Fgf-2 to cells 
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expressing its receptor demonstrates a putative Fgf-2/Fgf receptor complex when HS 
modified Gpcs are present in the same cell (Steinfeld et al., 1996). A conclusion that can be 
drawn from these studies is that cell-surface Gpcs by means of their HS modification can 
function as essential partners for the Fgf tyrosine kinase receptor. Potential mechanisms of 
action may include immobilizing of the ligand, increasing its local concentration, 
presenting it to a signalling receptor, or otherwise modifying the molecular encounters 
between ligands and receptors. The expected overall effect is thus enhancing receptor 
activation at low ligand concentrations. Interestingly, whereas Gpc-1 HS chains potentiate 
the biological activity of Fgf-1 they strongly inhibit Fgf-7 function (Berman et al., 1999; 
Bonneh-Barkay et al., 1997a). This suggests that HS chains can also act as a dual 
modulator of biological activities exerting both stimulatory and inhibitory effects 
depending on factors involved. More recently, experimental settings involving depletion 
of these sulphate groups both in vivo and in cultured cells have demonstrated that Gpcs 
HSs mediate interaction with additional HS binding proteins and impact their activity. 
This includes the binding and stimulation of Wg (the drosophila homolog of Wnt) 
signalling in the wing imaginal disc by Dally as well as the ability of human Gpc-5 to 
interact with Hh and enhance its growth promoting activity in rhabdomyosarcoma cells ( 
Yan and Lin, 2009; Li et al. , 2011, ). Interestingly, Dally HS chains are required in vivo to 
activate high-threshold but not low-threshold target genes of Dpp (Kirkpatrick et al., 
2006), suggesting that HSPG core proteins could serve distinct functions in low- versus 
high-threshold morphogenetic signalling.  
Recent studies have revealed that the co-receptor function of Gpcs can also provide a new 
paradigm of cell-cell communication. In the stem cell niche associated with germ cells the 
Gpc Dally is critical for making and maintaining the female germ cells (Hayashi et al., 
2009). However, in this stem cell niche, dally is expressed by the cap cells, which also 
produce the Dpp signalling molecule, but not in the receiving cells (germ cells), which 
instead express Dpp receptor (Hayashi et al., 2009). These findings have raised questions 
and interest about the underlying molecular mechanisms. Studies in cultured cells have 
provided evidence that Dally enhances Dpp signalling in trans through a contact-
dependent mechanism allowing the complementation of co-receptor-receptor complexes 
in adjacent cells (Dejima et al., 2011). Therefore, unlike typical co-receptor functions, Dally 
can serves as a trans co-receptor for Dpp when it has to enhance its signalling on 
neighboring cells. So far the mechanism for contact-dependent signalling has been mainly 
attributed to membrane-bound ligands and receptors such as Delta-Notch and Ephrins 
and their receptor tyrosine kinases (Hainaud et al., 2006). The fact that Gpcs act as trans 
activator partners establishes new strategies for crosstalk between adjacent cells during 
tissue assembly and maintenance.  
In conclusion, a common theme throughout all studies is that HS chains are responsible for 
different aspects of Gpc biology. By means of HS chains Gpcs sequester secreted soluble 
ligands and modulates their activity. As co-receptors and trans co-receptor, Gpcs modulate 
ligand-receptor encounters that can activate and inhibit cell proliferation, motility, and 
differentiation. Also HS side chains are not uniform and changes in the distribution of 
sulphate groups may affect ligand-binding properties and biological outcomes in a cell type-
specific manner. 
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attributed to membrane-bound ligands and receptors such as Delta-Notch and Ephrins 
and their receptor tyrosine kinases (Hainaud et al., 2006). The fact that Gpcs act as trans 
activator partners establishes new strategies for crosstalk between adjacent cells during 
tissue assembly and maintenance.  
In conclusion, a common theme throughout all studies is that HS chains are responsible for 
different aspects of Gpc biology. By means of HS chains Gpcs sequester secreted soluble 
ligands and modulates their activity. As co-receptors and trans co-receptor, Gpcs modulate 
ligand-receptor encounters that can activate and inhibit cell proliferation, motility, and 
differentiation. Also HS side chains are not uniform and changes in the distribution of 
sulphate groups may affect ligand-binding properties and biological outcomes in a cell type-
specific manner. 
 
Congenital Anomalies  Case Studies and Mechanisms 
 
28
3.2.2 The glypican core proteins 
The GPI anchor and the core protein are two additional structural motifs that impinge on 
functional versatility of Gpcs at different levels. Most insights have come from cell biological 
approaches undertaken to investigate how Gpcs affect Hh and Wg signalling and gradient 
formation.  
Concerning Wg, genetic analysis of Dally-like in the wing imaginal discs has highlighted a 
role for this Gpc in polarizing the Wg morphogenetic gradient. In the wing imaginal disc, 
Wg is secreted by a narrow strip of cells located at the dorsal–ventral boundary and 
spreads over a distance of up to 20 cell diameters. Wg first accumulates on the cell surface 
apical side in expressing cells to be then re-distributed to the basolateral membrane of 
receiving cells, where it is released in association with lipoprotein particles (Panakova et 
al., 2005; Strigini and Cohen, 2000). It has been proposed that polarizing Wg on the cell 
membrane allows the subsequent polarization of morphogen distribution within an 
epithelium, thus resulting in distinct tissue patterns (Marois et al., 2006). Therefore, one 
major question in the field is how Wg reaches the basolateral cell surface when it is 
secreted apically. Gallet and colleagues have investigated the subcellular localization of 
Dally-like in this cellular system and shown that Dally-like, which is apically targeted by 
means of its GPI anchor, undergoes internalization and redistribution to the basolateral 
membrane through a dynamin-dependent endocytosis (transcytosis; Fig. 3; Gallet et al., 
2008). Interestingly, Wg is no longer detected at the basolateral surface of cells away from 
the Wg source in mutant cells lacking Dally-like protein. Moreover, tethering Dally-like at 
the cell membrane (by replacing the GPI anchor with a trans-membrane domain) strongly 
stabilized Wg at the apical surface while decreasing the amount of Wg at the basolateral 
compartment (Gallet et al., 2008). Altogether, these findings support the view that Wg is 
secreted apically and it is then endocytosed with the help of Dally-like (Fig. 3). Once 
internalized, Dally-like targets Wg by transcytosis to the basolateral compartment, where it 
is stabilized and can then spread farther away in a polarized manner (Fig. 3); Gallet et al., 
2008). These findings also open the intriguing possibility that Dally-like-mediated 
basolateral polarization of Wg accounts for Wg activity in long-range signalling (Gallet et 
al., 2008). However, whether this mechanism underlies distinct Wg signalling activity 
remains a matter of debate (Williams et al.; Yan et al., 2009). 
In contrast to the Wg situation, GPI-mediated endocytosis of Gpcs appears directly implicated 
in modulating Hh signalling in a positive and negative manner. For example, Dally-like 
endocytosis from the cell surface catalyzes the internalization of Hh in flies. In this context, 
internalization of Hh occurs together with its receptor Patched (Fig. 4; Gallet et al., 2008). 
Removing Patched from the membrane alleviates the inhibition of the transmembrane protein 
Smoothened by Patched and enables Smoothened to activate Hh target genes (Fig. 4; Gallet  
et al., 2008). Complementary studies performed in mice have revealed that the mammalian 
Gpc-3, via its GPI-anchor, also mediates internalization of Shh (the vertebrate homolog of 
Hedgehog) and regulates its signalling, with however opposing outcomes. Indeed, through 
endocytosis Gpc-3 inhibits Shh activity rather than activating it as in flies (Fig. 4; Capurro et al., 
2008; Gallet et al., 2008). It has been proposed that Gpc-3 has high affinity for Shh and can, 
therefore, compete with Patched for Shh binding (Capurro et al., 2008). Upon binding, Gpc-3 
targets Shh to endocytic vesicles for degradation, thus leaving the unliganded Ptc at the cell 
surface, and free to inhibit Smoothened (Fig. 4; Capurro et al., 2008). This possibility is also 
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consistent with results showing that hyperactivation of Shh can in part explain the Simpson-
Golabi-Behmel overgrowth syndrome caused by loss-of-function mutations in Gpc-3, and with 
other experiments revealing an increased expression of Shh target genes in Gpc-3 deficient 
mice and mouse embryonic fibroblasts (Capurro et al., 2008). 
 
Fig. 3. The GPI anchor of Dally-like triggers Wg transcytosis. The GPI anchor of Dally-like is 
required for its apical targeting, subsequent internalization through dynamin-dependent 
endocytosis and relocalization to the basolateral compartment. It has been proposed that Wg 
is secreted apically and is then endocytosed with the help of Dally-like. Once internalized, 
Dally-like targets by transcytosis Wg to the basolateral compartment , where it is stabilized 
and can then spread farther away in a polarized manner (adapted from Dong Yan and 
Xinhua Lin 2008). 
Interestingly, the Gpc3 core protein (without HS chains) binds with high affinity to Shh in 
cultured cells independently of its HS chains, while it does not interact with Patched (Capurro 
et al., 2008). These findings raise the possibility that the Gpc core protein cooperate with the 
GPI motif to establish differences in Gpc binding properties of signalling molecules, which will 
in turn affect biological readout. Of note, Williams and colleagues found that the Dally-like 
core protein without HS chains substantially rescues lack of Hh signalling in Dally-like mutant 
embryos, demonstrating specific activity for this structural domain (Williams et al., 2010). 
Similarly, the core proteins of the mammalian Gpc-4 and -6, which are the closest relatives of 
Dally-like, allow full dose-dependent re-activation of Hh, in contrast to Gpc-2, -3 and -5 that 
have no activity (Williams et al., 2010). This configuration of sequence homology and 
functional conservation suggests that the two major Gpc subfamilies have evolved similar 
roles in Hh signalling control (see also above). Therefore, Gpc agonistic and antagonistic 
signalling activities should also be identifiable in the Gpc core protein.  
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Fig. 4. Opposing roles for Gpcs in Hh signalling. (A) In Drosophila wing discs, Dally-like 
promotes Hh signalling. The GPI anchor of Dally-like is required for its apical targeting and 
subsequent internalization through dynamin-dependent endocytosis. Dally-like endocytosis 
from the cell surface catalyzes the internalization of Hh in flies that occurs together with 
Patched (Ptc). Removing Ptc from the cell membrane alleviates the inhibition of the 
transmembrane protein Smoothened (Smo) by Patched and enables Smoothened to activate 
Hh target genes. (B) In mouse development, Gpc3 acts as an inhibitor of Hh signalling.  
The Gpc3 core binds Shh on the cell surface and compete with Patched for Shh binding. 
Upon binding, Gpc-3 targets Shh to endocytic vesicles for degradation, thus leaving the 
unliganded Ptc at the cell surface, and free to inhibit Smoothened (adapted from Dong Yan 
and Xinhua Lin 2008). 
To date, additional studies support the idea that the protein cores selectively impact on 
functions of distinct Gpcs. For example, as opposed to the positive role of Dally in Wg 
signalling (Lin and Perrimon, 1999), Dally-like shows biphasic activities: as repressor for Wg 
short-range signalling and as activator for long-range responsiveness. It has been proposed 
that the Dally-like core protein has high binding affinity for Wg (Yan et al., 2009), a property 
that allows Dally-like to bind and retain Wingless on the cell surface. Interestingly, ectopic 
expression of Dally-like inhibits activation of Wg targets. In contrast, increasing the 
expression of the Wg receptor Frizzled leads to their activation (Yan et al., 2009). These and 
other results suggest that the physiological role of Wg is linked to the cellular ratio between 
Dally-like and Frizzled (Yan et al., 2009). In other words, Dally-like binds and retains 
Wingless on the cell surface away from its receptor Frizzled. However, Dally-like can also 
facilitate Wg binding to Frizzled depending on the ratio of ligand, receptor and Dally-like. 
Although intriguing, these results arise additional question that need to be answered. For 
example, how different is the affinity of Dally and Dally-like core proteins for Wg? Do 
Dally-like related mammalian Gpcs show dual roles in Wg modulation? Is there any specific 
protein domain required for Wg binding? Concerning the latter question, it has been proposed 
that Wg binding could occur via the N-terminal domain of Dally-like (Yan et al., 2009). 
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Moreover, structural analysis combined with structure-guided mutagenesis also suggests that 
this domain could guide Dally-like/Shh interaction (Kim et al., 2011). Further studies will 
address whether and in which manner the N-terminal domain impacts Gpc activity. 
In conclusion, the studies above discussed begin to unravel how Gpcs fulfil diverse 
functions in signalling pathways during development. In particular, they highlight the 
importance of GPI-mediated Gpc endocytosis in participating at the control of Wingless 
intracellular trafficking and possibly gradient formation, and in the modulation of Hh 
signalling in different biological context. Other important findings are the demonstration 
that Gpcs core proteins show binding affinity for certain signals independent of HS-side 
chains, and that they can modulate events as opposed as signal activation and inhibition. 
Thus, core proteins of Gpcs appear to ensure on its own an additional degree of signal 
modulation that increases specificity of biological readouts. 
4. Glypicans in human diseases 
Genome-wide linkage scan and mutation analysis have revealed that alteration in GPC 
functions can underlie human congenital malformation compromising developmental 
events such as bone growth and heart pattern formation. This discovery has permitted a 
better comprehension of pathophysiology of these disorders, their diagnosis and 
management. The generation of animal models has significantly broadened the 
understanding of these distinct developmental processes and their molecular bases.  
4.1 The Simpson-Golabi-Behmel Syndrome 
The Simpson-Golabi-Behmel Syndrome is an X-linked overgrowth disorder characterized by 
pre- and postnatal overgrowth, minor facial anomalies, skeletal defects, polydactyly and 
fingernail hypoplasia, small bulge in the small intestine, umbilical or inguinal hernia, 
genitourinary abnormalities, heart defects, supernumerary nipples and an increased risk of 
neonatal death (Gurrieri et al. , 2011). In patients there is also an increased risk of embryonal 
tumour development, mainly Wilms’ tumour. Mental retardation is not constantly found 
and is usually mild (Gurrieri et al. , 2011).  
Pilia and colleagues uncovered the genetic bases of this disorder in 1996 with the 
demonstration that mutations in the Gpc-3 gene are responsible for a large proportion of 
Simpson-Golabi-Behmel Syndrome cases. Since then, different Gpc-3 mutations have been 
identified in patients and these were found to be rather heterogeneous ranging from large 
chromosomal rearrangements to micro deletions and point mutations in different exons 
(Gurrieri et al. , 2011; Hughes-Benzie et al., 1996; Pilia et al., 1996; Sakazume et al., 2007; 
Xuan et al., 1999). Sequence analysis of mutated loci, led to the proposal that Simpson-
Golabi-Behmel Syndrome is caused by a non-functional GPC-3 protein while additional 
unknown genetic factors were possibly responsible for the phenotypic variations among 
patients. The role of GPC-3 in this disorder was then confirmed by the generation of Gpc-3-
deficient mice, since these mice recapitulate several phenotypes of the Simpson-Golabi-
Behmel Syndrome patients including developmental outgrowth and dysplastic kidneys 
(Cano-Gauci et al., 1999; Paine-Saunders et al., 2000). Moreover, recent findings showing 
that GPC3 polymorphisms have a significant impact in the body size of mice have provided 
additional support for a role of GPC3 in the regulation of body size (Oliver et al., 2005).  
 




Fig. 4. Opposing roles for Gpcs in Hh signalling. (A) In Drosophila wing discs, Dally-like 
promotes Hh signalling. The GPI anchor of Dally-like is required for its apical targeting and 
subsequent internalization through dynamin-dependent endocytosis. Dally-like endocytosis 
from the cell surface catalyzes the internalization of Hh in flies that occurs together with 
Patched (Ptc). Removing Ptc from the cell membrane alleviates the inhibition of the 
transmembrane protein Smoothened (Smo) by Patched and enables Smoothened to activate 
Hh target genes. (B) In mouse development, Gpc3 acts as an inhibitor of Hh signalling.  
The Gpc3 core binds Shh on the cell surface and compete with Patched for Shh binding. 
Upon binding, Gpc-3 targets Shh to endocytic vesicles for degradation, thus leaving the 
unliganded Ptc at the cell surface, and free to inhibit Smoothened (adapted from Dong Yan 
and Xinhua Lin 2008). 
To date, additional studies support the idea that the protein cores selectively impact on 
functions of distinct Gpcs. For example, as opposed to the positive role of Dally in Wg 
signalling (Lin and Perrimon, 1999), Dally-like shows biphasic activities: as repressor for Wg 
short-range signalling and as activator for long-range responsiveness. It has been proposed 
that the Dally-like core protein has high binding affinity for Wg (Yan et al., 2009), a property 
that allows Dally-like to bind and retain Wingless on the cell surface. Interestingly, ectopic 
expression of Dally-like inhibits activation of Wg targets. In contrast, increasing the 
expression of the Wg receptor Frizzled leads to their activation (Yan et al., 2009). These and 
other results suggest that the physiological role of Wg is linked to the cellular ratio between 
Dally-like and Frizzled (Yan et al., 2009). In other words, Dally-like binds and retains 
Wingless on the cell surface away from its receptor Frizzled. However, Dally-like can also 
facilitate Wg binding to Frizzled depending on the ratio of ligand, receptor and Dally-like. 
Although intriguing, these results arise additional question that need to be answered. For 
example, how different is the affinity of Dally and Dally-like core proteins for Wg? Do 
Dally-like related mammalian Gpcs show dual roles in Wg modulation? Is there any specific 
protein domain required for Wg binding? Concerning the latter question, it has been proposed 
that Wg binding could occur via the N-terminal domain of Dally-like (Yan et al., 2009). 
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Moreover, structural analysis combined with structure-guided mutagenesis also suggests that 
this domain could guide Dally-like/Shh interaction (Kim et al., 2011). Further studies will 
address whether and in which manner the N-terminal domain impacts Gpc activity. 
In conclusion, the studies above discussed begin to unravel how Gpcs fulfil diverse 
functions in signalling pathways during development. In particular, they highlight the 
importance of GPI-mediated Gpc endocytosis in participating at the control of Wingless 
intracellular trafficking and possibly gradient formation, and in the modulation of Hh 
signalling in different biological context. Other important findings are the demonstration 
that Gpcs core proteins show binding affinity for certain signals independent of HS-side 
chains, and that they can modulate events as opposed as signal activation and inhibition. 
Thus, core proteins of Gpcs appear to ensure on its own an additional degree of signal 
modulation that increases specificity of biological readouts. 
4. Glypicans in human diseases 
Genome-wide linkage scan and mutation analysis have revealed that alteration in GPC 
functions can underlie human congenital malformation compromising developmental 
events such as bone growth and heart pattern formation. This discovery has permitted a 
better comprehension of pathophysiology of these disorders, their diagnosis and 
management. The generation of animal models has significantly broadened the 
understanding of these distinct developmental processes and their molecular bases.  
4.1 The Simpson-Golabi-Behmel Syndrome 
The Simpson-Golabi-Behmel Syndrome is an X-linked overgrowth disorder characterized by 
pre- and postnatal overgrowth, minor facial anomalies, skeletal defects, polydactyly and 
fingernail hypoplasia, small bulge in the small intestine, umbilical or inguinal hernia, 
genitourinary abnormalities, heart defects, supernumerary nipples and an increased risk of 
neonatal death (Gurrieri et al. , 2011). In patients there is also an increased risk of embryonal 
tumour development, mainly Wilms’ tumour. Mental retardation is not constantly found 
and is usually mild (Gurrieri et al. , 2011).  
Pilia and colleagues uncovered the genetic bases of this disorder in 1996 with the 
demonstration that mutations in the Gpc-3 gene are responsible for a large proportion of 
Simpson-Golabi-Behmel Syndrome cases. Since then, different Gpc-3 mutations have been 
identified in patients and these were found to be rather heterogeneous ranging from large 
chromosomal rearrangements to micro deletions and point mutations in different exons 
(Gurrieri et al. , 2011; Hughes-Benzie et al., 1996; Pilia et al., 1996; Sakazume et al., 2007; 
Xuan et al., 1999). Sequence analysis of mutated loci, led to the proposal that Simpson-
Golabi-Behmel Syndrome is caused by a non-functional GPC-3 protein while additional 
unknown genetic factors were possibly responsible for the phenotypic variations among 
patients. The role of GPC-3 in this disorder was then confirmed by the generation of Gpc-3-
deficient mice, since these mice recapitulate several phenotypes of the Simpson-Golabi-
Behmel Syndrome patients including developmental outgrowth and dysplastic kidneys 
(Cano-Gauci et al., 1999; Paine-Saunders et al., 2000). Moreover, recent findings showing 
that GPC3 polymorphisms have a significant impact in the body size of mice have provided 
additional support for a role of GPC3 in the regulation of body size (Oliver et al., 2005).  
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At a cellular level the tissue overgrowth syndrome of Gpc-3-deficient mice appears to be a 
consequence of an increased proliferation rate, which is consistent with the possibility that 
Gpc-3 acts as a negative regulator of cell proliferation in the mouse embryo (Hartwig et al., 
2005). However, Gpc-3 can also induce apoptosis in a cell-type specific manner suggesting 
that enhanced cell survival may also contribute to the overgrowth defects (Filmus, 2001), 
Interestingly, Simpson-Golabi-Behmel Syndrome patients develop embryonal tumours (see 
above). Moreover, Gpc-3 expression is markedly decreased in human gastric cancer. 
Therefore, it is likely that in humans Gpc-3 functions also as a tumour suppressor gene 
(Gonzalez et al., 1998).  
One of the current major challenges is to identify the GPC-3 targets relevant for the 
pathogenesis of this complex disease. It has been proposed that GPC-3 inhibits embryonic 
growth by negatively regulating Insulin-like growth factor-II (Pilia et al., 1996). However, 
studies in cultured cells have failed to detect any biochemical or genetic interaction between 
Gpc-3 and the Insulin-like growth factor-II signalling pathway (Cano-Gauci et al., 1999; 
Chiao et al., 2002; Song et al., 2005). Capurro and colleagues explored the possibility that 
Gpc-3 acts as a negative regulator of body size by inhibiting two mammalian Hh proteins: 
Shh and Indian Hh (see also above; Capurro et al., 2008; Capurro et al., 2009). The rational 
behind this approach is linked to findings revealing that 1) these two Hh family members 
are both present in the developing embryo, with Shh more widely expressed and Indian Hh 
restricted to the developing bones; 2) hyperactivation of the Hh signalling pathway in mice 
causes overgrowth phenotypes (Makino et al., 2001; Milenkovic et al., 1999); 3) in humans, 
Patched mutations are linked to Gorlin’s Syndrome, a disorder causing multiple 
basocellular carcinomas accompanied by large head size, longer-larger bones, and 
polydactyly (Hahn et al., 1996). As discussed above, secreted Hh proteins binds and 
antagonizes the function of the Patched receptor known to block the activity of the 
signalling effector Smoothened. Binding of Hhs to Patched thus results in the activation of 
Smoothened, which in turn transduces the Hh signal intracellularly leading to the activation 
of Hh target genes such as Gli and Patched (Hooper and Scott, 2005). In a first study, 
Capurro and colleagues compared the degree of activation of the Hh signalling pathway in 
gpc-3 null mouse embryos and culture cells as well as potential Gpc-3/Shh protein 
interaction (Capurro et al., 2008). Results showed that the levels of Shh protein and of its 
targets increases in structures affected by Simpson-Golabi-Behmel Syndrome (e.g. gut and 
digits). As discussed above, they also uncovered that Gpc-3 can bind Shh and activate its 
signalling pathway, and acts as a competitive inhibitor of the Shh-Patched interaction, and 
triggers Shh endocytosis and degradation (Capurro et al., 2008). Therefore, a reasonable 
picture that can be drawn from these studies is that Gpc-3 normally restrains Hh signalling 
to control body size. Lack of Gpc-3 leads to the hyperactivation of this pathway causing the 
overgrowth phenotype of the Simpson-Golabi-Behmel Syndrome patients (Capurro et al., 
2008). 
To provide further genetic evidence that the Hh signalling pathway mediates, at least in 
part, the regulatory activity of Gpc-3 on embryonic growth, Capurro and colleagues 
performed a second study where they attempted to rescue the overgrowth phenotype of 
Gpc-3 deficient embryos by crossing them with mice carrying an Indian Hh null allele 
(Capurro et al., 2009). Indian Hh was chosen because its activity is more confined to 
endochondral skeleton. Indeed, Indian Hh deficient mice show a severe growth deficiency 
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in the endochondral skeleton as a result of a reduced chondrocyte proliferation and 
maturation, as well as osteoblast formation (St-Jacques et al., 1999). In contrast, Viviano and 
colleagues reported an abnormal persistence of hypertrophic chondrocytes in Gpc-3-
deficient embryonic bones and a delay in endochondral ossification (Viviano et al., 2005). As 
for Shh, Gpc-3 deficient mice show more Indian Hh and Patched protein levels in the 
developing long bones (Capurro et al., 2009). Moreover the overgrowth syndrome of Gpc-3 
deficient mice is partially rescued in the Indian Hh null background (Capurro et al., 2009). 
Therefore, the author proposed that the accumulation of Indian Hh as a result of the lack of 
Gpc-3 might be the cause of an unbalance rate of chondrocyte proliferation versus 
differentiation, which ultimately causes the longer bone overgrowth found in mutant mice 
(Capurro et al., 2009; Viviano et al., 2005). Although further investigations will elucidate 
how lack of Gpc-3 affects development at the cellular level, these genetic studies provide 
important clues on the molecular basis of Simpson-Golabi-Behmel Syndrome in humans by 
beginning to unravel the aberrant signalling mechanisms. Moreover, they have also told us 
that more broad approaches such as tissue micro-arrays need to be taken into account to 
understand this complex disorder. In this context, the gpc-3-deficient mouse model will be 
instrumental to identify and evaluate the involvement of other signalling pathways as well 
as to determine whether Gpc-3 has tissue specific effects in this disease. Of note, there are 
the studies on the gpc-3-deficient mice indicating that an impairment of the Fgf/Shh 
signalling axis in the embryonic hearts could underlie the congenital cardiac malformations 
in Simpson-Golabi-Behmel syndrome (St-Jacques et al., 1999) while the renal dysplasia 
could be linked to an inbalance of stimulatory and inhibitory signals (e.g. Fgf-7 and Bmp-2 
respectively) during tissue morphogenesis (Grisaru et al., 2001).  
Further help in understanding the involvement of Gpc-3 in this human disorder could come 
from attempts to define structural-functional relationships associated with specific Gpc-3 
mutations in humans. Interestingly, one Simpson-Golabi-Behmel Syndrome patient has a 
deletion affecting both Gpc-3 and Gpc-4, which is found immediately centromeric to Gpc-3 at 
Xq26 (Veugelers et al., 1998). Recently, a wide screening has identified patients carrying 
mutations in the Gpc-4 but not in the Gpc-3 gene (Waterson et al., 2010). We anticipate that 
future research will extensively evaluate whether connections between GPC-4 functions and 
the clinical features of this syndrome exist.  
4.2 Autosomal-recessive omodysplasia 
Autosomal recessive omodysplasia is a genetic condition characterized by skeletal and 
craniofacial defects (Maroteaux et al., 1989). Skeletal abnormalities include shortening and 
distal tapering of the humerus and femur, proximal radioulnar diastasis, and anterolateral 
radial head dislocation. In patients with autosomal recessive omodysplasia both upper and 
lower limbs are affected in contrast to the dominant form of the disorder in which the lower 
limbs are normal. Facial defects comprise frontal bossing, a flat nasal bridge, low set ears, a 
long philtrum, anteverted nostrils, and frontal capillary hemangiomas. Variable findings are 
hernias, congenital heart defects, mental retardation and delayed motor development. Being 
recessive, autosomal recessive omodysplasia is a rare disorder with an incidence of <1 / 
1000000 and, to date, around 22 cases of recessive omodysplasia have been described. 
Recent advances in understanding its pathophysiology have come from Campos-Xavier and 
collaborators reporting that the autosomal-recessive omodysplasia maps to chromosome 13 
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At a cellular level the tissue overgrowth syndrome of Gpc-3-deficient mice appears to be a 
consequence of an increased proliferation rate, which is consistent with the possibility that 
Gpc-3 acts as a negative regulator of cell proliferation in the mouse embryo (Hartwig et al., 
2005). However, Gpc-3 can also induce apoptosis in a cell-type specific manner suggesting 
that enhanced cell survival may also contribute to the overgrowth defects (Filmus, 2001), 
Interestingly, Simpson-Golabi-Behmel Syndrome patients develop embryonal tumours (see 
above). Moreover, Gpc-3 expression is markedly decreased in human gastric cancer. 
Therefore, it is likely that in humans Gpc-3 functions also as a tumour suppressor gene 
(Gonzalez et al., 1998).  
One of the current major challenges is to identify the GPC-3 targets relevant for the 
pathogenesis of this complex disease. It has been proposed that GPC-3 inhibits embryonic 
growth by negatively regulating Insulin-like growth factor-II (Pilia et al., 1996). However, 
studies in cultured cells have failed to detect any biochemical or genetic interaction between 
Gpc-3 and the Insulin-like growth factor-II signalling pathway (Cano-Gauci et al., 1999; 
Chiao et al., 2002; Song et al., 2005). Capurro and colleagues explored the possibility that 
Gpc-3 acts as a negative regulator of body size by inhibiting two mammalian Hh proteins: 
Shh and Indian Hh (see also above; Capurro et al., 2008; Capurro et al., 2009). The rational 
behind this approach is linked to findings revealing that 1) these two Hh family members 
are both present in the developing embryo, with Shh more widely expressed and Indian Hh 
restricted to the developing bones; 2) hyperactivation of the Hh signalling pathway in mice 
causes overgrowth phenotypes (Makino et al., 2001; Milenkovic et al., 1999); 3) in humans, 
Patched mutations are linked to Gorlin’s Syndrome, a disorder causing multiple 
basocellular carcinomas accompanied by large head size, longer-larger bones, and 
polydactyly (Hahn et al., 1996). As discussed above, secreted Hh proteins binds and 
antagonizes the function of the Patched receptor known to block the activity of the 
signalling effector Smoothened. Binding of Hhs to Patched thus results in the activation of 
Smoothened, which in turn transduces the Hh signal intracellularly leading to the activation 
of Hh target genes such as Gli and Patched (Hooper and Scott, 2005). In a first study, 
Capurro and colleagues compared the degree of activation of the Hh signalling pathway in 
gpc-3 null mouse embryos and culture cells as well as potential Gpc-3/Shh protein 
interaction (Capurro et al., 2008). Results showed that the levels of Shh protein and of its 
targets increases in structures affected by Simpson-Golabi-Behmel Syndrome (e.g. gut and 
digits). As discussed above, they also uncovered that Gpc-3 can bind Shh and activate its 
signalling pathway, and acts as a competitive inhibitor of the Shh-Patched interaction, and 
triggers Shh endocytosis and degradation (Capurro et al., 2008). Therefore, a reasonable 
picture that can be drawn from these studies is that Gpc-3 normally restrains Hh signalling 
to control body size. Lack of Gpc-3 leads to the hyperactivation of this pathway causing the 
overgrowth phenotype of the Simpson-Golabi-Behmel Syndrome patients (Capurro et al., 
2008). 
To provide further genetic evidence that the Hh signalling pathway mediates, at least in 
part, the regulatory activity of Gpc-3 on embryonic growth, Capurro and colleagues 
performed a second study where they attempted to rescue the overgrowth phenotype of 
Gpc-3 deficient embryos by crossing them with mice carrying an Indian Hh null allele 
(Capurro et al., 2009). Indian Hh was chosen because its activity is more confined to 
endochondral skeleton. Indeed, Indian Hh deficient mice show a severe growth deficiency 
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in the endochondral skeleton as a result of a reduced chondrocyte proliferation and 
maturation, as well as osteoblast formation (St-Jacques et al., 1999). In contrast, Viviano and 
colleagues reported an abnormal persistence of hypertrophic chondrocytes in Gpc-3-
deficient embryonic bones and a delay in endochondral ossification (Viviano et al., 2005). As 
for Shh, Gpc-3 deficient mice show more Indian Hh and Patched protein levels in the 
developing long bones (Capurro et al., 2009). Moreover the overgrowth syndrome of Gpc-3 
deficient mice is partially rescued in the Indian Hh null background (Capurro et al., 2009). 
Therefore, the author proposed that the accumulation of Indian Hh as a result of the lack of 
Gpc-3 might be the cause of an unbalance rate of chondrocyte proliferation versus 
differentiation, which ultimately causes the longer bone overgrowth found in mutant mice 
(Capurro et al., 2009; Viviano et al., 2005). Although further investigations will elucidate 
how lack of Gpc-3 affects development at the cellular level, these genetic studies provide 
important clues on the molecular basis of Simpson-Golabi-Behmel Syndrome in humans by 
beginning to unravel the aberrant signalling mechanisms. Moreover, they have also told us 
that more broad approaches such as tissue micro-arrays need to be taken into account to 
understand this complex disorder. In this context, the gpc-3-deficient mouse model will be 
instrumental to identify and evaluate the involvement of other signalling pathways as well 
as to determine whether Gpc-3 has tissue specific effects in this disease. Of note, there are 
the studies on the gpc-3-deficient mice indicating that an impairment of the Fgf/Shh 
signalling axis in the embryonic hearts could underlie the congenital cardiac malformations 
in Simpson-Golabi-Behmel syndrome (St-Jacques et al., 1999) while the renal dysplasia 
could be linked to an inbalance of stimulatory and inhibitory signals (e.g. Fgf-7 and Bmp-2 
respectively) during tissue morphogenesis (Grisaru et al., 2001).  
Further help in understanding the involvement of Gpc-3 in this human disorder could come 
from attempts to define structural-functional relationships associated with specific Gpc-3 
mutations in humans. Interestingly, one Simpson-Golabi-Behmel Syndrome patient has a 
deletion affecting both Gpc-3 and Gpc-4, which is found immediately centromeric to Gpc-3 at 
Xq26 (Veugelers et al., 1998). Recently, a wide screening has identified patients carrying 
mutations in the Gpc-4 but not in the Gpc-3 gene (Waterson et al., 2010). We anticipate that 
future research will extensively evaluate whether connections between GPC-4 functions and 
the clinical features of this syndrome exist.  
4.2 Autosomal-recessive omodysplasia 
Autosomal recessive omodysplasia is a genetic condition characterized by skeletal and 
craniofacial defects (Maroteaux et al., 1989). Skeletal abnormalities include shortening and 
distal tapering of the humerus and femur, proximal radioulnar diastasis, and anterolateral 
radial head dislocation. In patients with autosomal recessive omodysplasia both upper and 
lower limbs are affected in contrast to the dominant form of the disorder in which the lower 
limbs are normal. Facial defects comprise frontal bossing, a flat nasal bridge, low set ears, a 
long philtrum, anteverted nostrils, and frontal capillary hemangiomas. Variable findings are 
hernias, congenital heart defects, mental retardation and delayed motor development. Being 
recessive, autosomal recessive omodysplasia is a rare disorder with an incidence of <1 / 
1000000 and, to date, around 22 cases of recessive omodysplasia have been described. 
Recent advances in understanding its pathophysiology have come from Campos-Xavier and 
collaborators reporting that the autosomal-recessive omodysplasia maps to chromosome 13 
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(13q31.1-q32.2; (Campos-Xavier et al., 2009). By performing fine analysis of candidate genes, 
Campos-Xavier and collaborators have further linked autosomal recessive omodysplasia to 
point mutations or to larger genomic rearrangements in the Gpc-6 gene (Campos-Xavier et 
al., 2009).  
All mutations found in the individuals affected by omodysplasia predict absence of a 
functional protein. Hypothetical mutant proteins would be truncated and thereby lose both 
the GPI and the HS-binding sites, essential for the putative GPC-6 functions (Campos-Xavier 
et al., 2009). Similarly to Gpc-3, Gpc-6 mutations are also found in the entire coding region 
without any mutational hotspot and include one or more exons. Recently, Gpc-5 
haploinsufficiency has been proposed as the molecular cause of upper limb anomalies and 
growth retardation in 13q deletion syndrome because of its expression in the developing 
limb (Quelin et al., 2009). Gpc-5 colocalises with Gpc-6 on 13q31.2–q31.3, and the two genes 
are clustered, similarly to Gpc-3 and Gpc-4 on chromosome X, suggesting that these 
members of the Gpc family share an evolutionary link (see also above; Filmus, 2001) that 
might reflect a common function (De Cat and David, 2001; Paine-Saunders et al., 2002; see 
also above). However, because GPC-5 does not compensate for loss of GPC-6 in 
omodysplasia patients, their functional relationship is not supported. 
Axial bone growth occurs through growth plates in which chondrocytes undergo 
proliferation, hypertrophy, cell death, and osteoblastic replacement (Ornitz and Marie, 
2002). The immature chondrocytes are rapidly proliferating cells characterized by a small 
size and irregular shape. In the hypertrophic cartilage zone, chondrocytes make matrix and 
enlarged lacunae. The pathological characteristics of the omodysplastic growth plates are an 
expanded zone of proliferating cartilage and an increased number of closely packed, small 
chondrocytes suggesting that omodysplasia is due to an impaired endochondral ossification 
(Borochowitz et al., 1998). During endochondral ossification, Gpc-6 is predominanlty 
expressed in the proliferative zone decreasing dramatically in the prehypertrophic and 
hypertrophic zones (Campos-Xavier et al., 2009). These expression data correlate with the 
morphologic findings in the human omodysplasia. They also correlate with the distribution 
of Indian Hh, Fgf, Bmp and Wnt proteins, which are known to regulate endochondral 
ossification (Ornitz and Marie, 2002) and to have the potential of functionally interacting 
with Gpc-6. Moreover, the etiology of many other human skeletal dysplasias with defects in 
endochondral ossification has been attributed to specific mutations in the gene encoding 
FGF receptor 3 (Ornitz and Marie, 2002). The international mouse strain resource (IMSR ; 
http://www.findmice.org/) has recently generated different mouse strains carrying loss of 
function mutations in the gpc-6 gene but to our knowledge, no studies have been yet 
reported. The functional analysis of gpc-6 mutant mice will be crucial to establish the 
involvement of Gpc-6 functions in this disorder and to uncover the cellular and molecular 
basis of all associated clinical features.  
5. Conclusion and future direction 
Research over the past years has advanced our understanding of Gpc functions during 
mammalian development and the list of human syndromes associated with their aberrant 
function is likely to grow. Indeed, recent studies have described Gpc-5 and Gpc-6 as 
candidate genes for postaxial polydactyly type A, an inherited human condition causing 
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digit duplications (van der Zwaag et al. , 2010). Gpc genes have also been linked to other 
less defined human diseases, such bipolar disorder and Sudden Cardiac Arrest (Arking et 
al. 2011; Maheshwari et al., 2002) and further studies will clarify their involvement. We and 
others have shown that Gpcs are among the most abundant HSPGs in the developing 
nervous system and are expressed in embryonic and adult neural stem cells (Bandtlow and 
Zimmermann, 2000; Hagihara et al., 2000; Luxardi et al., 2007). Our embryological 
manipulations in Xenopus embryos have begun to provide insight into their role in brain size 
as abrogation of Gpc4 activity in Xenopus embryos disrupts forebrain patterning and cell 
survival, and causes microcephaly (see also above and Ficure 2; Galli et al., 2003). Therefore, 
our findings raise the possibility that some of the congenital microcephalies may arise as a 
consequence of disrupting Glpc-4 gene function during brain development.  
As discussed above, Gpc genes are inclined to cluster on the same chromosome. Simpson-
Golabi-Behmel patients can carry deletions that affect not only the Gpc-3 but also the Gpc-4 
gene. In mouse, gpc-3 shows distinct expression patterns compared to gpc-4 and the latter is 
highly expressed in the developing brain and kidney (Luxardi et al., 2007). Therefore, it is 
possible that mutation in the Gpc-4 gene also contribute to aspects of the Simpson-Golabi-
Behmel syndrome. Further studies will require the analysis of gpc compound mutant 
embryos and mice as they could recapitulates additional clinical features of this syndrome.  
A second major area of research will concern the identification of the pathological signalling 
events underlying the clinical features of disorders associated with abnormal GPC 
functions. When analysing pathologies involving GPC, it is important to take into account 
that these diseases might be also linked to GPC gain-of-functions rather then loss-of-
functions. The gene targeting approach in mice has begun to clarify this issue. As described 
above, Gpcs control different signalling proteins in a cell-type and developmental-stage 
specific manner. Therefore, further studies will require tissue- and stage-specific loss-of-
function mutations of gpc genes. We think that a better understanding of Gpc involvement 
in normal and pathological processes, as well as the identification of the associated signals 
can hopefully provide a wider clinical spectrum for the development of targeted therapies. 
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point mutations or to larger genomic rearrangements in the Gpc-6 gene (Campos-Xavier et 
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All mutations found in the individuals affected by omodysplasia predict absence of a 
functional protein. Hypothetical mutant proteins would be truncated and thereby lose both 
the GPI and the HS-binding sites, essential for the putative GPC-6 functions (Campos-Xavier 
et al., 2009). Similarly to Gpc-3, Gpc-6 mutations are also found in the entire coding region 
without any mutational hotspot and include one or more exons. Recently, Gpc-5 
haploinsufficiency has been proposed as the molecular cause of upper limb anomalies and 
growth retardation in 13q deletion syndrome because of its expression in the developing 
limb (Quelin et al., 2009). Gpc-5 colocalises with Gpc-6 on 13q31.2–q31.3, and the two genes 
are clustered, similarly to Gpc-3 and Gpc-4 on chromosome X, suggesting that these 
members of the Gpc family share an evolutionary link (see also above; Filmus, 2001) that 
might reflect a common function (De Cat and David, 2001; Paine-Saunders et al., 2002; see 
also above). However, because GPC-5 does not compensate for loss of GPC-6 in 
omodysplasia patients, their functional relationship is not supported. 
Axial bone growth occurs through growth plates in which chondrocytes undergo 
proliferation, hypertrophy, cell death, and osteoblastic replacement (Ornitz and Marie, 
2002). The immature chondrocytes are rapidly proliferating cells characterized by a small 
size and irregular shape. In the hypertrophic cartilage zone, chondrocytes make matrix and 
enlarged lacunae. The pathological characteristics of the omodysplastic growth plates are an 
expanded zone of proliferating cartilage and an increased number of closely packed, small 
chondrocytes suggesting that omodysplasia is due to an impaired endochondral ossification 
(Borochowitz et al., 1998). During endochondral ossification, Gpc-6 is predominanlty 
expressed in the proliferative zone decreasing dramatically in the prehypertrophic and 
hypertrophic zones (Campos-Xavier et al., 2009). These expression data correlate with the 
morphologic findings in the human omodysplasia. They also correlate with the distribution 
of Indian Hh, Fgf, Bmp and Wnt proteins, which are known to regulate endochondral 
ossification (Ornitz and Marie, 2002) and to have the potential of functionally interacting 
with Gpc-6. Moreover, the etiology of many other human skeletal dysplasias with defects in 
endochondral ossification has been attributed to specific mutations in the gene encoding 
FGF receptor 3 (Ornitz and Marie, 2002). The international mouse strain resource (IMSR ; 
http://www.findmice.org/) has recently generated different mouse strains carrying loss of 
function mutations in the gpc-6 gene but to our knowledge, no studies have been yet 
reported. The functional analysis of gpc-6 mutant mice will be crucial to establish the 
involvement of Gpc-6 functions in this disorder and to uncover the cellular and molecular 
basis of all associated clinical features.  
5. Conclusion and future direction 
Research over the past years has advanced our understanding of Gpc functions during 
mammalian development and the list of human syndromes associated with their aberrant 
function is likely to grow. Indeed, recent studies have described Gpc-5 and Gpc-6 as 
candidate genes for postaxial polydactyly type A, an inherited human condition causing 
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digit duplications (van der Zwaag et al. , 2010). Gpc genes have also been linked to other 
less defined human diseases, such bipolar disorder and Sudden Cardiac Arrest (Arking et 
al. 2011; Maheshwari et al., 2002) and further studies will clarify their involvement. We and 
others have shown that Gpcs are among the most abundant HSPGs in the developing 
nervous system and are expressed in embryonic and adult neural stem cells (Bandtlow and 
Zimmermann, 2000; Hagihara et al., 2000; Luxardi et al., 2007). Our embryological 
manipulations in Xenopus embryos have begun to provide insight into their role in brain size 
as abrogation of Gpc4 activity in Xenopus embryos disrupts forebrain patterning and cell 
survival, and causes microcephaly (see also above and Ficure 2; Galli et al., 2003). Therefore, 
our findings raise the possibility that some of the congenital microcephalies may arise as a 
consequence of disrupting Glpc-4 gene function during brain development.  
As discussed above, Gpc genes are inclined to cluster on the same chromosome. Simpson-
Golabi-Behmel patients can carry deletions that affect not only the Gpc-3 but also the Gpc-4 
gene. In mouse, gpc-3 shows distinct expression patterns compared to gpc-4 and the latter is 
highly expressed in the developing brain and kidney (Luxardi et al., 2007). Therefore, it is 
possible that mutation in the Gpc-4 gene also contribute to aspects of the Simpson-Golabi-
Behmel syndrome. Further studies will require the analysis of gpc compound mutant 
embryos and mice as they could recapitulates additional clinical features of this syndrome.  
A second major area of research will concern the identification of the pathological signalling 
events underlying the clinical features of disorders associated with abnormal GPC 
functions. When analysing pathologies involving GPC, it is important to take into account 
that these diseases might be also linked to GPC gain-of-functions rather then loss-of-
functions. The gene targeting approach in mice has begun to clarify this issue. As described 
above, Gpcs control different signalling proteins in a cell-type and developmental-stage 
specific manner. Therefore, further studies will require tissue- and stage-specific loss-of-
function mutations of gpc genes. We think that a better understanding of Gpc involvement 
in normal and pathological processes, as well as the identification of the associated signals 
can hopefully provide a wider clinical spectrum for the development of targeted therapies. 
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1. Introduction 
A detailed understanding of vascular anatomy and embryology is essential to facilitate 
appropriate decision-making by clinicians responsible for treating vascular malformations 
of the central nervous system. The development of the cerebral vasculature has been 
extensively described in the original works of Streeter [1, 2] and Padgett [3-5], and 
summarized by Davidson and Morgan [6]. 
1.1 Development of the cerebral arterial system 
With the growth of the developing embryonic brain, increasing requirements for oxygen 
and metabolic substrates demand a more comprehensive and complex vascular system. 
Covering the entire neuraxis is a primitive network of mesenchymal cells known as the 
meninx primitiva. The meninx follows the folds that appear during development of the 
brain, filling the interhemispheric fissure that forms between the two lateral telencephalic 
bulges to ultimately become the falx cerebri. At this early stage (embryo < 4 mm length), 
there is no differentiation into arteries and veins; the irregular network of endothelial 
vascular channels constitutes a primitive germinal bed of endothelium rather than a true 
circulatory system. The meninx primitiva differentiates into three discreet layers, which will 
ultimately become the dura mater, the arachnoid, and the pia mater [7]. Ultimately, 
angioblastic cells from the meninx become applied to the superficial surface of the 
developing brain, then penetrate the surface and extend perpendicularly to the pial surface 
between the glial elements, forming an extensive capillary-like network of endothelial cells 
(endothelial “buds”) [2, 7-9]. 
Vascular buds ultimately coalesce into larger vascular channels, with afferent channels 
forming arteries and efferent channels forming veins. On the pial surface of the brain, 
arterial vessels rise above those that become venous, and where these vessel cross, the artery 
crosses the vein at approximately right angles. Islands of endothelial cells proliferating 
within the outer layer of the meninx will eventually coalesce to form the dural venous 
sinuses; those within the middle layer will develop into the major veins that link the cortex 
to the dural venous sinuses, and the vessels that ultimately supply and drain the brain 
parenchyma develop from the inner layer [2]. 
 
Congenital Anomalies  Case Studies and Mechanisms 
 
42
Yan, D., Wu, Y., Feng, Y., Lin, S.C. and Lin, X. (2009) The core protein of glypican Dally-like 
determines its biphasic activity in wingless morphogen signaling. Dev Cell, 17, 470-
481. 
3 
Central Nervous System  
Vascular Malformations 
Andrew S. Davidson and Marcus A. Stoodley 
Neurosurgery Unit, Australian School of Advanced Medicine, 
Macquarie University, Sydney,  
Australia 
1. Introduction 
A detailed understanding of vascular anatomy and embryology is essential to facilitate 
appropriate decision-making by clinicians responsible for treating vascular malformations 
of the central nervous system. The development of the cerebral vasculature has been 
extensively described in the original works of Streeter [1, 2] and Padgett [3-5], and 
summarized by Davidson and Morgan [6]. 
1.1 Development of the cerebral arterial system 
With the growth of the developing embryonic brain, increasing requirements for oxygen 
and metabolic substrates demand a more comprehensive and complex vascular system. 
Covering the entire neuraxis is a primitive network of mesenchymal cells known as the 
meninx primitiva. The meninx follows the folds that appear during development of the 
brain, filling the interhemispheric fissure that forms between the two lateral telencephalic 
bulges to ultimately become the falx cerebri. At this early stage (embryo < 4 mm length), 
there is no differentiation into arteries and veins; the irregular network of endothelial 
vascular channels constitutes a primitive germinal bed of endothelium rather than a true 
circulatory system. The meninx primitiva differentiates into three discreet layers, which will 
ultimately become the dura mater, the arachnoid, and the pia mater [7]. Ultimately, 
angioblastic cells from the meninx become applied to the superficial surface of the 
developing brain, then penetrate the surface and extend perpendicularly to the pial surface 
between the glial elements, forming an extensive capillary-like network of endothelial cells 
(endothelial “buds”) [2, 7-9]. 
Vascular buds ultimately coalesce into larger vascular channels, with afferent channels 
forming arteries and efferent channels forming veins. On the pial surface of the brain, 
arterial vessels rise above those that become venous, and where these vessel cross, the artery 
crosses the vein at approximately right angles. Islands of endothelial cells proliferating 
within the outer layer of the meninx will eventually coalesce to form the dural venous 
sinuses; those within the middle layer will develop into the major veins that link the cortex 
to the dural venous sinuses, and the vessels that ultimately supply and drain the brain 
parenchyma develop from the inner layer [2]. 
 
Congenital Anomalies − Case Studies and Mechanisms 44
The primitive internal carotid artery (ICA) develops mainly from the third aortic arch 
(although minor contributions are made from the first and second arches as well). During 
the early stages of brain development, the ICA supplies most of the blood to the entire brain 
through several named branches including the trigeminal, hypoglossal, otic, and the 
proatlantal intersegmental arteries. These primitive branches are usually transient, although 
rarely they persist in adults.  
Next, two parallel collections of primitive arterial arcades appear along the lateral aspect of 
the rhombencephalon. These longitudinal neural arteries are supplied from the ICA via the 
trigeminal arteries, and from what will become the posterior circulation via the developing 
cervical intersegmental arteries. Ultimately, most of these vascular communications recede, 
with the fused portion of the longitudinal neural arteries forming the midline basilar artery, 
and the posterior communicating artery replacing the tentorial artery as the source of 
collateral supply between the anterior and posterior circulation. 
Later, the cervical intersegmental arteries develop into the paired vertebral arteries, and the 
anterior cerebral artery, anterior choroidal artery and middle cerebral artery arise from the 
ICA. An arterial plexus develops deep within the anterior interhemispheric fissure, which 
will later become the anterior communicating artery. Through a series of arterial 
anastomoses and regressions, the primitive dorsal and ventral ophthalmic arteries evolve 
into the adult form of the ophthalmic artery. Further evolution of the middle cerebral artery 
occurs, with hemispheric branches and choroidal arteries developing further, and the 
posterior cerebral artery arises from the ICA. 
Finally, the major components of the arterial Circle of Willis near completion, with the 
posterior cerebral artery taking up the majority of its supply from the posterior circulation, 
leaving the posterior communicating artery as an embryological remnant in the majority of 
cases. The development of the cerebellar arteries occurs later, corresponding to the delayed 
development of the cerebellum compared to the cerebrum. 
1.2 Development of the cerebral venous system 
At about the 4 mm stage of embryonic development, a primordial venous channel develops 
within the meninx primitiva, called the vena capitis medialis. This carries no flow, and 
merely represents proliferative endothelial cells. The vena capitis medialis quickly 
disappears, and in its place the vena capitis lateralis, or primitive head sinus, forms. The 
primitive head sinus develops into three separate dural venous plexuses – anterior 
(telencephalic, diencephalic, and mesencephalic), middle (metencephalic), and posterior 
(myelencephalic). The primitive maxillary vein joins the primitive head sinus as its only 
direct tributary, which drains the optic vesicle. 
In subsequent stages, the anterior, middle and posterior plexuses of the primitive head sinus 
unite to become the adult transverse and sigmoid sinuses [7]. The inferior portion of the 
primitive head sinus later migrates laterally to become the internal jugular vein, whilst the 
cranial portion of the sinus ultimately becomes the cavernous sinus.  
As the telencephalii develop and expand, expansion of the anterior dural venous plexus 
occurs, and it is the medial aspects of these expansions that fuse to form the primitive 
marginal sinus, which fuses with its contralateral counterpart to form the early superior 
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sagittal sinus. This is the dominant venous structure anteriorly, and with further 
development it progressively incorporates more posterior portions of the dural venous 
sinuses. 
With deepening of the interhemispheric fissure, and lateral evagination of the telencephalic-
diencephalic sulcus, the choroidal fissures form. The meninx primitiva, primitive choroid, 
and arterial supply are drawn into the fissure, which drains via the median prosencephalic 
vein [7]. With the development of the basal ganglia, primitive internal cerebral veins form 
and fuse in the midline to form the vein of Galen and straight sinus, replacing the median 
prosencephalic vein as the main venous drainage of the choroid plexus. The caudal remnant 
of the median prosencephalic vein becomes part of the vein of Galen complex. Persistence of 
the median prosencephalic vein is a common finding in vein of Galen malformations. The 
presence of a persistent falcine sinus (which normally regresses as the straight sinus 
develops) is also indicative of the arrested venous development that commonly occurs in the 
setting of a vein of Galen malformation [10]. 
As the developing cerebral and cerebellar hemispheres expand, the dorsal meninges at the 
junction of the prosencephalon and mesencephalon remain relatively fixed, forming the 
tentorial edge. The plexus of veins within the leaves of the tentorium and the tentorial sinus 
(located medially within the tentorium) persist until after birth [8]. The expanding cerebral 
hemispheres exert more of an influence on the orientation of the tentorium than the 
cerebellum, and the tentorium changes from its initial vertical orientation to a more 
horizontal alignment, causing the transverse sinus to alter its vertical alignment to a more 
horizontal direction. 
Development of emissary veins occurs during the latter stages of venous development. 
Elongation of the primary pial vein during development of the diencephalon and 
telencephalon produces the basal vein of Rosenthal, which secondarily becomes connected 
to the internal cerebral vein [7]. Elongation of the numerous subarachnoid veins that bridge 
from pia to dura during enlargement of the cerebral hemispheres results in the superficial 
anastomotic veins, including the vein of Trollard and the vein of Labbé. The middle cerebral 
vein assumes its adult form only after closure of the Sylvian fissure, and remains separate 
from the cavernous sinus until after birth [8]. The presence of arteriovenous malformations 
(AVMs) with venous drainage into the Sylvian veins and cavernous sinus suggests that 
these malformations develop post-natally. 
Although the arterial system is well formed by the end of the embryonic period, the venous 
system continues to evolve until late in fetal development, with some important changes to 
the developing venous system occurring after birth. 
2. Arteriovenous malformations 
2.1 Theories of pathogenesis 
AVMs have traditionally been considered congenital lesions, occurring as a result of 
disordered development of the primordial vasculature in a process described by Yaşargil as 
a ‘proliferative capillaropathy’ [11]. This hypothesis has become enshrined as neurosurgical 
doctrine, even in the absence of any strong evidence to support the theory.  
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As early as 1984, doubts had arisen regarding the congenital nature of AVMs. Warkany and 
Lemire recognized that AVMs “are generally considered congenital, although patients usually are 
adults 20 to 60 years of age and few have signs or symptoms that go back to early life”. They 
acknowledge that AVMs “are puzzling to teratologists because they occur sporadically and are 
unassociated with congenital malformations outside the central nervous system”, and point out “the 
unsatisfactory state of our understanding of these malformations … and recommend them to 
teratologists for further study” [12]. In his 1996 paper on the embryological basis of AVMs, 
Mullan noted that the “theories of origin are not susceptible to experimental proof and should be 
accepted or rejected on the basis of the available evidence” [8]. 
Conflicting evidence exists regarding the pathophysiology of brain AVMs, with reports of 
clinical cases supportive of both post-natal development and an embryologic origin [6]. A 
study examining the difference between birth-to-diagnosis and diagnosis-to-hemorrhage 
timelines in over 1500 cases suggested that a biological change occurs around 10 years from 
birth that influences hemorrhage rates in patients with AVMs. The authors concluded that 
the AVM either was not present before age 10 years, or was present but was biologically 
inactive prior to this stage [13]. 
As further research is undertaken exploring the molecular biology of AVMs, evidence is 
accumulating in support of the alternative hypothesis – that AVMs are an acquired 
abnormality, developing in the postnatal period. Although an initiating event has yet to be 
defined, possible candidates include trauma, tissue hypoxia, venous hypertension, infection, 
inflammation, irradiation, or compression [14, 15]. The primary vascular defect may be the 
development of a simple arteriovenous fistula [16], with altered hemodynamic stresses 
occurring in the affected vessels. Further pro-angiogenic vascular remodeling and 
secondary vascular changes would occur secondary to the hemodynamic stress, producing 
the characteristic AVM seen in clinical practice [17]. 
2.2 Genetics 
Relatively few cases of familial occurrence of AVM have been reported [18], and genome-
wide linkage studies in twins have failed to identify a genetic locus for inherited AVM [19]. 
Although familial cases can occur, AVMs typically occur in a sporadic fashion [20].  
One exception to this rule is the development of multiple AVMs in patients with hereditary 
hemorrhagic telangiectasia (HHT, or Rendu-Osler-Weber syndrome). HHT is an autosomal 
dominant disorder producing vascular malformations in multiple organs [21]. Small 
mucocutaneous telangiectasias typically occur in the oral cavity, nose, conjunctivae, and on 
the fingertips; AVMs occur in the lung (50% of HHT patients), liver (30%), brain (10%), and 
spine (1%) [22]. HHT patients represent a very small subset of patients with AVMs 
(approximately 2% of all AVM patients) [23, 24].  
HHT usually results from mutations in the Endoglin (HHT1) gene, or ACVRL1 (HHT2) 
gene; other less common subtypes include HHT in association with juvenile polyposis 
(JPHT), HHT3, and HHT4. All of the genes responsible for HHT are involved in the 
transforming growth factor (TGR-β) superfamily signaling pathway, and mutations result in 
the development of abnormal vascular structures [22]. 
The prevalence of AVMs in the population is approximately 0.01% [25]. The estimated 
prevalence of AVMs in the population of patients with HHT is approximately 5-10% [26], 
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although this may be an under-representation because of the controversy surrounding 
screening of asymptomatic patients for brain AVMs [22]. In one study where screening was 
performed in 268 of 1291 HHT patients, 15% of HHT1 patients and 1% of HHT2 patients 
harbored AVMs [21]. 
There is an increased risk of multiple AVMs in HHT patients [27]. AVMs in HHT patients 
do not follow the typical pattern of sporadic AVMs; they can grow or regress, and can recur 
after angiographically confirmed complete resection [28].  
Other developmental syndromes associated with brain AVMs include Wyburn-Mason 
syndrome and Sturge-Weber syndrome [29-31]. The pathogenesis of these developmental 
abnormalities is poorly understood, and provides little insight into the molecular biology of 
sporadic AVMs. 
Several studies have examined gene expression in AVMs using gene microarray techniques, 
with hundreds to thousands of genes of interest reported. In one study, where over 1700 
differentially expressed genes were identified, the majority belonged to angiogenesis, 
vascular matrix, or apoptosis pathways [32]. Significantly upregulated genes include those 
coding for Ang-2, VEGF-A, the VEGF receptor (Flt1), Integrin αv, Endoglin, MMP-9, and 
Ephrin-A1; significantly downregulated genes include Krit1, Ang-1, Tie, Tek, Laminin α3, 
Smoothelin, and Connexin 37 [32-35]. Conflicting gene microarray results have been 
obtained for CD31 (PECAM-1), with one study demonstrating upregulation, and another 
demonstrating downregulation [32, 34]. 
Gene single nucleotide polymorphisms (SNPs) have also been studied in groups of patients 
with AVMs, with a view to identifying potential genes that may be of prognostic and 
pathophysiological significance. Polymorphisms in the IL-6, IL-1β, TNF-α, and 
apolipoprotein-E (ApoE) genes have been associated with increased risk of hemorrhage [36-
39], and SNPs in ALK-1 are associated with a susceptibility for AVM formation [15]. 
2.3 Clinical features 
Arteriovenous malformations most commonly present in young patients, with a mean age at 
diagnosis around 35 years. There does not appear to be a gender predilection. They most 
commonly present with hemorrhage; many population-based studies and large natural 
history studies demonstrate that approximately 50% of patients present with AVM rupture 
[40-51]. The next most common presenting feature is seizure, with 24-36% of patients 
presenting with generalized or partial seizures. Other reasons for presentation include focal 
neurologic deficit [52], headache [53-55], or as incidental imaging findings in asymptomatic 
patients [56, 57]. 
2.4 Diagnosis, including early detection 
Noninvasive imaging modalities including CT, CT angiography, MRI, and MR angiography 
are extremely valuable in the diagnosis and characterization of brain AVM. Determination 
of proximity to eloquent structures and accurate measurement of nidal dimensions is 
important in determining surgical risk. In selected cases, functional MRI [58] and diffusion 
tensor imaging-based tractography [59] may be useful for providing additional information 
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about the relationship of an AVM to critical neurological structures. Non-enhanced CT and 
gradient-echo or susceptibility-weighted MRI sequences are particularly useful in 
demonstrating previous hemorrhage. However, digital subtraction angiograpy remains the 
gold standard for demonstrating AVM angioarchitecture, and is essential for planning 
appropriate management strategies [60].  
2.5 Treatment 
Several options are available for the management of patients with AVMs: microsurgical 
resection, stereotactic radiosurgery, endovascular treatment, multi-modality treatment, or 
observation. The preferred management option in each case depends on many factors, 
including AVM specific factors (such as size, location, arterial and venous anatomy, and 
mode of presentation), institutional factors (experience of cerebrovascular surgical team, 
access to stereotactic radiosurgery, availability of endovascular treatment options,), and 
patient factors (general medical condition, co-morbidities, age, patient preference).  
In determining the most appropriate management for an individual patient, the surgeon 
must balance the risk of intervention with the risk of the natural history and recommend the 
safest, most efficacious option. Sometimes, the safest option is to do nothing [61]. Ultimately, 
the risks of management must be acceptable to the patient. 
2.6 Prognosis 
Without treatment, the overall risk of AVM hemorrhage has been estimated to be 2 to 4.6% 
per year [40-46]. Previous hemorrhage is a significant risk factor for further hemorrhage; the 
risk may be as high as 18% in the first year after hemorrhagic presentation [62], returning to 
baseline within 5 years [63]. Large AVM size, deep and infratentorial location, deep venous 
drainage, and the presence of associated aneurysms have also been implicated as factors 
associated with a higher risk of rupture. 
Early studies, relying on retrospective audits of hospital charts and taken from the era 
before modern brain imaging and improvements in intensive care management, reported 
neurological morbidity and mortality as high as 52-81% following AVM hemorrhage [41, 42, 
64]. More recent studies have indicated that the morbidity from AVM hemorrhage is not 
quite as bad as these figures suggest, with 30-47% of patients suffering a neurologic deficit 
resulting in a modified Rankin Scale score (mRS) > 1 [44, 65, 66]. Long-term population 
studies have demonstrated that untreated AVMs are associated with a significant risk of 
long-term excess mortality that is dramatically reduced but not completely normalized 
following total excision or occlusion of the AVM [67]. 
Numerous authors have reported the results of surgical resection. It is generally accepted 
that the risk of surgery is low (<10%) in Spetzler-Martin (SM) grade 1 and 2 lesions [68-71]. 
Spetzler-Martin grade 3 AVMs are a heterogenous group, and complication rates depend 
largely on the morphology of these lesions, with some having a risk profile similar to that of 
small (SM grade 1 & 2) AVMs, and some having a risk profile similar to that of large (SM 
grade 4 & 5) AVMs [72-74]. 
Very few series report the results of surgery for large or giant AVMs. There are many 
groups who advocate against surgery for SM grade 4 & 5 AVMs because of the perceived 
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high risk of surgery [75]. In those series where surgery was undertaken, even in carefully 
selected patients, complications occurred in up to 30% [76-81].  
Ultimately, each of these sets of published results needs to be taken in context, as the results 
from different neurosurgical centers will differ as a result of referral patterns, treatment 
selection biases, and experience of the clinicians. Davidson and Morgan reported the risk of 
surgery in 640 patient with brain AVM, including an analysis of cases excluded from 
surgery because of the perceived surgical risk; in this series, the observed risk of adverse 
outcome related to surgery in SM Grade 1 & 2 patients was 1%, the risk in Grade 3 patients 
was 14%, and the risk in Grade 4 & 5 patients was 34% [82]. 
The primary goal of AVM treatment with stereotactic radiosurgery is to obliterate the nidus 
without the need for operative surgical intervention, removing the risk of future 
hemorrhage. The efficacy of AVM radiosurgery is much lower than with surgery 
(obliteration rates range from 36% to 92%, depending on the size of the lesion treated) [83, 
84]. Unlike surgery, obliteration is delayed by up to 3 years, and during this time the AVM 
is still at risk of rupture [85]. 
There are many reports in the literature relating to the risks of stereotactic radiosurgery, 
including the risk of rupture during the ‘latent interval’ between treatment and AVM 
occlusion. More recent series report hemorrhage after radiosurgery in 3% to 9% of patients 
[86, 87], radiological imaging changes in up to 46% to 66% (severe in 19%) [84, 88], transient 
neurological complications in 5% to 17% [89, 90], and permanent neurological complications 
in 1% to 13% [89, 91]. 
Complete occlusion of an AVM is rarely achieved with endovascular treatment alone, with 
most published angiographic cure rates ranging from 16-28% [92-97]. Many of the 
angiographic cures are in small AVMs, with very few complete occlusions in SM grade 3 
AVMs or larger. Even in the most experienced hands, complete occlusion was reported in 
51% of patients; however, only 12.5% of patient with SM Grade 3-5 AVMs experienced 
angiographic cure after Onyx embolization [98]. Combined morbidity and mortality rates in 
these series range from 5-12%, with more aggressive attempts at complete occlusion 
generally resulting in higher complication rates [93].  
Although multi-modality treatment (incorporating combinations of surgery, embolization, 
and radiosurgery) appears to be an attractive option for treating these large lesions, cure 
rates are only in the order of 36% [76], and the cumulative effects of treatment-related 
morbidity may be much higher than single- or dual-modality management. 
2.7 Screening of relatives 
There is currently no evidence to support the use of diagnostic imaging to screen for the 
presence of brain AVMs in asymptomatic patients. However, considerable controversy 
surrounds the role of screening in HHT patients. Some authors argue that the low risk of 
hemorrhage combined with the significant risk of treatment does not support the use of 
screening [22]; others have demonstrated a higher risk of hemorrhage in HHT patients with 
asymptomatic AVMs, and argue in favor of screening [99]. In these patients, the use of non-
invasive imaging (such as MR angiography or contrast-enhanced CT angiography) may be 
considered. 
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about the relationship of an AVM to critical neurological structures. Non-enhanced CT and 
gradient-echo or susceptibility-weighted MRI sequences are particularly useful in 
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Several options are available for the management of patients with AVMs: microsurgical 
resection, stereotactic radiosurgery, endovascular treatment, multi-modality treatment, or 
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mode of presentation), institutional factors (experience of cerebrovascular surgical team, 
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neurological morbidity and mortality as high as 52-81% following AVM hemorrhage [41, 42, 
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high risk of surgery [75]. In those series where surgery was undertaken, even in carefully 
selected patients, complications occurred in up to 30% [76-81].  
Ultimately, each of these sets of published results needs to be taken in context, as the results 
from different neurosurgical centers will differ as a result of referral patterns, treatment 
selection biases, and experience of the clinicians. Davidson and Morgan reported the risk of 
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2.7 Screening of relatives 
There is currently no evidence to support the use of diagnostic imaging to screen for the 
presence of brain AVMs in asymptomatic patients. However, considerable controversy 
surrounds the role of screening in HHT patients. Some authors argue that the low risk of 
hemorrhage combined with the significant risk of treatment does not support the use of 
screening [22]; others have demonstrated a higher risk of hemorrhage in HHT patients with 
asymptomatic AVMs, and argue in favor of screening [99]. In these patients, the use of non-
invasive imaging (such as MR angiography or contrast-enhanced CT angiography) may be 
considered. 
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3. Dural arteriovenous malformations 
3.1 Theories of pathogenesis 
The earliest discussions of the pathogenesis of dural arteriovenous malformations (DAVMs) 
focussed on a possible congenital origin [100-103]. Reinforcing this belief is the observation 
that 3% of DAVMs present before the age of 1 year [104]. The occurrence of DAVMs in the 
neonatal and pediatric population suggests that congenital factors are at play in at least 
some of these lesions. Dural sinus malformations almost certainly represent disorders of 
embryonic venous development [105]; it is unclear whether infantile type DAVMs represent 
a similar embryological malfunction or reflect a response to intrauterine thrombosis. Adult-
type fistulous DAVMs are extremely rare in the pediatric population, representing 0.8% of 
all pediatric vascular malformations [105]. It is now thought that most of these lesions are 
acquired in adulthood, and that that congenital DAVMs are exceptionally rare. 
Possible precipitating factors such as trauma, tumour, cerebral thrombophlebitis, 
neurological surgery, or ENT infection, can be demonstrated in 15-32% of cases [106-109]. By 
including patients with generalised hypercoagulable states (such as peripheral DVT, 
pregnancy, and use of oral contraceptive pill), a large meta-analysis reported that 66% of 
DAVMs had some possible predisposing factor [110]. In the remainder, however, no 
demonstrable precipitant can be identified, and the DAVM is considered to be idiopathic. 
Two hypotheses have been proposed in an attempt to explain the development of 
spontaneous or idiopathic DAVMs. In the first, neovascularization of an organising 
thrombus within a dural venous sinus is described as the primary event leading to the 
development of a DAVM [111]. The second theory suggests that some unspecified event 
(which may be a factor other than venous sinus thrombosis) results in opening of 
physiological arteriovenous shunts normally located within the dura mater [112, 113].  
3.2 Genetics 
In contrast to parenchymal AVMs of the brain, which may be congenital lesions, DAVMs 
are now thought to be acquired. DAVMs have been reported to occur in patients with 
various systemic conditions, particularly syndromes characterised by connective tissue 
disorders. Potential associations include: atypical Sturge-Weber related syndrome [114], 
blue rubber-bleb nevus syndrome [115], congenital toxoplasmosis [116], Ehlers-Danlos 
syndrome [117-119], fibromuscular dysplasia [117, 120, 121], hereditary hemorrhagic 
telangiectasia [122, 123], Marfan’s syndrome [124], osteogenesis imperfecta [117], 
polyarteritis nodosa [125], pseudoxanthoma elasticum [126], Rendu-Osler-Weber syndrome 
[127], syndactyly [128], and von Recklinghausen’s disease [129]. 
These reports are generally isolated to single cases, and whilst an association may be 
proposed on the basis of sound physiological principles, there is little convincing evidence 
of a causal relationship. 
3.3 Clinical features 
The clinical features of DAVMs are almost exclusively related to the pattern of venous 
drainage. Very few clinical manifestations have been related to arterial phenomena and all 
of these clinical scenarios can be equally well explained by venous hypertension and 
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congestion causing focal impaired perfusion of neural structures [111, 130]. No angiographic 
evidence for arterial ‘steal’ in DAVMs has ever been provided. Orbital venous congestion 
and hypoxic retinopathy have been proposed as suitable explanations for the common 
ophthalmological symptoms occasionally attributed to arterial insufficiency [131]. Elevated 
ocular venous pressures may result in oedema and inflammation in surrounding extra-
ocular muscles, causing diplopia unrelated to cranial nerve compression [108].  
In most DAVM series, pulsatile tinnitus is the most common complaint, occurring in up to 
two thirds of patients [132-134]. A bruit is detectable in a variable proportion of patients 
with subjective tinnitus, with reports ranging from 40% [135] to 96% [136]. 
In the presence of a DAVM, venous hypertension may occur through one of two 
mechanisms: increased blood flow through a draining vein, caused directly by 
arteriovenous shunting; or restricted venous outflow distal to the DAVM (including sinus 
occlusion) as a result of increased blood flow, elevated pressures, and turbulence in the 
draining vein [137, 138]. Venous congestion is capable of producing neurological deficits 
[139], and when this occurs locally, focal neurological deficits occur.  
Orbital venous hypertension may result in the ‘red-eyed shunt syndrome’ [140] or ‘dural 
shunt syndrome’ [141]. In the presence of a direct, high flow carotico-cavernous fistula 
(CCF) the clinical features can occur dramatically; however, with an indirect, low-flow 
DAVM the patient may be asymptomatic, or gradually develop symptoms that are generally 
less severe than with a direct CCF [126, 140, 141].  
Headache is one of the most common complaints leading to a neurologic assessment [142]; 
however, patients often present with incidental headache unrelated to their pathology. The 
headache attributed to DAVM is likely to occur in conjunction with signs of intracranial 
hypertension due to a decrease in venous outflow or sinus thrombosis [143]. Clinicians must 
rely on the clinical features of headache to differentiate a clinically significant secondary 
headache from an unrelated benign headache. These clinical features include: sudden onset 
of headache; worsening pattern of headache; headache with systemic illness or focal 
neurological signs and symptoms, including papilledema; headache triggered by cough, 
exertion, or Valsalva manouver; and headache during pregnancy or post-partum [142]. 
As opposed to parenchymal AVMs, DAVMs consist of a nidus that is supported by a strong 
collagenous and fibrous stroma (the dura mater), and as such the nidus of a DAVM is rarely 
the source of hemorrhage [144]. Accordingly, the presence of retrograde parenchymal 
venous drainage has been shown to be the primary factor responsible for intracranial 
hemorrhage in DAVMs. It is the parenchymal veins that traverse the space between the dura 
and the adjacent brain that are generally the source of intracranial hemorrhage in DAVMs 
[145]. When these veins fail under hemodynamic stress, intracerebral, subarachnoid, or 
subdural hemorrhage may occur. Of these anatomical locations, intraparenchymal 
hemorrhage occurs most commonly [146].  
Increased venous pressure at the torcular region can cause headaches, papilledema, and 
infantile hydrocephalus as a result of global venous hypertension [104]. At the more severe 
end of the spectrum, global venous hypertension with gross impairment of cerebral venous 
drainage may result in a more severe, progressive, generalized neurological deficit [147]. 
Patients may present with an extrapyramidal movement disorder, similar to Parkinson’s 
 
Congenital Anomalies − Case Studies and Mechanisms 50
3. Dural arteriovenous malformations 
3.1 Theories of pathogenesis 
The earliest discussions of the pathogenesis of dural arteriovenous malformations (DAVMs) 
focussed on a possible congenital origin [100-103]. Reinforcing this belief is the observation 
that 3% of DAVMs present before the age of 1 year [104]. The occurrence of DAVMs in the 
neonatal and pediatric population suggests that congenital factors are at play in at least 
some of these lesions. Dural sinus malformations almost certainly represent disorders of 
embryonic venous development [105]; it is unclear whether infantile type DAVMs represent 
a similar embryological malfunction or reflect a response to intrauterine thrombosis. Adult-
type fistulous DAVMs are extremely rare in the pediatric population, representing 0.8% of 
all pediatric vascular malformations [105]. It is now thought that most of these lesions are 
acquired in adulthood, and that that congenital DAVMs are exceptionally rare. 
Possible precipitating factors such as trauma, tumour, cerebral thrombophlebitis, 
neurological surgery, or ENT infection, can be demonstrated in 15-32% of cases [106-109]. By 
including patients with generalised hypercoagulable states (such as peripheral DVT, 
pregnancy, and use of oral contraceptive pill), a large meta-analysis reported that 66% of 
DAVMs had some possible predisposing factor [110]. In the remainder, however, no 
demonstrable precipitant can be identified, and the DAVM is considered to be idiopathic. 
Two hypotheses have been proposed in an attempt to explain the development of 
spontaneous or idiopathic DAVMs. In the first, neovascularization of an organising 
thrombus within a dural venous sinus is described as the primary event leading to the 
development of a DAVM [111]. The second theory suggests that some unspecified event 
(which may be a factor other than venous sinus thrombosis) results in opening of 
physiological arteriovenous shunts normally located within the dura mater [112, 113].  
3.2 Genetics 
In contrast to parenchymal AVMs of the brain, which may be congenital lesions, DAVMs 
are now thought to be acquired. DAVMs have been reported to occur in patients with 
various systemic conditions, particularly syndromes characterised by connective tissue 
disorders. Potential associations include: atypical Sturge-Weber related syndrome [114], 
blue rubber-bleb nevus syndrome [115], congenital toxoplasmosis [116], Ehlers-Danlos 
syndrome [117-119], fibromuscular dysplasia [117, 120, 121], hereditary hemorrhagic 
telangiectasia [122, 123], Marfan’s syndrome [124], osteogenesis imperfecta [117], 
polyarteritis nodosa [125], pseudoxanthoma elasticum [126], Rendu-Osler-Weber syndrome 
[127], syndactyly [128], and von Recklinghausen’s disease [129]. 
These reports are generally isolated to single cases, and whilst an association may be 
proposed on the basis of sound physiological principles, there is little convincing evidence 
of a causal relationship. 
3.3 Clinical features 
The clinical features of DAVMs are almost exclusively related to the pattern of venous 
drainage. Very few clinical manifestations have been related to arterial phenomena and all 
of these clinical scenarios can be equally well explained by venous hypertension and 
 
Central Nervous System Vascular Malformations 51 
congestion causing focal impaired perfusion of neural structures [111, 130]. No angiographic 
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disease [148, 149]. In extreme cases, patients may present with progressive global cognitive 
decline, which is often mistakenly diagnosed as Alzheimer’s dementia. The dementia 
occurring as a result of DAVMs presents as a severe, rapidly progressive cognitive decline 
that resolves following obliteration of the DAVM in most cases. 
3.4 Diagnosis 
Angiography is the most important diagnostic test in the evaluation of a patient suspected 
of having a DAVM. Complete 6-vessel cerebral digital subtraction angiography, including 
assessment of bilateral internal carotid, external carotid, and vertebral arteries is required to 
confirm the diagnosis, and to adequately define the dural origin of the nidus, the arterial 
supply, and the pattern of venous drainage. Other imaging modalities may be useful when 
used in conjunction with angiography. 
Standard axial CT images are useful in patients with DAVMs, and are able to complement 
the angiographic findings by adding information on the following: cerebral abnormalities 
(including intracranial hemorrhage, cerebral edema, hydrocephalus, infarction, and contrast 
enhancement of dilated intradural venous structures), osseous abnormalities, and abnormal 
dural enhancement.  
MR imaging plays an important complementary role in the evaluation of DAVMs, 
particularly in the evaluation of venous congestion, local and regional perfusion, and the 
assessment of venous sinus thrombosis [150]. It may also permit non-invasive follow-up of 
treated lesions.  
3.5 Treatment 
Various management options are available for the management of cranial DAVMs: 
compression therapy, surgical intervention, endovascular treatment, radiation therapy, or 
observation. The preferred management option in each case depends on many factors, 
including DAVM specific factors (such as the location of the DAVM, pattern of venous 
drainage, number of arterial feeders), institutional factors, and patient specific factors. The 
natural history of DAVMs with retrograde parenchymal venous drainage suggests that 
treatment should be considered unless unusual circumstances make the risks of intervention 
prohibitive. A more conservative approach may be considered in patients with a benign 
DAVM. The reasons for considering treatment in these patients include progressive 
neurological deficit (including progressive orbital venous hypertension), or disabling tinnitus. 
In a meta-analysis of treatment options, surgery (either alone or in association with pre-
operative embolization) was the most effective management option for DAVMs located in 
the transverse or sigmoid sinus, tentorial incisura, and anterior cranial fossa (ACF) [110]. 
The small number of cases of superior sagittal sinus (SSS) DAVMs precluded a meaningful 
statistical analysis; however, the authors also recommended surgical treatment in this 
group. 
With the development of better techniques and materials, the role for endovascular 
treatments in the management of DAVMs continues to evolve. Endovascular management is 
often considered the primary treatment option for DAVMs in the cavernous sinus; for 
DAVMs of the transverse and sigmoid sinus regions, the combination therapy of 
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transarterial embolization and surgery provides a more effective treatment than either 
treatment alone. Embolization alone may be relatively ineffective in DAVMs of the tentorial 
incisura, however when used in conjunction with surgery may provide a slight advantage 
over surgery alone [110]. There is little evidence supporting the use of endovascular 
treatment in the management of DAVMs of the ACF, SSS, or middle cranial fossa (MCF) 
location. 
One of the greatest problems with transarterial embolization is the high rate of incomplete 
occlusion due to revascularization of the lesion, particularly if not all feeding vessels have 
been embolized [151]. The theoretical benefit of transvenous embolization includes a greater 
likelihood of complete occlusion of the abnormal AV shunts [130]. However, the corollary is 
that although the transvenous approach may be effective in occluding the site of AV 
shunting, the draining veins and dural sinuses are thin-walled structures and may be 
perforated by catheters and guidewires [152].  
Although stereotactic radiosurgery is claimed to avoid many of the potential complications 
of embolization and surgery, it is not completely risk-free. Transient neurological deficits 
due to treatment occur in up to 10% [153-155], and serious neurological complications have 
been reported [156]. Questions also remain regarding the long-term efficacy of occlusion 
following radiosurgery, with recurrences reported after complete angiographic obliteration 
[157]. 
3.6 Prognosis 
For many years, the location of a DAVM was believed to be an important determinant of its 
behaviour [158]. Subsequently, more detailed studies have demonstrated that after 
accounting for the pattern of venous drainage, location has no direct correlation with the 
behavior or natural history of a particular lesion [106, 107, 134]. Instead, due to local venous 
anatomy, DAVMs in some locations (such as the ACF and tentorial incisura) are more likely 
to develop retrograde parenchymal venous drainage; it is this pattern of venous drainage 
that has been demonstrated to be predictive of aggressive behavior [106, 107, 159-161]. 
The pattern of venous drainage may be defined according to two commonly used 
classification systems [106, 107]: Borden type I, or Cognard type I and IIa are benign lesions 
with no retrograde parenchymal venous drainage; Borden type II and III, or Cognard type 
IIb, IIa+b, and III-V are aggressive lesions exhibiting various degrees of retrograde 
parenchymal venous drainage. 
The natural history of DAVMs relates to the pattern of venous drainage. In general, the risk 
of intracranial hemorrhage for all DAVMs is approximately 1.8% per year [132]. However, 
DAVMs that demonstrate retrograde parenchymal venous drainage are associated with a 
more aggressive natural history [106, 107, 159, 160]. The risk of intracranial hemorrhage or 
non-hemorrhagic neurological deficit in DAVMs with retrograde parenchymal venous 
drainage is 15-30% per year, with an annual risk of death of 10-19% [162, 163]. When 
intracranial hemorrhage occurs, the effects can be devastating, with a 15-25% risk of death 
[132, 159, 164], and a 35% risk of rebleeding within 2 weeks if the DAVM remains untreated 
[164].  
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shunting, the draining veins and dural sinuses are thin-walled structures and may be 
perforated by catheters and guidewires [152].  
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Effective treatment of DAVMs, with obliteration of all AV shunting, has been shown to 
result in reversal of neurological deficits [148, 165-172], including visual loss [173, 174]. 
However, complications can occur from all modalities of management (including 
observation alone), and progression of venous thrombosis and venous hypertension 
resulting in death can occur despite multiple attempts at intervention [175, 176]. 
Many published series report the initial post-treatment angiogram results as confirmation of 
angiographic obliteration, without performing delayed angiography. Recurrent DAVM, as 
well as development of new DAVM at sites remote from the initial lesion, can occur after 
complete obliteration [177-180]. In view of this finding, some authors recommend 
angiographic follow-up at least 1 year after treatment, to ensure that long-term occlusion 
has occurred [179]. Other forms of non-invasive angiography (such as CT or MR 
angiography) are becoming increasingly useful in the follow-up of these lesions. 
3.7 Screening of relatives 
There is currently no evidence to support the use of diagnostic imaging to screen for the 
presence of dural AVMs in asymptomatic patients. 
4. Vein of galen malformations 
4.1 Theories of pathogenesis 
Vein of Galen malformations represent a particular subtype of intracranial vascular 
malformation, and consist of a single midline venous sac with a direct AV fistula within 
the wall. True vein of Galen malformations represent an embryonic malformation [181], 
with the malformation corresponding to the persistent fetal median prosencephalic vein, 
often in association with other abnormalities of arrested venous development [182]. 
Aneurysmal dilatation of an embryologically normal vein of Galen due to increased 
venous drainage from another vascular abnormality within its venous territory does not 
represent a true vein of Galen malformation. Although this type of aneurysmal dilatation 
has been classified as a type 4 vein of Galen malformation in the classification system of 
Yasargil [183], a descriptive term such as secondary vein of Galen aneurysmal dilatation is 
more informative [182, 184].  
The true embryonic form of vein of Galen malformation is different from other pediatric 
DAVMs [105]. As well as having a different pathogenesis, one of the primary differences 
between DAVMs and vein of Galen malformations is the primary blood supply of the lesion 
[185]. In DAVMs the primary blood supply is that of the adjacent dura, whereas in vein of 
Galen malformations it is that of the adjacent brain parenchyma (arising from the fetal 
prosencephalic and mesencephalic arterial systems) [181]. Lasjaunias, et al. classified 
pediatric DAVMs into three types [105]: dural sinus malformations, infantile type dural 
arteriovenous shunts, and adult type dural arteriovenous shunts. 
Dural sinus malformations and infantile DAVMs present in neonates and early childhood, 
and are more likely to represent a congenital abnormality in venous development. The adult 
type is less frequent, representing less than 1% of all pediatric intracranial AVMs; and when 
presenting in the pediatric population, tends to occur in older children [105]. 
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4.2 Genetics 
At present, the role of genetic factors in the formation of VOGM is unknown. Only 1 case of 
familial VOGM has been reported [186]. However, mutations in the RASA1 gene have been 
investigated in association with cutaneous capillary malformation-arteriovenous 
malformation syndrome, including two patients who also harboured VOGMs [187], raising 
the possibility that genetic influences may play a role in the development of these 
malformations. 
4.3 Clinical features 
Typically, neonates present with severe congestive cardiac failure (CCF), infants present 
with macrocephaly or hydrocephalus, and older children or adults present with seizures, 
headaches, or cranial neuropathies resulting from mass effect [186]. 
4.4 Diagnosis, including early detection 
The diagnosis of VOGM is made after detailed clinical examination and investigation. Initial 
radiological examination includes transfontanel ultrasound and cardiac ultrasound (to 
assess for associated cardiac abnormalities), and MR Imaging of the brain. Angiography is 
not recommended in neonates unless urgent endovascular treatment is considered [188].The 
Bicetre Neonatal Evaluation Score [188] requires evaluation of cardiac, cerebral, respiratory, 
hepatic, and renal function in order to guide management decisions, and is used to triage 
neonates to either conservative management, or immediate or delayed endovascular 
management. 
Non-invasive vascular imaging using contrast-enhanced CT angiography and MR 
angiography is becoming increasingly useful, particularly in neonates where the risk of 
catheter angiography is greatest. However, digital subtraction cerebral angiography is best 
for precise evaluation of vascular architecture in VOGMs [189]. 
Fetal ultrasound and MRI are useful for the antenatal diagnosis of aneurysmal malformations 
of the Vein of Galen, and allow for early management decisions to be made [190-192]. 
4.5 Treatment and prognosis 
Many patients are not offered invasive treatment for their VOGM, usually due to poor 
cardiac or neurological condition at the time of diagnosis. Without treatment, VOGM is 
associated with a fatal outcome in >90% [193], usually from cardiac failure or neurological 
complications such as hydrocephalus.  
Treatments strategies have evolved dramatically over the past decades, with series 
published before the year 2000 reporting a 15% mortality rate with endovascular 
management, and an 85% mortality rate with microsurgical management [193]. For this 
reason, surgery is rarely recommended as a first-line management option for VOGM. 
Although ventricular shunting may be required for the management of hydrocephalus in 
older children and adults, this may be avoided with early endovascular occlusion of the 
arteriovenous shunt in neonates and infants [194]. The published experience on stereotactic 
radiosurgery for VOGM is extremely limited [195]. 
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Endovascular approaches to treatment are usually performed with the goal of obtaining 
complete exclusion of the malformation through a combination of transarterial and 
transvenous routes (with transarterial being the preferred route, and transvenous access 
only required in 2%) [194]. Multiple treatment sessions are usually required (average 2.4 
sessions per child), and total or near-total occlusion was obtained in 55% of patients in this 
series. 
Although published series in the past 10 years have not reported a change in the mortality 
rate significantly [193], the extensive experience reported from the Hospital de Bicetre, 
France, describes good clinical outcomes in 74% of patients and a mortality rate of 11% 
[194]. 
Outcome from endovascular treatment is highly dependent on the age of the patient at the 
time of presentation. Mortality rates as high as 50% have been recorded in neonates, with 
death rates around 7% in infants (<2 yrs) and 0-3% in children and adults undergoing 
treatment [193, 194]. 
4.6 Screening of relatives 
There is no evidence to suggest that antenatal diagnosis of VOGM is associated with 
improved treatment outcomes, although it may assist with early referral to a center with 
experience in management of the complex cardiac and neurological issues facing these 
patients [192]. In spite of this, there is currently no evidence to support the use of diagnostic 
imaging to screen for the presence of VOMG in asymptomatic patients. 
5. Capillary telangiectasia 
5.1 Theories of pathogenesis 
Capillary telangiectasias consist of multiple abnormally dilated capillary vessels, with 
normal intervening brain parenchyma. They are relatively common, rarely symptomatic, 
and are most commonly found in the region of the pons [196, 197]. They are traditionally 
considered to be congenital malformations, arising as a result of aberrant angiogenesis or 
failure of capillary involution during development [198]. This belief is based on the 
assumption that brain capillary telangiectasias are the same as cutaneous capillary 
malformations (or ‘port wine stains’) [29], although little evidence exists to support this 
theory of pathogenesis. Capillary telangiectasias have been reported to co-exist with 
developmental venous anomalies and cerebral cavernous malformations [198, 199], as well 
as developing after resection of a cavernous malformation [213]. This last case in particular 
indicates that de novo capillary telangiectasias may develop in adults, and suggests that these 
lesions may represent a spectrum of the same disease process. 
5.2 Genetics 
Although several genetic loci have been implicated in the development of cutaneous 
capillary malformations (including mutations of the RASA1 gene, located on chromosome 
5q13-22, and implicated in Parkes-Weber Syndrome, a condition associated with cutaneous 
capillary malformations and brain AVMs) [187], very little is known about the role of 
genetic abnormalities in capillary telangiectasias of the brain. 
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5.3 Clinical features 
It is very rare for capillary telangiectasias to present clinically; they are often found as an 
incidental finding at autopsy or during MR imaging for other unrelated conditions [197, 
200]. Occasionally, they can present with hemorrhage or mass effect on surrounding 
structures, resulting in seizures, cranial nerve dysfunction, confusion, dizziness, visual 
disturbance, vertigo, tinnitus, or motor deficits [200, 201]. They have been implicated as a 
potential cause of non-aneurysmal perimesencephalic subarachnoid hemorrhage [202]. 
5.4 Diagnosis, including early detection 
Brain capillary telangiectasias are not seen on CT, and are difficult to detect on MRI with 
standard T1- and T2- weighted imaging. However, they display mild homogenous 
enhancement with contrast material, and are often markedly hypo-intense on Gradient Echo 
sequences [200, 203]. They are not demonstrable on digital subtraction cerebral 
angiography. 
5.5 Treatment 
It is extremely rare for small brain capillary telangiectasias (<1 cm in maximum dimension) 
to present with symptoms, and the majority of cases do not require active treatment. Larger 
lesions may be symptomatic, and require surgical resection [200]. 
5.6 Prognosis 
Capillary telangiectasias are benign lesions that usually do not cause neurological 
symptoms. In a large series of over 100 patients with brain capillary telangiectasias, only 2 
patients were symptomatic, and 1 patient required surgical resection [200]. Other smaller 
series have reported on lesions where symptoms have improved with medical management 
of seizures, or have resolved spontaneously [201]. Rarely have reports described progressive 
neurological symptoms or death from unruptured capillary telangiectasias [204, 205]. 
Although hemorrhage from a capillary telangiectasia has been reported [202], the risk of 
hemorrhagic complications from these lesions is not known. 
5.7 Screening of relatives 
There is no evidence to support the use of diagnostic imaging to screen for the presence of 
capillary telangiectasias in asymptomatic patients. 
6. Cavernous malformation 
6.1 Theories of pathogenesis 
Cavernous malformations (cavernomas, cavernous hemangioma) consist of abnormal, thin-
walled sinusoidal vascular channels. There is not generally any brain parenchyma between 
the vessels and there is lack of basement membrane, smooth muscle, elastin, and adventitia 
[228,229]. Most cases have either imaging or pathological evidence of prior hemorrhage and 
organizing thrombus; calcification is also frequently seen. 
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As with other vascular malformations described in this chapter, there was an initial 
assumption of a congenital origin, which has recently been brought in to question. New 
malformations have been documented in familial and non-familial cases and in regions of 
brain treated with radiotherapy for other conditions [228]. Genetic abnormalities have been 
identified in patients with familial cavernous malformations. The genes identified code for 
proteins that are important for vascular development. 
Another proposed mechanism of cavernous malformation development is venous 
hypertension, particularly in cases associated with developmental venous anomalies [232]. 
The proposal is that chronically raised venous pressure influences the development of 
cavernous malformations or may at least predispose to their recurrence after surgical 
removal. 
6.2 Genetics 
Cavernous malformations occur in all races and there is no sex predilection. The prevalence 
is approximately 0.5% [228], although the rate is higher in the Hispanic population. In some 
familial forms there is almost 100% penetrance [228]. Almost all Hispanic patients and 40% 
of Caucasian patients with familial cavernous malformations have a constitutional defect in 
the KRIT1 gene, also known as CCM1 [230]. KRIT1 codes for a protein that plays an 
important role in blood vessel development and may play a role in blood-brain-barrier 
formation. Over 100 mutations of the KRIT1 gene have been identified that are associated 
with the development of cavernous malformations. 
Defects in other genes, (CCM2 and CCM3), are also associated with cavernous malformation 
development. CCM2 and CCM3 code for proteins that are thought to be important in the 
signaling between neurons and developing vascular cells in the central nervous system. 
Many different mutations of these genes have been identified in cavernous malformation 
patients, accounting for approximately one third of familial cases [231]. 
6.3 Clinical features 
Cavernous malformations account for up to 10% of central nervous system vascular 
malformations and the mean age at presentation is approximately 40 [228]. In familial cases 
there are often multiple lesions, whereas sporadic cases usually have only one lesion. 
Presentation is with headache or neurological deficit from hemorrhage, or with seizures. In 
contrast to AVMs, hemorrhages from cavernous malformations are generally not life-
threatening. Neurological deficits occur when the lesions are in eloquent regions of the brain 
such as the brain stem or primary motor cortex. The annual risk of hemorrhage has been 
estimated at 4%, with higher risks accompanying familial cases, after an initial clinical 
hemorrhage, or for lesions located in the brain stem [228]. There may be a higher risk during 
pregnancy.  
6.4 Diagnosis, including early detection 
Catheter angiography will often not reveal cavernous malformations. Subtle hyperdensity 
may be seen on non-contrast CT, although even a contrast scan will not detect many lesions. 
The hemosiderin deposition resulting from prior hemorrhages makes MRI an exquisitely 
 
Central Nervous System Vascular Malformations 59 
sensitive diagnostic technique. In addition to making the diagnosis, MRI is important for 
determining the location of the lesion and its relationship to pial or ependymal surfaces, 
which are important factors in surgical decision-making. 
6.5 Treatment 
Surgical excision is the only effective treatment for cavernous malformations; there is no role 
for endovascular therapy and there is little evidence supporting the efficacy of radiosurgery. 
The indications for surgery are to prevent hemorrhage and to improve control of seizures. 
Excision of lesions in asymptomatic patients is usually not justified. Surgery is reasonable 
for lesions in the brain stem that have bled at least once, and where the lesion comes to 
either a pial or ependymal surface. If seizure control is the main concern, it may be 
preferable to proceed with surgery within the first year after presentation, as there is some 
evidence that this improves seizure outcomes [228]. 
6.6 Prognosis 
Left untreated, cavernous malformations remain at risk of hemorrhage. Neurological 
deficits are particularly common after hemorrhage in the brain stem and the effects are 
cumulative with each hemorrhage. Surgical excision of cavernous malformations relieves 
mass effect on surrounding brain and may be effective in controlling seizures, especially if 
surrounding hemosiderin-stained tissue is removed. Unfortunately, removal of lesions in 
the brain stem does not necessarily eliminate the risk of hemorrhage: there is a growing 
awareness of a moderately high rate of recurrence in this region and the spinal cord [233]. 
Whether recurrence is related to further growth of residual malformation or development of 
a new lesion remains to be determined. 
6.7 Screening of relatives 
Although familial forms of the condition are well recognized, there is not a clear indication 
for screening relatives of affected patients. Since there is not usually an indication for 
treatment of asymptomatic patients with cavernous malformations of the brain, we do not 
generally recommend screening. For relatives in familial cases who request screening, it is 
reasonable to obtain an MR scan. 
7. Developmental venous anomalies 
7.1 Theories of pathogenesis 
Developmental venous anomalies (also known as developmental venous malformations and 
venous angiomas) are composed of a radially-arranged cluster of venous radicles 
converging into a larger, mature venous channel [206, 207]. The venous structures are 
angiographically mature, and express normal structural proteins in their walls [208].  
There are several broad theories of pathogenesis for DVAs, and all assume that they form in 
utero. The first theory is that DVAs represent anatomical variants formed by the opening of 
transhemispheric anastomotic pathways between the superficial venous system and the 
deep venous system of the brain in response to hemodynamic demand [209]. In this model, 
the DVA is a normal structure, performing a normal physiological function. 
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angiographically mature, and express normal structural proteins in their walls [208].  
There are several broad theories of pathogenesis for DVAs, and all assume that they form in 
utero. The first theory is that DVAs represent anatomical variants formed by the opening of 
transhemispheric anastomotic pathways between the superficial venous system and the 
deep venous system of the brain in response to hemodynamic demand [209]. In this model, 
the DVA is a normal structure, performing a normal physiological function. 
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Other theories propose that DVAs form in response to thrombosis or occlusion of normal 
parenchymal veins, or as a result of abnormal fetal angiogenesis [210, 211]. These theories 
consider the DVA to be a response to an antenatal pathological event rather than a normal 
anatomical variant [212]. 
7.2 Genetics 
Developmental venous anomalies are associated with other cerebral vascular 
malformations, in particular cerebral cavernous malformations, in up to 40% of cases [206]. 
Isolated case reports have described the temporal development of a cerebral cavernous 
malformation in the region of a DVA; prompting the suggestion that regional venous 
hypertension may serve as a common pathogenetic mechanism [213, 214]. Familial 
cavernous malformations are unlikely to be associated with the presence of a DVA, whereas 
a DVA is likely to co-exist with a sporadic CCM in almost half of cases [215], countering the 
argument that a simple genetic defect is responsible for the co-existence of these two 
vascular malformations. 
Intracranial DVAs are also associated with peripheral vascular abnormalities, and are 
present in 20% of patients with cutaneous venous malformations [207]. In particular, DVAs 
have been reported in patients with blue rubber bleb nevus syndrome and sinus pericranii, 
prompting the suggestion that sinus pericranii should be considered the extracranial 
manifestation of a common spectrum of venous malformations [216, 217]. 
The vast majority (about 95%) of cutaneous venous malformations are sporadic, but a small 
proportion of cutaneomucosal venous malformations are inherited in an autosomal 
dominant pattern. The genetic defect responsible for this form of venous malformations is a 
mutation in the TEK gene (encoding for the angiopoieten receptor, TIE2; located on 
chromosome 9p21) [218, 219]. Despite the potential for a link between these malformations 
and DVAs, there is no evidence to support the hypothesis that this gene defect is responsible 
for the development of intracranial DVAs. 
Intracranial DVAs have also been reported in associated with the spectrum of vascular 
anomalies occurring in patients with mutations of the PTEN gene [220]. 
7.3 Clinical features 
Developmental venous anomalies are the most common cerebral vascular malformation, 
with a prevalence in imaging series of 0.5-0.7%, and in autopsy series of 2.6% [207]. The vast 
majority are asymptomatic, and are often found as an incidental finding during imaging for 
other unrelated conditions.  
The most common reason for neuroimaging in patients with a DVA is headache; however, 
an exact causal relationship is often difficult to prove, as symptoms may resolve over time 
without treatment of the vascular anomaly. Similarly, in patients presenting with seizure or 
neurological deficit, there is often no direct correlation between the anatomical location of 
the DVA and the neurological symptoms [207]. 
The risk of hemorrhage from a DVA is low, with retrospective series reporting an annual 
hemorrhage rate of 0.6%, and prospective series reporting an annual hemorrhage rate of 
0.7% (with a symptomatic hemorrhage rate of 0.3%) [221]. Cerebral edema, venous 
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infarction, and hemorrhage may occur following stenosis or thrombosis of the draining vein 
of the DVA [212, 222].  
7.4 Diagnosis, including early detection 
Developmental venous anomalies are rarely visible on non-contrast CT imaging, unless 
associated with a cavernous malformation. Following the administration of intravenous 
contrast, the DVA is visualized as a collection of venous tributaries or ‘caput medusa’ draining 
via an enlarged draining vein [214]. CT perfusion studies may be useful in determining the 
hemodynamic alterations present as a result of the altered regional venous drainage [223]. 
Similarly, DVAs may be seen on T1- and T2-weighted MR imaging, but are best visualized 
on gadolinium-enhanced T1-weighted imaging. Gradient echo sequences may show a ring 
of hypointensity if previous hemorrhage or an associated cavernous malformation is 
present. MR imaging is also valuable for the detection of parenchymal abnormalities often 
associated with DVAs [214].  
Conventional digital subtraction angiography shows normal arterial and capillary phase, 
with typical venous phase demonstrating the ‘caput meduase’ of dilated medullary veins 
converging upon an enlarged subcortical or subependymal draining vein [207, 224] 
7.5 Treatment 
Traditionally, neurosurgeons have understood that DVAs represent a variant of normal 
venous drainage, and as such should never be a target for treatment [209]. However, others 
have challenged this belief, suggesting that removal of CCM without removal of the 
underlying DVA results in recurrence of the CCM in up to one third of patients. Particularly 
in this group of patients, cautious coagulation and dissection of the large transcerebral DVA 
may be considered [225]. 
We advocate a conservative approach, and recommend that surgical treatment never be 
offered to patients with asymptomatic DVAs. In the setting where hemorrhage has 
occurred, then evacuation of the hematoma may be considered, but surgical disruption of 
the DVA should be avoided. Associated cavernous malformations should be completely 
excised, with preservation of the anomalous venous drainage wherever possible. We do not 
believe that sufficient evidence exists to support the routine removal of DVAs to prevent the 
development of recurrent cavernous malformation. 
7.6 Prognosis 
Most of the evidence relating to DVAs suggests that they are a variant of normal venous 
drainage; they are a normal structure, performing a normal physiological function. Once 
considered a rarity, with a high propensity for hemorrhage, they are in fact the most 
frequently encountered vascular malformation, occurring in up to 3% of the population 
[226]. Developmental venous anomalies themselves have a very low risk of hemorrhage, 
with prospective series reporting a symptomatic hemorrhage rate as low as 0.3% [221]. They 
are, however, associated with the development of other vascular malformations (in 
particular cavernous malformation), which increase the risk of symptomatic hemorrhage to 
as high as 6% per year [227]. 
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7.7 Screening of relatives 
There is currently no evidence to support the use of diagnostic imaging to screen for the 
presence of DVAs in asymptomatic patients. Although of little clinical benefit, there may be 
research interest in screening relatives of patients with blue rubber-bleb nevus syndrome for 
intracranial venous anomalies, in order to improve our understanding of the genetic and 
molecular influences responsible for the development of vascular malformations in these 
patients. 
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Congenital malformations affect approximately 2-3% of all live births every year (Whiteman 
et al, 1994; Atlas et al, 1985). Congenital brain anomalies, whether they are isolated (single) 
or part of syndromes, are a common cause of medical intervention, long-term illness, and 
death. The neonatologist or perinatologist often is the first person to identify necessary 
evaluations and management and to explain the cause of the anomalies and the prognosis 
for the child to the parents. Different anomalies may be classified as malformations, 
deformations and disruptions (Smith & Smith 2006; Barkovich  et al 2001, Barkovich, 2005). 
Co-existent group of anomalies is described as polytopic field defect, sequence, syndrome 
and association. Other classification may be major and minor anomalies. Major anomaly is 
one with a medical, surgical or cosmetic importance and with impact on morbidity and 
mortality. Minor anomaly is one that does not have a serious surgical, medical or cosmetic 
significance and does not affect normal life expectancy or lifestyle. 
Central nervous system (CNS) anomalies are the second most frequent serious congenital 
anomaly, after congenital heart disease. There is significant variation in incidences of 
congenital CNS anomalies in different regions of world including Europe (Barkovich, 2005). 
Congenital CNS anomalies are a heterogeneous disease for which genetic, infectious, 
teratogenic and neoplastic causes have been implicated (Bendon, 1987; Barkovich et al, 2005). 
Table 1. show the frequency of different CNS congenital anomalies which were detected in 
our institute during fourth years study period.  
The development of the brain and spinal cord is an extremely complicated process which 
continues into second decade before final maturity is achieved. Abnormality in the 
development of CNS are common, up to 75 % of fetal deaths and 40% of deaths in infancy 
are due to CNS malformations (Barkovich, 2005). Furthermore, one third of all congenital 
abnormalities identified in the perinatal period arise from the central nervous system. These 
abnormalities are often evident at birth, but some cerebral malformations may not be 
immediately obvious. The neonates with dysmorphic feature or abnormal neurological 
behaviour may suggest cerebral malformations, and various imaging techniques are 
essential for further clarification. Due to the wide spectrum of congenital CNS 
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abnormalities, only the more common ones amenable will be discussed here. Ultrasound 
(US) examination is an effective modality for the diagnosis of these anomalies in 
experienced hands. Cranial US correlate well with anatomical and pathological findings and 
clinical outcomes. Cranial US detection of congenital brain anomalies is useful for diagnostic 
purposes, and it also may allow for more appropriate management and more accurate 
neurological prognostication.  
Congenital CNS 
anomalies 
2005 2006 2007 2008 ∑ Incidence 
ACC 1 1 2 0.07 : 1000 
Arachnoid cysts  1 1 0.03 : 1000 
CSD 3 3 8 11 25 0.9 : 1000 
DWM 1 1 2 0.07 : 1000 
Encephaloceles 1 1 0.03 : 1000 
Spinal lipoma 1 1 0.03 : 1000 
Holoprosencephaly 2 1 3 0.1 : 1000 
Hydrocephalus 9 2 1 4 15 0.5 : 1000 
MCM 1 1 0.03 : 1000 
Myelomeningoceles 4 1 5 2 12 0.4 : 1000 
Microcephaly 1 1 1 3 0.1 : 1000 
Schizencephaly 1 1 0.03 : 1000 
VGA 1 1 0.03 : 1000 
Ventriculomegaly 12 8 7 13 40 1.3 : 1000 
Births 7091 7070 7015 7012 28818 3.6 : 1000 
Table 1. The frequency of different CNS congenital anomalies (ACC- Agenesis of the  
corpus callosum; CSD- Closed spinal dysraphisms; DWM- Dandy-Walker malformation; 
MCM- Mega cistern magna; VGA-Vein  of Galen aneurysm). 
2. Cranial ultrasonography 
In the neonatal period cranial US can be used as the initial modality to exclude a major 
structural malformation (Fawer, 1985; Carty et al, 2001, Barkovich, 2005; Von Wezel-Meijler 
G, 2007). Cranial ultrasonography (US) was introduced into neonatology in the late 1970s 
and has become an essential diagnostic tool in modern neonatology. It is non-invasive 
highly sensitive, safe, easily repeatable, accurate and cost effective neuroimaging technique. 
The advantages of cranial US are that it can be performed at the bedside with minimal 
disturbance to the neonates and patients do not require sedation. It is a useful modality for 
detecting congenital and acquired anomalies of the brain and the most frequently occurring 
patterns of brain injury in both preterm and full-term neonates. Cranial US is also suitable 
for assessing brain maturation and timing of cerebral injury. It can be initiated at a very 
early stage, even immediately after birth. Cranial US is relatively inexpensive compared 
with other neuro-imaging techniques. The non-invasive nature of cranial US make it an 
ideal imaging technique in the neonate. During the late foetal and perinatal period and 
during early infancy, major maturational processes and growth of the brain take place 
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(Barkovich et al, 2001; Carty et al 2001). Maturational processes include a major increase in 
volume, weight, and surface area of the brain; gyration; cell migration; germinal matrix 
involution; and myelination. These maturation processes can be visualised by modern 
neuro-imaging techniques. Gyration is a phenomenon occurring late during fetal 
development and can be observed by the second month of intrauterine life. It goes on to the 
end of the pregnancy and even later after birth. The primary sulci appear as shallow grooves 
on the surface of the brain that become progressively more deeply infolded and that develop 
side branches, designated secondary sulci. Gyration proceeds with the formation of other 
side branches of the secondary sulci, referred to as tertiary sulci. The timing of the 
appearance of these different types of sulci is so precise that neuropathologists consider 
gyration to be a reliable estimate of gestational age and consequently a good marker of fetal 
brain maturation (Figure 1.). 
 
Fig. 1. Comparative sagittal sections show a gyral pattern from 26-38+ weeks of gestation. 
It is possible to assess the gestation age of the infant from the ultrasound images (Figure.2.). 
In extremely preterm infants (gestation age from 24–26 weeks), the brain surface is still very 
smooth and has a lissencephalic appearance. The process of gyration can be followed by 
cranial US and cortical sulcation is considered to be a good marker of neonatal brain 
maturation by neuropathologists (Barkovich, 2005; Von Wezel-Meijler, 2007). Familiarity 
with the normal ultrasonographic imaging appearances of the fetal/neonatal cerebral cortex 
at various stages of gestation is essential for the early detection of abnormal sulcal 
development. Abnormal cortical development is the main manifestation of lissencephaly, 
although other associated CNS anomalies (e.g. ventriculomegaly, holoprosencephaly, 
agenesis of the corpus callosum, porencephaly, encephalocele). 
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Fig. 2. Comparative US sagittal sections show a gyral pattern in neonate with 27 weeks of 
gestation (A) and 38 weeks of gestation (B). 
The germinal matrix is an abundant, highly cellular and vascular “strip” of subependymal 
tissue. During early gestation it lines the entire wall of the lateral ventricles and third 
ventricle. It produces neuroblasts and glioblasts and is the origin of migrating neurons (first 
trimester) and glial cells (second and third trimesters). Regression of the germinal matrix 
starts from 24–26 weeks of gestation onwards. After 34 weeks, remnants remain in the 
thalamo-caudate notch and temporal horns of the lateral ventricles. In the foetus and very 
preterm infant, the lateral ventricles are often wide and asymmetric (usually the left is larger 
than the right) with very wide occipital horns. Subarachnoid spaces may also be wide. The 
cerebral lateral ventricles have a complex threedimensional architecture that undergoes 
major developmental changes throughout gestation. Normal sizes of ventricles provide 
reassurance of the normal development of the neonatal brain. Lateral ventricles are slightly, 
but significantly, larger in male than in female fetuses. Therefore, it is not surprising that 
males are found to have borderline ventriculomegaly more frequently, and to have a 
significantly lesser degree of neurological compromise than females (Pilu et al, 1999). 
Spontaneous remission of borderline ventriculomegaly is frequently documented. It is 
unclear whether or not this implies an amelioration of the prognosis. Some investigators 
failed to demonstrate a difference in the outcome between cases with stable or progressing 
ventriculomegaly and cases with spontaneous remission (Pilu et al, 1999). Mild 
ventriculomegaly may be the first sign of abnormal or delayed brain maturation. It is 
possible that isolated borderline ventriculomegaly may represent the earliest manifestation 
of brain damage from heterogeneous causes including primary cerebral maldevelopment 
(e.g. obstructive hydrocephalus, lissencephaly) and destructive lesions (e.g. periventricular 
leukomalacia) arising from hypoxia and/or infections. Gross enlargement consistently 
indicates major cerebral anomalies. 
Standard cranial US scanning is performed through the anterior fontanel, the whole brain is 
scanned, and images are recorded in at least six coronal and five sagittal planes with a high 
frequency sector transducer (7.5-10 MHz). These imaging planes are shown in Figure 3.  
 





Fig. 3. Technique of intracranial scanning: (A) coronal planes; (B) sagittal planes. 
An additional scan series can be obtained in the axial plane through the temporoparietal 
bone. The standard coronal and sagittal views are used to assess the symmetry of the 
cerebral hemispheres, absence of the CSP and the corpus callosum, morphology of the 
cerebral ventricles, thalami and the posterior cranial fossa structures (e.g. cerebellum, the 
cisterna magna and the fourth ventricle). A high frequency linear transducer (10 MHz) is 
very useful to examine the subarachnoid and subdural space and integrity of the spine 
(Figure 4.a.). Doppler is extremely useful for the routine cranial examination. This is 
particularly true when trying to differentiate subdural from subarachnoid fluid in the 
subarachnoid spaces (Figure 4.b.) and in any suspected vascular lesion such as a vein of 
Galen anomaly (Chavhan et al, 2008). Cranial US are correlated with anatomical and 
pathological findings and clinical outcomes. Appropriate correlation of the US features with 
clinical history can assist in improving the diagnostic yield. Familiarity with the US features 
of congenital brain anomalies is therefore an extremely valuable tool, as it facilitates an 
accurate diagnosis and treatment these anomalies. 
 
a b 
Fig. 4. Normal surface subdural and subarachnoid spaces in coronal view using a high 
frequency linear transducer (A) and color Doppler (B). 
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Fig. 4. Normal surface subdural and subarachnoid spaces in coronal view using a high 
frequency linear transducer (A) and color Doppler (B). 
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2.1 Color doppler ultrasound 
The use of pulsed and continuous color Doppler US allows simultaneous examination of 
parenchymal and vascular cerebral structures (Cheung et al, 1994; Vasiljevic et al, 2011). Pulsed 
and continuous color Doppler neuroimaging are used to assess cerebral blood flow in many 
pathological states including hypoxic ischemic change and congenital abnormalities. Doppler 
flow measurements may help to distinguish between vascular structures and non-vascular 
lesions. Cerebral blood flow accounts for 22%–25% of the cardiac output in neonates and 15% 
of that in adults (Couture, 2001). Every major vessel in the human body has a characteristic 
flow pattern that is visible in spectral waveforms obtained in that vessel with Doppler US. 
Familiarity with the Doppler waveforms characteristic of cerebral arteries and veins in 
neonates is important for accurate diagnosis of brain abnormalities (Figure 5.).  
 
a b 
Fig. 5. Normal color Doppler wave forms from the anterior cerebral artery (A) and the 
superior sagittal sinus (B). 
The wave forms may be affected by age- and development-related hemodynamic 
differences (Chavhan et al, 2008, Romagnol et al, 2006). Values of cerebral blood flow 
velocities progressive increase with gestation age on consequence of progressive increase 
cardiac output, blood pressure and closing ductus arterosus (Vasiljevic et al, 2010). Values of 
Doppler indices (Pourcelot index or the resistance index and Gossling index or the 
pulsatility index) gradually increase with gestation age in consequence of progressive 
maturation and opening of vascular cerebral bed with a reduction of the cerebrovascular 
resistance (Vasiljevic et al, 2008; Deeg & Rupprecht, 1988). In the first 2 or 3 months after 
birth, complex variations in cerebral hemodynamics occur in association with changes in 
pO2, pCO2, and ductus arteriosus closure. Vasodilatation is seen with hypoxemia and 
hypercapnea. After the 3rd day of life, there is a gradual increase in peak systolic velocity 
and end-diastolic velocity. All cerebral arteries display a low-resistance flow pattern with 
continuous forward flow during systole and diastole (Figure 5.a.). Because these arteries 
usually have a diameter of less than 5 mm, the spectral lines are broad and the spectral 
window is filled. Knowledge of normal values of cerebral blood flow velocities and Doppler 
indices in neonates different gestation age is important for the monitoring maturational 
processes and growth of the immature brain and also useful for differential diagnosis of 
congenital and acquired CNS anomalies in both preterm and full-term neonates (Chavhan et 
 
Ultrasound Diagnosis of Congenital Brain Anomalies 
 
81 
al, 2008;). Normal neonatal values and postnatal changes of cerebral blood flow velocities 
have been reported by several examiners (Deeg & Rupprecht 1989; Romagnol et al, 2006; 
Vasiljevic  et al, 2010). Table 2. shows the normal values of cerebral blood flow velocities and 
3 Doppler indices in the anterior cerebral artery in neonates different gestation age. These 
values we have obtained with color Doppler technique in seventy healthy neonates different 
gestation age during two years study period.  
Neonates GA BW (g) PSV(cm/s)
EDV
(cm/s) RI PI 
10 27.3±0.5 950±110 21.30 ±0.45 6.40±0.20 0.59±0.10 1.06±0.08 
20 29.5±1.2 1350±170 24.20 ±0.65 7.00±0.30 0.60±0.10 1.10±0.15 
20 34.5±0.6 1950±340 27.00 ±0.75 7.80±0.50 0.63±0.08 1.15±0.30 
20 38.6±1.3 3540±640 32.50 ±0.90 9.95±0.40 0.65±0.05 1.18±0.35 
Σ 70 34.5± 5.5 2540 ±950 26.25±0.68 7.78±0.35 0.61±0.08 1.12±0.22 
Table 2. Normal values of cerebral blood low velocities in the neonates in the neonates (GA-
gestational age; PSV- peak-systolic velocity; EDV- end-diastolic velocity; RI- resistive index 
and PI- pulsatility index).  
Referred cardiac pulsations normally can be seen in the intracranial veins. Venous waveforms 
in the superior sagittal sinus may be continuous and monophasic or may fluctuate in 
synchronicity with arterial pulsations (Figure 5.b.). Intracranial venous flow velocities 
gradually increase after birth (Dean & Taylor, 1995). The mean velocity in the superior sagittal 
sinus usually ranges between 8 and 12 cm/s in neonates. The transverse sinus usually can be 
assessed in neonates and shows an intracranial venous flow velocity of 2.7–3.3 cm/s. 
However, great variations can be seen in flow velocity with factors such as head rotation, 
crying, and other activities. Cardiac output fluctuates in an unstable neonate, altering carotid 
artery and cerebral perfusion. Color Doppler imaging is also useful in defining the limit of the 
arterial system within the subarachnoid space. This helps differentiate fluid in the subdural 
space from adhesions within the arachnoid space, as the arterial system is confined to the 
subarachnoid space (Chavhan et al, 2008; Dean & Taylor, 1995) 
2.2 Ultrasnography of the spine 
Ultrasound does not penetrate through bone but in the neonate the posterior spinal arches 
are poorly mineralized, allowing US assessment of the cord and dural sac from the foramen 
magnum down to the sacral hiatus. Spinal US is used as an initial screening tool in the 
neonate with spinal and other congenital abnormalities. There is a high incidence of spinal 
abnormalities in babies who have other congenital syndromes (e.g., ano-rectal malformation, 
cloacal exstrophy, caudal regression and spinal segmentation abnormalities—the 
VATER/VACTEROL anomaly) (Pilu & Hobbins, 2002). Two types of scanning planes can be 
used to evaluate the integrity of the spine. In transverse planes or axial planes, the examination 
of the spine is a dynamic process performed by sweeping the transducer along the entire 
length of the spine and at the same time keeping in the axial plane of the level being examined. 
In transverse sections, the neural canal appears as a closed circle. It is lined anteriorly by the 
ossification center in the body of the vertebrae and posteriorly by the two ossification centers 
of the laminae (Figure 6.). The vertebrae have different anatomic configurations at different 
levels. Thoracic and lumbar vertebrae have a triangular shape, while the first cervical 
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vertebrae are quadrangular in shape, and sacral vertebrae are flat. In the longitudinal or 
saggital section, the spine appears as three parallel lines converging caudally in the sacrum. 
The lines correspond to the anterior and posterior walls of the spinal cord and a central 
echogenic line the central canal (Figure 6.). Spinal cord appears hypo-echoic. The cord is 
surrounded by the cerebrospinal fluid (CSF) which appears anechoic. In term neonates the 
conus medullaris is usually found at the level of L2-L3. If a true longitudinal section can be 
obtained, visualizing the conus medullaris in its normal location further strengthens the 
diagnosis of normalcy (Robbin et al, 1994). The filum terminale extends to the sacral region as a 
thin extension of the cord. The normal filum terminale is 1.0-1.5 mm in diameter. Filing the 
cord in this area are echogenic lines, nerve fibres, which almost fill the arachnoid space and 
can be seen to move on real-time imagining and form cauda eqina. 
  
a b
Fig. 6. The longitudinal section of the neonatal spine (A) and the transverse views of the 
neonatal spine (B). 
More recently three-dimensional ultrasound has become available. Three-dimensional 
ultrasound may facilitate the examination of the fetal brain and spine. 
Its utility in the neonatal nursery needs further assessment, but it may be useful in assessing 
ventricular volumes and producing more meaningful images of cerebral abnormalities and 
brain damage (Riccabona et al, 2003). The main indication for MRI of the neonatal brain is 
further evaluation of inconclusive ultrasound findings in neonates with dysmorphic feature 
or abnormal neurological behavior. 
3. Cerebral ventriculomegaly and hydrocephaly 
Hydrocephalus and ventriculomegaly are both terms used to describe dilatation of the 
lateral ventricles. However, they should be distinguished: hydrocephalus signifies dilated 
lateral ventricles resulting from an increased amount of CSF inside the ventricles and 
increased intracranial pressure, while ventriculomegaly is a dilatation of the lateral 
ventricles without increased intracranial, from any cause, nonobstructive or obstructive. 
Ventriculomegaly is the most common congenital CNS anomaly with an incidence of 0.3 to 
1.5 per 1000 births, probably higher in utero (Fransen et al, 1996). Couples with a previously 
affected child have a recurrence risk of 4% (Griffiths et al, 2006). Ventriculomegaly can be 
isolated or associated with other congenital (e.g. Dandy Walker malformation, corpus 
callosum agenesis, arachnoid cysts, vein of Galen aneurysms and a spinal defect with 
myelomeningocele) or acquired CNS anomalies (hemorrhage, infections). Extra-cranial 
abnormalities occur in 30% of cases and included meningomyelocele, renal anomalies (e.g. 
bilateral or unilateral renal agenesis, dysplastic kidneys), cardiac anomalies (e.g. ventricular 
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septal defect, tetralogy of Fallot), gastrointestinal anomalies (e.g. colon and anal agenesis, 
malrotation of the bowel), cleft lip and palate, Meckel syndrome, gonadal dysgenesis, 
arthrogryposis, and dysplastic phalanges. Chromosomal aberrations are found in 11% of 
cases, mostly trisomy 21 (Schwanitz et al, 1993; Gaglioti et al, 2005). Isolated congenital 
ventriculomegaly accounts for 30-60% of neonates with enlarged lateral cerebral ventricles 
(Mercier et al, 2001). In the majority of cases, isolated ventriculomegaly is the consequence of 
an obstruction along the normal pathway of CSF (e.g. obstructive ventriculomegaly). 
Nonobstructive causes of ventriculomegaly include a congenital CNS malformation (failure of 
development of portions of the normal brain), brain destruction (e.g. congenital infection or a 
vascular mechanism) and overproduction of CSF (choroid plexus papillomas). Congenital 
ventriculomegaly is a heterogeneous disease for which genetic, infectious, teratogenic and 
neoplastic causes have been implicated. A multifactorial pattern of inheritance is probably 
responsible for most cases of congenital ventriculomegaly (Renier et al, 1988). X-linked 
hydrocephalus comprises approximately 5% of all cases. This condition is caused by mutations 
in the gene at Xq28 encoding for L1, a neural cell adhesion molecule. Mutations in this gene are 
also responsible for other syndromes with clinical overlap that are frequently referred to as the 
X-linked hydrocephalus spectrum and include MASA (e.g. mental retardation, aphasia, 
shuffling gait, adducted thumbs) syndrome, X-linked mental retardation-clasped thumb (MR-
CT) syndrome, X-linked complicated spastic paraparesis (SP1), and some forms of X-linked 
agenesis of the corpus callosum (Kenwick et al, 1996). The presence of uni- or bilateral 
ventriculomegaly seems to be of some discriminatory value. Ventriculomegaly tends to be 
unilateral in cases of brain destruction and bilateral in cases of CNS malformation, and this 
difference is statistically significant. In apparently isolated ventriculomegaly, we must 
distinguish between borderline and moderate to severe ventriculomegaly (Graham et al, 2001; 
Toma & Granata, 2005). US is an effective mode for imaging the ventricular system and 
sensitive to ventricular dilatation and minor degrees of ventricular asymmetry (Kenwick et al, 
1996). In the clinically normal term infant the ventricles are often small (slit-like) for the few 
days after vaginal delivery. The normal ventricular system, which appears as anechogenic fluid-
filled space becomes dilated and increase in size (Figure 7.).  
 
a b 
Fig. 7. Normal ventricular system (A) and ventricular dilatation (B) in coronal view.  
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vertebrae are quadrangular in shape, and sacral vertebrae are flat. In the longitudinal or 
saggital section, the spine appears as three parallel lines converging caudally in the sacrum. 
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diagnosis of normalcy (Robbin et al, 1994). The filum terminale extends to the sacral region as a 
thin extension of the cord. The normal filum terminale is 1.0-1.5 mm in diameter. Filing the 
cord in this area are echogenic lines, nerve fibres, which almost fill the arachnoid space and 
can be seen to move on real-time imagining and form cauda eqina. 
  
a b
Fig. 6. The longitudinal section of the neonatal spine (A) and the transverse views of the 
neonatal spine (B). 
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The most useful qualitative US features of early ventricular dilatation are ballooning of the 
supratentorial angles of the ventricles of the frontal horns in coronal plane. These areas 
dilate more than the trigones and bodies of the ventricles because they are lager and require 
less pressure for distension (Carty et al, 2001). Despite that, ventricular dilatation is usually 
first seen in the occipital horns of the lateral ventricles, but there is considerable variation in 
the size of this part of the ventricular system in normal babies. With modern real-time 
ultrasound, clear visualisation of the lateral ventricles can be obtained and exact anatomical 
landmarks identified. Lateral ventricular size has been measured with number of different 
methods. Levine et al measured the ventricular size from midline to the lateral-most point of 
the lateral ventricles (ventricular index) in 273 infant from 26 to 42week’s gestation and 
described normal ranges of ventricular size at differing gestation (Levine et al, 1985). In 
addition, London et al measured the biventricular diameter at the level of the frontal horns, 
diagonal width of the frontal horns at level of the caudate nucleus, intercaudate distance 
and biventricular diameter at the body of the lateral ventricles (London et al, 1980). Allan et 
al and Qusling et al measured of the lateral ventricules at the mid-body near the atrium of 
ventricule in sagittal plane (Qusling yet al, 1983). This is regarded as a “standard table” for 
assessment of ventricular dilatation. The term borderline ventriculomegaly is commonly used 
to indicate cases characterized by an atrial width of 10–15 mm. Some authors have reported a 
different rate of abnormal neurologic outcome in fetuses with atria > 12 mm compared with 
those with atria measuring 10–12 mm (a mild form of borderline ventriculomegaly). In fact, an 
isolated borderline ventriculomegaly of 10–12 mm might be considered as a variant of the 
norm (Signorelli et al, 2004). When the atrial width is between 15–20 mm the ventriculomegaly 
is defined moderate. Aqueductal stenosis, regardless of its cause, is responsible for the 
progression of ventricular dilatation. Severe ventriculomegaly is usually referred to as 
hydrocephalus and is defined on the basis of an atrial width of more than 20 mm (Bloom et al, 
1997) (Figure 7.b.). Congenital hydrocephalus is classified into three categories by causes that 
disturb the CSF circulation pathway: simple hydrocephalus, dysgenetic hydrocephalus, and 
secondary hydrocephalus. Simple hydrocephalus is caused by a developmental abnormality 
localized within the CSF circulation pathway and includes aqueductal stenosis, atresia of the 
foramen of Monro, Magendie or Luschka, and maldevelopment of arachnoid granulation. 
Dysgenetic hydrocephalus results from a cerebral developmental disorder in the early stages 
of development, and includes hydranencephaly, holoprosencephaly, porencephaly, 
schizencephaly, Dandy–Walker malformation, dysraphism, and Chiari malformation. 
Secondary hydrocephalus is a generic term indicating hydrocephalus caused by an intracranial 
pathologic condition, such as intracranial infection, hemorrhage or brain tumor.  
Pediatric data suggest that a correlation exists between cortical mantle thickness before 
shunting and long-term intellectual performances. Thickness of less than 1 cm has been 
associated with a poor outcome, but the most important prognostic consideration is the 
presence and nature of the associated anomalies. The available evidence suggests that 
borderline ventriculomegaly is most frequently without consequences (Bloom et al, 1997). 
Some authors have opposite results, and suggest that borderline ventriculomegaly carries an 
increased risk of cerebral maldevelopment, delayed neurologic development, and possibly 
chromosomal aberrations (Pilu Falco et al, 1999; Mercier  et al, 2001). The main problem in 
these cases with borderline ventriculomegaly is to exclude other CNS and extra-cranial 
malformations. Macrocrania at birth, ventricular size and age at surgery had no influence on 
the outcome. Ventriculomegaly may develop in late gestation or after birth, particularly 
with the X-linked hydrocephalus spectrum.  
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4. Agenesis of the corpus callosum 
Agenesis of the corpus callosum is an anomaly that may occur in isolation or in association 
with other CNS or systemic malformations. Because the corpus callosum may be partially or 
completely absent, the term dysgenesis has also been used to describe the spectrum of 
callosal anomalies (Barkovich & Norman, 1988; Davila-Gutierrez, 2002). With complete 
agenesis, the corpus callosum is totally absent. With partial agenesis (hypoplasia), the 
anterior portion (posterior genu and anterior body) is formed, but the posterior portion 
(posterior body and splenium) is not. An atypical appearance occurs when the anterior to 
posterior formation is not respected (Barkovich, 1990). Development the corpus callosum 
occurs at the same time as cerebral and cerebellar development, and therefore agenesis of 
the corpus callosum is associated with other brain anomalies in 80% of cases. Associated 
CNS anomalies may include midline intracerebral lipomas, encephalocele, interhemispheric 
arachnoid cyst, microcephaly, Dandy-Walker malformation, Arnold-Chiari malformation, 
holoprosencephaly, hydrocephalus, disorders of neuronal migration, such as neuronal 
heterotopias, lissencephaly, pachygyria, and schizencephaly (Hetts et al, 2006; Volpe, 2009). 
With partial agenesis (hypogenesis), the anterior portion (posterior genu and anterior body) 
is formed, but the posterior portion (posterior body and splenium) is not. The rostrum and 
the anterior/inferior genu are also not formed. Secondary destruction of the corpus 
callosum occurs when the genu and anterior body are destroyed, leaving the posterior 
portion of the corpus callosum intact. Primary dysgenesis/agenesis of the corpus callosum 
should be differentiated from secondary destruction of an initially normally developed 
corpus callosum as can be observed in trauma, infarction, hemorrhage and in several 
metabolic diseases. Agenesis of the corpus callosum can occur in chromosomal 
abnormalities, such as trisomy 8, trisomy 13 and trisomy 18, as a part of the 
holoprosencephalic sequence, and also may be found in chromosomal translocation 
syndromes (Tang et al, 2009). Callosal anomalies are found in several syndromes, including 
X-linked Aicardi syndrome, the median cleft face syndrome, Andermann syndrome, F.G. 
syndrome, and acrocallosal syndrome. An association with maternal rubella and 
toxoplasmosis has been reported. Because they develop embryonically in close proximity, 
agenesis of the corpus callosum is commonly associated with malformations of local limbic 
structures, particularly the septum and hippocampal formations. Extra-CNS malformations 
may include anomalies of the face, musculoskeletal system, gastrointestinal tract, 
genitourinary tract, cardiovascular system, and respiratory system. 
The incidence of agenesis of the corpus callosum is from 0.3–0.7% in the general population 
to 2–3% in the developmentally disabled population. Dependent on etiology, a recurrence 
risk is from 1% (if sporadic or chromosomal) to 25% (if autosomal recessive) or even 50% in 
males (if X-linked recessive). 
The corpus callosum is a white matter structure connecting the cerebral hemispheres and is 
important in coordinating information and bilateral exchange of sensory stimuli. It develops 
between the 10th and 20th weeks of gestation, from the lamina reuniens, which is the 
thickened dorsal aspect of the lamina terminalis (Bennet et al, 1996). If the commissural plate 
fails to develop or is damaged, the uncrossed callosal fibers run parallel to the medial walls 
of the lateral ventricles, forming the bundles of Probst. These bundles do not cross the 
midline. Pathogenesis agenesis of the corpus callosum is uncertain, but callosal dysgenesis 
may be associated with a migration disorder (Smith et al, 2008). When complete, corpus 
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callosum consist of genu, body, splenum and rostrum. The normal development sequence is 
anterior to posterior, which allows one to distinguish between a partial primary and 
secondary dysgenesis of the corpus callosum. The genu is the first area to develop. 
Antenatal diagnosis of agenesis of the corpus callosum is possible from about 20 weeks' 
gestation. 
The characteristic findings agenesis of the corpus callosum on ultasonography included 
absent corpus callosum and cavum pellucidum in coronal and saggital planes, widely 
separated lateral venticles, colpocephaly or “teardrop” configuration of lateral ventricles, 
elevation and variable dilatation of the third ventricle (“interhemispheric cyst”), distended 
interhemispheric fissure, abnormal radial orientation of medial cerebral gyri extending from 
the roof of the third ventricle (“sunburst sign”) and abnormal branching of anterior cerebral 
artery (Figure 8.) (Penny, 2006; Atlas  et al, 1985; Byrd et al, 1990).  
 
a b c 
Fig. 8. Agenesis of the corpus callosum in the sagittal planes (A) and coronal planes; (B and C).  
Color Doppler scan showing the absence of the corpus callosum and abnormal course of the 
pericallosal artery (Figure 9.). (Schell-Apacik et al, 2008). Lipoma of the corpus callosum is 
demonstrated as a highly echogenic mass in the region of the corpus callosum. 
 
Fig. 9. Sagittal color Doppler scan shows the agenesis of the corpus callosum. 
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Agenesis of the corpus callosum may be a completely asymptomatic (found incidentally) or 
with subtle developmental deficits and severe neurologic problems, such as seizures, 
intellectual impairment, and psychosis. However, these conditions are believed to be caused 
by abnormalities in associated cerebral and chromosomal anomalies rather than in the 
corpus callosum per se (Goodyear et al, 2001). Hence, prognosis is determined primarily by 
the underlying or associated malformations. Studies of persons with isolated agenesis of the 
corpus callosum without other abnormalities show that some have normal intelligence, 
while others are developmentally delayed (Taylor et al, 1998). Complete agenesis has a 
worse prognosis than partial agenesis. 
5. Holoprosencephaly 
Holoprosencephaly is a heterogeneous entity of CNS anomalies caused by the impaired 
midline cleavage of the forebrain (prosencephalon) into the right and left hemispheres, and the 
malformation of the diencephalon, telencephalon, olfactory, and optic bulbs (Volpe, 2001). 
Holoprosencephaly is graded according to the severity of the brains anomaly as alobar, 
semilobar and lobar (Figure 10.)(Peebles, 2001).  
 
a b c d 
Fig. 10. Schematic drawing of the normal neonatal brain (A), alobar holoprosencephaly (B), 
semilobar holoprosencephaly (C) and. lobar holoprosencephaly (D).  
In alobar holoprosencephaly, the most severe form, the cerebral hemispheres are fused and 
enclose a single prosencephalic ventricle. There is a complete failure of cleavage of the 
forebrain into two hemispheres. It results in a single ventricular cavity with fusion of 
thalami, absence of corpus callosus, falx cerebri, optic tracts and olfactory bulbs. Partial 
cleavage results in semilobar holoprosencephaly, with posterior separation of the cerebral 
hemispheres, variable degrees of fusion of the thalami and absent olfactory bulbs and 
corpus callosus. In lobar holoprosencephaly, the abnormalities may be confined to absence of 
the corpus callosus and fusion of the lateral ventricles and cingulate gyrus. The two 
hemispheres are separated anteriorly and posteriorly. Because of a mechanism of reciprocal 
induction between the brain and the skull, the facial structures are also abnormal (Edison & 
Muenke, 2003). The severity of the facial malformation reflects the severity of the intracranial 
anomalies and include: cyclopia (median monoophthalmia, synophthalmia or anophthalmia 
with proboscis), cebocephaly or« monkey head », (ocular hypotelorism and a blind single 
nostril nose), ethmocephaly (ocular hypotelorism with proboscis) and median cleft lip. 
Holoprosencephaly is found in several syndromes, including Meckel-Gruber syndrome, 
holoprosencephaly-fetal akinesia syndrome and Steinfield syndrome (Cho et al, 2005). The 
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most frequently associated CNS anomalies are microcephaly, macrocephaly, and Dandy–
Walker malformations. Associated extra-cranial abnormalities are congenital heart defects, 
renal dysplasias, omphalocele and polydactyly.  
The incidence holoprosencephaly is about to 0.6-1.9 per 1000 births, but 4 per 1000 in 
embryos. Half of these are associated with trisomy 13. Holoprosencephaly occurs in about 
70% of the patients with trisomy 13 (Roessler & Muenke, 1998). The sex distribution 
shows a female predominance. The risk of recurrence depends of the basis for the actual 
condition, such as chromosome defect or syndrome. In the cases without chromosomal 
abnormalities, the recurrence risk is estimated to be 6%. 
The etiology of holoprosencephaly is heterogeneous and not completely known. Most cases 
are sporadic and environmental, and genetic factors have all been implicated as possible 
causes (Muenke & Beachey, 2000). This is probably due to mutations in the gene for the sonic 
hedgehog morphogen and genes that encode its downstream intracellular signaling pathway 
(Wallis & Muenke, 2000). There is also some evidence for a defect in the cholesterol 
biosynthesis. Holoprosencephaly in association with extra cephalic malformations suggests 
aneuploidy, particularly trisomy 13. Familial holoprosencephaly is known. It can be inherited 
in an autosomal dominant fashion with varied penetrance, or as an autosomal recessive. In 
addition to the genetic component to holoprosencephaly , environmental factors are also 
critical. In experimental animal studies, holoprosencephaly has been induced by teratogenic 
agents (retinoic acid, ethanol). An association with maternal infectious (cytomegalovirus, 
toxoplasmosis), conditions such as gestational diabetes have also been reported.  
The ultrasound of alobar holoprosencephaly is characteristic and shows a large central 
echo-free monoventricular cavity surrounded by a varying amount of residual cortical 
mantle. No midlines structures are visible. The infratentorial structures are usually 
present with fusion of the thalami on the midline. The semilobar holoprosencephaly is 
characterized by the presence of rudimentary lateral ventricles with sketchy posterior 
horns, and a more developed cortex, partial development of the interhemispheric fissure 
and of the falx cerebri, which is present only posteriorly and partial fusion of the thalami 
(Figure 11.). The lobar holoprosencephaly has a well developed interhemispheric fissure, 
partial fusion of the frontal horns with the third ventricle, hypoagenesis of the corpus 
callosum and the cavum septum pellucidum is absent. 
 
Fig. 11. Coronal scan shows the semilobar holoprosencephaly. 
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Prognosis depends on the form of holoprosencephaly. The severe forms are incompatible 
with prolonged survival. In the lobar type, the prognosis is less well defined, but mental 
retardation, olfactory and visual anomalies are often present Termination of pregnancy can 
be offered for the severe cases holoprosencephaly (semi-lobar, alobar). 
6. Hydranencephaly 
Hydranencephaly is characterized by the absence of the cerebral hemispheres, an 
incomplete or absent falx and a huge saclike structure containing cerebral spinal fluid 
covered by leptomeninges and dura. The brain stem is usually present, although the basal 
ganglia and cerebellum may be smaller than normal. The presence of the falx and of the 
cranial nerves demonstrates that the hemispheres have developed but have subsequently 
been destroyed (Dixon, 2005).  
Etiology of this disorder includes: bilateral occlusion of the internal carotid or middle 
cerebral arteries, necrotizing vasculitis caused by infection (congenital cytomegalovirus, 
toxoplasmosis and herpes simplex infections), diffuse hypoxic-ischemic brain necrosis based 
on fetal hypoxia, leukomalacia formed by confluence of multiple cystic cavities and 
thromboplastic material from a deceased co-twin. The most accepted hypothesis to explain 
this particular lesion is interruption of the blood supply in early pregnancy (Barkovich, 
2005). The occlusion of internal carotid arteries results in ischemic insult of the areas 
supplied by anterior and middle cerebral artery. There is variability in the extent of 
destruction of the cerebral hemispheres. Destruction may be complete or may spare portions 
of the temporal and occipital cortex. Liquefaction of the brain tissue in the area involved 
(usually the hemispheres), with replacement of the neural tissue by CSF and preservation of 
the membranes. Blood supply for the posterior brain fossa stays intact which explains the 
presence of brainstem and cerebellum 
Hydranencephaly is a rare destructive brain lesions with prevalence to 0.1-0.2 in 1000 
newborns. Hydranencephaly is found in 0.2% of infant autopsies. Recurrence risk is 
unknown. Aside from consequential arthrogryposis, hydranencephaly has been associated 
with syndromes including renal aplastic dysplasia, polyvalvular developmental heart 
defect, porencephaly, microcephaly and with trisomy 13 (Bendon et al, 1987). Familial cases 
are rare. 
On ultrasound, hydrancephaly presents as a large cystic mass filling the entire cranial cavity 
with absence or discontinuity of the cerebral cortex (Figure 12.). Falx cerebri is partially 
missing or absent and brainstem is preserved. The pused and continuous color Doppler US 
show abnormal pathway and occlusion of the anterior cerebral artery crawling under the 
skull (Bernard et al, 2002; Stevenson et al, 2001).  
The most common diagnostic problem is differentiation among hydranencephaly, extreme 
hydrocephalus, alobar holoprosencephaly and porencephaly. With extreme hydrocephaly, 
alobar holoprosencephaly or porencephaly, these structures should still be surrounded by a 
rim of cortex, and the choroid plexuses should be normally visible. Magnetic resonance 
imaging (MRI) and evoked potentials may serve as an additional means for confirming the 
ultrasound diagnosis (Hanigan & Aldrich, 1988). Diagnosis can be done prenatally by 
ultrasound (Lam & Tang, 2000).  
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Fig. 12. Sagittal scan show sthe typical features of hydranencephaly. 
The prognosis is universally very poor and incompatible with post-natal life. 
Hydranencephaly is associated with severe psychomotor delay, nystagmus, optic atrophy, 
epilepsy, and hypothermia. Survival may last several months if an intact hypothalamus 
permits thermoregulation, but most die in the first two years of life. It has been suggested 
termination of pregnancy when an antenatal diagnosis of hydranencephaly is made. 
7. Schizencephaly 
Schizencephaly is an uncommon CNS congenital disorder of neuronal migration, 
characterized abnormal cleft by brain (Oh et al, 2005). The cleft can be localized anywhere on 
the brain, but they are usually localized on the perisylvian regions. The cleft can be 
unilateral or bilateral and be either symmetric or asymmetric. The clefts may extend through 
the entire hemisphere from the ependymal lining of the lateral ventricles to the pial surface 
covering the cortex of some part of the brain. The gray matter lining can be dysplastic. There 
are two types of schizencephaly: 
Type I: The clefts can be unilateral or bilateral and may be closed (fused lips). In closed-lip, 
the cleft walls are in apposition, causing obliteration of the CSF space within the cleft. 
Type II: The clefts can be unilateral or bilateral and may be separated (open lips). In open-
lips, the clefts walls are separated. The CSF fills the cleft from the lateral ventricles to the 
subarachnoid space that surrounds the hemispheres. The ventricle system may be enlarged, 
particularly with the open lip form of schizencephaly. 
Schizencephaly has an extremely rare prevalence, with an unknown incidence. There is 
neither sex nor race predilection. Schizencephaly type II is more frequent than 
schizencephaly type I. Different CNS anomalies can be associated with schizencephaly: 
gray-matter heterotopias, polymicrogyria, arachnoid cysts, microcephaly, agenesis of the 
corpus callosus (Briellmann et al, 1998; Hayashi et al, 2002). The septum pellucidum is absent 
in 50-85 % of the patients and may coexist with septo-optic dysplasia. Some individuals 
affected by schizencephaly, may have an excessive accumulation of CSF in the brain and 
caused ventriculomegaly and the hydrocephaly with macrocrania. 
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Etiology of schizencephaly remains unclear, some environmental events have been 
proposed. No specific prenatal events have been identified, but genetic, toxic, metabolic, 
vascular of infectious etiology (congenital cytomegalovirus infection) can be responsible 
(Montenegro et al, 2002; Iannetti et al, 1998). Schizencephaly have an autosomal dominant 
inheritance with incomplete penetrance and variable expression. Familial cases have been 
reported, suggesting a possible genetic origin within a group of neuronal migration 
disorders (Guerrini & Carrozzo, 2001). Recent studies have linked schizencephaly with a 
mutated gene called EMX2 homeobox gene (Guerrini & Carrozzo, 2001; Granata et al, 1997). 
If the gene EMX-2 is missing or defective, nerve cell growth and migration will not occur 
normally and lead to the formation of the clefts associated with schizencephaly. 
Two theories are currently accepted. One argues a failure in neuronal migration from the 
germinal matrix, while the other argues a post-migrational vascular insult (Montenegro et al, 
2002; Oh et al, 2005). Schizencephaly results from an early, focal destruction of the germinal 
matrix and surrounding brain, before the hemispheres are fully formed. Schizencephaly can 
occur due to an abnormal neuronal migration from the germinal matrix zone. According to 
other authors, schizencephaly and polymicrogyria are the result of the same cortical 
damage, because of the frequent association of an unlayered cortex lining surrounding the 
cleft. Schizencephaly would be an extreme variant of cortical dysplasia in which the 
infolding of the cortex extends all the way into the lateral ventricles. 
Schizencephaly may be suspected by the appearance of focal ventricular dilatation and by 
visualization of gray matter lined cleft on ultrasound (Hayashi et al, 2002). This space is 
filled with CSF. In unilateral schizencephaly, the clefts is only on one side of the brain, while 
in bilateral schizencephaly is on both sides (Figure 13.). The septum pellucidum is absent in 
most patient with schizencephaly. MRI is the best method to differentiate schizencephaly 
from porencephaly and arachnoid cyst (Hayashi et al, 2002; Liang et al, 2002).  
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Fig. 13. Coronal scan (A) and axial scan (B) show the typical features of bilateral 
schizencephaly. 
The clinical features of schizencephaly are extremely variable. Usually the severity of these 
symptoms is related to the extent of cortex involved in the defect and associated CNS 
anomalies (Denis at al 2000; Hayashi et al, 2002). Children with unilateral clefts have often 
hemiparesis, but may also have mild-to-moderate developmental delay. Children with 
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bilateral clefts have severe mental and motor impairments, early onset of epilepsy and 
frequently blindness, deafness. Sometimes, closed-lip schizencephaly may not present 
clinically until later during the childhood and may live to early adulthood.  
8. Lissencephaly  
Cerebral cortical development is an extremely complex process, comprising three major, but 
overlapping, steps: cell proliferation, neuronal migration and cortical organization. 
Neuronal migration disorders (also, and better, called cortical developmental anomaly) are 
caused by abnormal proliferation, migration, and organization (lamination, gyration, and 
sulcation). Lissencephaly is a rare cortical developmental disorder, with reduced or absent 
brain gyri, which is caused by abnormal neuronal migration in the neocortex.  
The incidence lissencephaly is unknown but rare. There is female predilection. 
Lissencephaly have been associated with deletion of a number of genes on chromosome 
17p13, including LIS1. Identification of LIS1 as the causative gene for lissencephaly did not 
come until 1993, and the role of DCX in both lissencephaly and subcortical band heterotopia 
was not determined until 1998. DCX is located on the long arm of the X chromosome and 
therefore is inherited in an X-linked dominant form, with female subjects showing a milder 
phenotype (subcortical band heterotopia) than male subjects (anterior greater than posterior 
lissencephaly). If de novo deletion or translocation occurs, the recurrence risk is low. If the 
translocation is inherited from one parent (who has a balanced translocation), the recurrence 
risk may be as high as 25%.  
Lissencephaly is characterized by agyria, accompanied or not by pachygyria, minimal or no 
ventriculomegaly, and characteristic dysmorphic features (Verloes et al, 2007). The most 
frequently associated anomalies are duodenal atresia, urinary tract abnormalities, congenital 
heart defects, cryptorchidism, inguinal hernia, clinodactyly, polydactyly, and ear anomalies 
may be found. The classification of lissencephaly has undergone significant revision in the 
last decade, as a result of recent discoveries regarding the molecular biological basis of such 
malformations, and findings on MRI and autopsy. There are three main groups of 
lissencephaly (Barkovich et al, 2001). 
Group A lissencephaly (or classical lissencephaly) is characterized by agyria with or 
without pachygyria, a wide cortical mantle and minimal or no hydrocephalus. In classical 
lissencephaly (agyria/pachygyria), the normal six-layered cortex is replaced by an 
abnormally thick four-layered cortex and characterized by simplified or absent 
gyration. The incidence of all forms of type I lissencephaly is around 1 in 100,000 births. The 
subtypes of group A lissencephaly are: 
1. Miller-Dieker syndrome is associated with a deletion at the chromosome 17p13.3 locus. 
This syndrome has lissencephaly combined with dysmorphic facial features and other 
possible associated CNS anomalies (dysgenesis of the corpus callosum, 
ventriculomegaly, midline calcifications, and mild cortical cerebellar dysplasia). 
Microcephaly is common. Associated abnormalities include heart malformations, 
omphalocele, kidney dysplasia, and genital anomalies). Transverse palmar creases and 
clinodactyly are common. Among extracranial abnormalities, the most common is 
intrauterine growth restriction.  
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2. In Norman-Roberts syndrome, no abnormal karyotype is fond. This syndrome is 
autosomal recessively inherited. It is a type I lissencephaly with sloping forehead and 
other minor facial features described in a consanguineous family. 
3. Isolated type I lissencephaly is not associated with deletion at the chromosome 17p13.3 
locus or abnormalities limited to the LIS1 gene. Patients with isolated lissencephaly do 
not have other congenital anomalies or severe dysmorphic features.  
Group B lissencephaly (or type II) is characterised by global disorganisation of cerebral 
organogenesis with an uneven cortical surface Lissencephaly, type II typically has 
hydrocephalus and additional serious CNS defects. The subtypes of group B lissencephaly 
are: 
1. HARD+/-E syndrome, an acronym for Hydrocephalus, Agyria, Retinal dysplasia, 
Encephalocele (Walker-Warburg syndrome), is an autosomal recessive lethal disorder. 
Associated abnormalities include other serious CNS malformations such as dysgenesis 
of the corpus callosum, cerebellar dysplasia with Dandy-Walker malformation, and 
white brain substance atrophy are found. 
2. Cerebro-oculomuscular syndrome with congenital muscular dysplasia is possibly a 
variant of the HARD+/-E syndrome, and is supposed to be autosomal recessively 
inherited. Other subtypes of type II lissencephaly are possible. 
Group C lissencephaly is found in lissencephaly associated with Neu-Laxova syndrome 
which is a lethal autosomal recessive inherited disorder consisting of growth retardation, 
microcephaly, lissencephaly, dysgenesis of the corpus callosum, intracranial calcifications, 
cerebellar hypoplasia, facial dysmorphism, microphthalmia, exophthalmus, cataracts, absent 
eyelids, hydrops, ichthyosis, contractures of extremities and syndactyly.  
Lssencephaly may be suspected if appear a smooth gyral pattern, ventriculomegaly, and a 
prominent subarachnoid space on ultrasound (Barkovich et al, 2001) (Figure 14.). The 
progressive microcephaly and failure of development of both sulci and gyri (which in 
normal conditions is well defined from 26 to 28 weeks) are suggestive of lissencephaly (Fong 
et al, 2004). MRI may be better able to detect the pachygyric appearance of the cerebral 
cortex and subcortical band heterotopia (Garel et al, 2001; Levente, 2005). 
 
Fig. 14. Coronal scan shows the typical features of lissencephaly. 
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2. In Norman-Roberts syndrome, no abnormal karyotype is fond. This syndrome is 
autosomal recessively inherited. It is a type I lissencephaly with sloping forehead and 
other minor facial features described in a consanguineous family. 
3. Isolated type I lissencephaly is not associated with deletion at the chromosome 17p13.3 
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not have other congenital anomalies or severe dysmorphic features.  
Group B lissencephaly (or type II) is characterised by global disorganisation of cerebral 
organogenesis with an uneven cortical surface Lissencephaly, type II typically has 
hydrocephalus and additional serious CNS defects. The subtypes of group B lissencephaly 
are: 
1. HARD+/-E syndrome, an acronym for Hydrocephalus, Agyria, Retinal dysplasia, 
Encephalocele (Walker-Warburg syndrome), is an autosomal recessive lethal disorder. 
Associated abnormalities include other serious CNS malformations such as dysgenesis 
of the corpus callosum, cerebellar dysplasia with Dandy-Walker malformation, and 
white brain substance atrophy are found. 
2. Cerebro-oculomuscular syndrome with congenital muscular dysplasia is possibly a 
variant of the HARD+/-E syndrome, and is supposed to be autosomal recessively 
inherited. Other subtypes of type II lissencephaly are possible. 
Group C lissencephaly is found in lissencephaly associated with Neu-Laxova syndrome 
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microcephaly, lissencephaly, dysgenesis of the corpus callosum, intracranial calcifications, 
cerebellar hypoplasia, facial dysmorphism, microphthalmia, exophthalmus, cataracts, absent 
eyelids, hydrops, ichthyosis, contractures of extremities and syndactyly.  
Lssencephaly may be suspected if appear a smooth gyral pattern, ventriculomegaly, and a 
prominent subarachnoid space on ultrasound (Barkovich et al, 2001) (Figure 14.). The 
progressive microcephaly and failure of development of both sulci and gyri (which in 
normal conditions is well defined from 26 to 28 weeks) are suggestive of lissencephaly (Fong 
et al, 2004). MRI may be better able to detect the pachygyric appearance of the cerebral 
cortex and subcortical band heterotopia (Garel et al, 2001; Levente, 2005). 
 
Fig. 14. Coronal scan shows the typical features of lissencephaly. 
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The prognosis of lissencephaly is universally poor, regardless of etiological type, and death 
occurs usually within the first 2 years of life. Usually severe mental retardation affects these 
patients. Failure to thrive, infantile spasms, and seizures are also expected.  
9. Porencephaly  
The term ‘porencephaly’ includes every type of destructive brain lesion with cavitary 
character, i.e. a fluid-filled spaces within the brain that commonly communicates with the 
ventricles, subarachnoid spaces, or both. It involves the destruction of previously developed 
brain tissue, with subsequent cavity formation. It may be isolated or associated with 
ventriculomegaly. Some authors consider two types of porencephaly.  
Type I porencephaly or encephaloclastic porencephaly is due to parenchymal damage 
followed by liquification/reabsorption, resulting from an insult (ischemia, hemorrhage, etc.) 
during the 3rd trimester. It is more frequent and usually unilateral. It has a round or 
irregular shape.  
Type II porencephaly or schizencephalic porencephaly, which is usually bilateral, caused 
by abnormal neural migration and cortical organization. It is best considered separately as a 
primary developmental abnormality.  
Etiology of porencephaly disorder includes: ischemic episode, trauma, demise of one twin, 
intercerebral hemorrhage and infection (Scher et al, 1991). This occurs when the immature 
brain has a propensity to dissolution and cavitations (due to high water content or a 
deficient astroglial response). The timing of ischemic injury (maybe as early as the 2nd 
trimester) is closely related to porencephaly and hydranencephaly. 
Porencephaly is a rare destructive brain lesion with prevalence to 0.1-0.2 in 1000 newborns. 
Risk of non-chromosomal syndromes is low. Type II porencephaly may be associated with 
orofaciodigital syndrome type I, and other CNS anomalies. The most frequently associated 
anomalies are hydrocephalus. 
On ultrasound, porencephaly appears as a unilateral cystic lesion, usually communicating 
with the ipsilateral ventricle and/or the subarachnoid space (Figure 15.). A porencephalic 
cyst never causes a mass effect, which is observed with arachnoid cysts and other cystic  
 
Fig. 15. Sagittal scan shows the typical features of porencephalic cyst. 
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mass lesions. This condition is an acquired brain insult and should be differentiated from 
schizencephaly of migration disorder. The cystic walls and the content of the cyst may vary 
according to the gestational age at which the insult occurs. If it is secondary to hemorrhage, 
it is possible to visualize a hyperechoic focus evolving into an anechoic CSF-filled cyst. 
Diagnosis can be done prenatally by ultrasound (Meizner & Elchalal, 1996). 
Prognosis is variable, depending on the timing and extent of the lesion. Epilepsy 
psychomotor retardation and cerebral palsy often occur. In type II, due to the bilaterality of 
the lesion and the tendency to be part of a syndrome, the prognosis is worse. A 
ventriculoperitoneal shunt should be applied if hydrocephalus progresses. 
10. Arachnoid cysts  
Arachnoid cysts are congenital lesions of the arachnoid membrane that expand with CSF 
secretion. They exist between the brain substance and dura and that may exist separately as 
a loculated accumulation between two arachnoid membranes or may communicate with the 
subarachnoid space. They represent 1% of all intracranial masses in newborns and they are 
found at 0.5% of autopsies. Arachnoid cysts are fluid-filled cavities lined completely or 
partially by the arachnoid membrane. The cysts are mostly single, but two or more can 
occasionally be observed. Arachnoid cysts have been found anywhere in the CNS, including 
the spinal canal. The most frequent locations are the surface of the cerebral hemispheres in 
the sites of the major fissures (sylvian, rolandic, and interhemispheric), the region of sella 
turcica, the anterior fossa, and the middle fossa (Nakamura et al, 2001). Less frequently, they 
are seen in the posterior fossa. Arachnoid cysts may increase or decrease in size. 
Arachnoid cysts have been associated with hydrocephalus, Aicardi syndrome, glutaric acid-
uria type I, and unbalanced X,9 translocation. Interhemispheric cysts are often associated 
with dysgenesis of the corpus callosum (Hirohata et al, 1992). Recurrence risk is unknown. 
Intracranial arachnoid cysts may be primary (congenital) or secondary (acquired). 
Congenital types are believed to be formed by maldevelopment arachnoid membranes and 
do not freely communicate with subarachnoid space. Acquired types are formed as the 
result of hemorrhage, trauma, and infection and often communicate with subarachnoid 
space. Arachnoid cysts have the potential to grow as the result of some communication with 
the subarachnoid space. The accumulation of fluid is believed to result from a ball valve 
mechanism. Furthermore, a choroid plexus-like tissue within the cyst wall, which secretes 
CSF and thus contributes to a progressive distension of the lesion, has been reported by 
several investigators. It contains clear cerebrospinal fluid and has been diagnosed prenatally 
by ultrasound. 
On ultrasound, arachnoid cysts present as a well-defined anechoic cystic structure with 
adjacent mass effect. The primary manifestation of an arachnoid cyst is a localized fluid 
collection occasionally causing hydrocephallus. Large arachnoid cysts may obstruct the 
circulation of CSF, leading to secondary obstructive hydrocephalus. The cyst can obstruct 
the foramen of Monro, displace the aqueduct posteriorly, and block the basal cisterns. 
Application of color Doppler will not demonstrate high flow (Figure 16.).  
The differential diagnosis from other cystic lesions may be difficult. Porencephaly is often 
associated with ventriculomegaly, communicates with the ventricles and follows a vascular 
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the subarachnoid space. The accumulation of fluid is believed to result from a ball valve 
mechanism. Furthermore, a choroid plexus-like tissue within the cyst wall, which secretes 
CSF and thus contributes to a progressive distension of the lesion, has been reported by 
several investigators. It contains clear cerebrospinal fluid and has been diagnosed prenatally 
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On ultrasound, arachnoid cysts present as a well-defined anechoic cystic structure with 
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collection occasionally causing hydrocephallus. Large arachnoid cysts may obstruct the 
circulation of CSF, leading to secondary obstructive hydrocephalus. The cyst can obstruct 
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The differential diagnosis from other cystic lesions may be difficult. Porencephaly is often 
associated with ventriculomegaly, communicates with the ventricles and follows a vascular 
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distribution. Brain tumors are usually solid or of mixed echogenicity and are rarely 
completely cystic. Posterior fossa arachnoid cysts should be differentiated from 
Dandy-Walker malformation. The main criterion in these cases is the integrity of the 
cerebellar vermis in arachnoid cysts. Suprasellar arachnoid cysts are rounded and should be 
differentiated from a large third ventricle. The dilated third ventricle appears oval with 
tapered edges posteriorly when aqueductal stenosis is present. An arachnoid cyst in the 
midline should be differentiated from dysgenesis of corpus callosum with an associated 
interhemispheric cyst. In cases of corpus callosal dysgenesis, the enlarged third ventricle is 
high in location at the level of the lateral ventricles, and the ventricular atria are prominent. 
A vein of Galen aneurysm, is a midline occipital lesion with characteristic Doppler flow. 
  
Fig. 16. Sagittal scan shows the typical features of arachnoid cysts.  
Prognosis is generally good (Elbers & Furness, 1999). In many cases, arachnoid cysts are 
asymptomatic, but they may cause epilepsy, mild motor or sensory abnormalities, or hydro-
cephalus. Depending on the location and extent of the lesion, these cysts can be resected or 
shunted. Conversely, suprasellar arachnoid cysts are rare, representing approximately 10% 
of intracranial arachnoid cysts, however, they have a propensity to become symptomatic 
and they may manifest with hydrocephalus, visual impairment, and endocrine dysfunctions 
(typically precocious puberty).  
11. Posterior fossa cystic lesions 
Despite decades of knowledge of the existence of posterior fossa cystic anomalies and efforts 
to understand their pathogenesis, there is little consensus about how these malformations 
occur and how they cause clinical symptoms/signs (Altman, 1992; Barkovich et al, 1989). 
However, their differential diagnosis can be particularly difficult because the recognition of 
the subtle anatomic features that differentiate them may be challenging or sometimes 
impossible. 
Some cysts are related to massive dilatation of the fourth ventricle, others to persistence of 
embryonic structures, such as Blake’s pouch, others to malformative dilatation of 
subarachnoid spaces, and others to true arachnoid loculations. 
 
Ultrasound Diagnosis of Congenital Brain Anomalies 
 
97 
The mainstay of the diagnosis is represented by the assessment of a number of direct and 
indirect signs, including the following: the relationship of the cyst with the fourth ventricle 
and subarachnoid spaces; the morphology, position and biometry of the vermis and the 
cerebellar hemispheres, association with hydrocephalus; the size of the posterior fossa and 
the position of the tentorium. 
11.1 Mega cisterna magna  
The cisterna magna is the basal cistern behind and below the cerebellum. Mega cisterna 
magna is defined as a cystic posterior fossa malformation characterized by an intact vermis, 
an enlarged cisterna magna, freely communicating with the perimedullary subarachnoid 
spaces, absence of hydrocephalus, and a normal size of the fourth ventricle. The tentorium 
cerebelli is superiorly displaced in almost 10% of cases.  
Mega cisterna magna occurs in approximately 1% of all brains imaged postnatally. Mega 
cisterna magna has been associated with infarction, inflammation, and infection, particularly 
cytomegalovirus, as well as with chromosomal abnormalities, especially trisomy 18. In the 
absence of other findings to suggest a posterior fossa lesion, a mega cisterna magna is 
unlikely to be clinically significant. 
On ultrasound, normal cisterna magna characteristically measures 3–8 mm when 
measurements are taken in the midsagittal plane from the posterior lip of the foramen 
magnum to the caudal margin of the inferior vermis (Goodwin & Quisling, 1983). 
Ultrasound examination reveals a cystic posterior fossa malformation characterized by an 
intact vermis, an enlarged cisterna magna, absence of hydrocephalus, and a normal size of 
the fourth ventricle (Figure 17.). The extent of the CSF collection is variable; it may remain 
purely infravermian or it may extend far beyond the normal borders of the cisterna magna 
laterally, posteriorly, and superiorly, reaching in some cases the quadrigeminal plate cistern. 
The tentorium are usually in normal position. 
 
Fig. 17. Sagittal scan shows the typical features of Mega cisterna magna. 
Prognosis is commonly favorable if Mega cisterna magna is isolated. In syndromic 
conditions, the final prognosis is that of the underlying syndrome. 
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11.2 Blake’s pouch cyst 
The Blake’s pouch is a normal, transient embryological structure (superior medullary 
velum), which initially does not communicate with the surrounding sub-arachnoid spaces. 
Subsequent spontaneous perforation of the pouch forms the foramen of Magendie. If the 
Blake’s pouch fails to perforate, CSF accumulates and determines the fingerlike expansion 
Blake’s pouch cyst within the posterior fossa and produce hydrocephalus. 
Some authors put forward the theory that Blake’s pouch cyst and retrocerebellar arachnoid 
cysts are the same entity because at some stage the communication with the fourth ventricle 
is lost and contact with the developing arachnoid matter is made (Strand et al, 1993). 
Another authors clearly distinguish between Blake’s pouch cysts and retrocerebellar 
arachnoid cysts although they recognize differentiation of the two on imaging is difficult 
and can only be resolved on histological analysis (Calabro et al, 2000). 
Sonographically, Blake’s pouch cysts is characterized by a normal but displaced cerebellar 
vermis, a CSF collection in the posterior fossa, consisting of the expanded and imperforated 
Blake’s pouch widely communicating with the fourth ventricle. Ventriculomegaly/ 
hydrocephalus is often associated. The tentorium is usually in normal position. A normal 
appearance of the cerebellar vermis rules out the diagnosis of the Dandy–Walker 
malformation, in which the vermis is agnetic/hypoplastic and rotated counterclockwise 
(Calabro et al, 2000).  
The prognosis of Blake’s pouch cysts is generally good. 
11.3 Dandy-Walker malformation 
The term Dandy–Walker malformation was suggested to describe a malformation consisting 
of a cystic enlargement of the fourth ventricle associated with partial or complete agenesis of 
the vermis (Nelson et al, 2004) 
Incidence of the Dandy-Walker is about 1 in 25,000–35,000 births. 
There is a high association with other CNS abnormalities (in 50–60% of cases), including 
failed commissuration, cortical formation malformations, midline anomalies and 
encephalocoeles. An association with facial clefts and other extra-CNS anomalies (especially 
congenital heart disease and urinary anomalies) has been described, often in the context of 
chromosomal and genetic syndromes. Risk of chromosomal anomalies is high, with up to 
35% of cases being associated with aneuploidy, mainly trisomies 18 and 13. The most 
common syndromes that can be associated with the Dandy–Walker malformation are: 
Walker–Warburg syndrome, Meckel–Gruber syndrome, Aicardi syndrome and Neu–Laxova 
syndrome. 
The Dandy–Walker malformation is a result of defective development of the structures 
originating from the rhomboencephalic roof (Calabro et al, 2000; Nelson et al, 2004). Failure 
of assimilation of the area membranacea anterior, leading to anomalous development of the 
fourth ventricle, atresia of the foramen of Magendie and sometimes the foramen of Luschka. 
The cystic dilatation of the fourth ventricle fills the posterior fossa and extends into cisterna 
magna, which is compressed between the dilated fourth ventricle and the dura mater. 
Ventriculomegaly develops in up to 80% of cases. The high insertion of the tentorium 
 
Ultrasound Diagnosis of Congenital Brain Anomalies 
 
99 
encountered in the Dandy-Walker malformation is considered an indicator that the 
malformation occurred before the end of the embryonic period. 
On ultrasound, the Dandy–Walker malformation is characterized by an expansion of the 
posterior cranial fossa with upward displacement of the tentorium, a cystic dilatation of the 
fourth ventricle, and partial or complete vermian agenesis (Figure 18.). In addition, when 
present, the cerebellar vermis is rotated counter clockwise. Some cases of Dandy–Walker 
malformation show a partial agenesis/ hypoplasia, whereas others feature vermian 
dysplasia.  
  
a   b 
Fig. 18. Sagittal scan (A) and coronal (B)show the typical features of Dandy–Walker 
malformation. 
Prognosis is poor when associated with other CNS anomalies and chromosomal and genetic 
syndromes (Klein et al, 2004). Isolated the Dandy–Walker malformation forms have a better 
intellectual prognosis and lower mortality  
Less-pronounced malformations are often termed Dandy-Walker varianta.  
The Dandy–Walker variant has a very similar appearance but there is a lesser degree of 
hypoplasia of the cerebellar vermis. The foramen of Magendie is, however, patent. The 
fourth ventricle is less dilated. The Dandy–Walker variant is a mild form of the Dandy–
Walker malformation or represents a generalized form of cerebellar hypoplasia. However, 
the demarcation between classic Dandy-Walker malformation and Dandy-Walker variant is 
vague, and thus the term Dandy-Walker continuum is more appropriate. To further simplify 
these lesions, the definition of Dandy-Walker malformation has been modified and Blake’s 
pouch cyst has been included in the “Dandy-Walker continuum”. 
12. Vein of Galen aneurysm 
The vein of Galen is part off the venous sinus complex which drains blood from brain. 
Aneurysm of the vein of Galen is a complex arteriovenous malformation consisting of 
multiple communications between the system of the vein of Galen and the cerebral arteries 
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encountered in the Dandy-Walker malformation is considered an indicator that the 
malformation occurred before the end of the embryonic period. 
On ultrasound, the Dandy–Walker malformation is characterized by an expansion of the 
posterior cranial fossa with upward displacement of the tentorium, a cystic dilatation of the 
fourth ventricle, and partial or complete vermian agenesis (Figure 18.). In addition, when 
present, the cerebellar vermis is rotated counter clockwise. Some cases of Dandy–Walker 
malformation show a partial agenesis/ hypoplasia, whereas others feature vermian 
dysplasia.  
  
a   b 
Fig. 18. Sagittal scan (A) and coronal (B)show the typical features of Dandy–Walker 
malformation. 
Prognosis is poor when associated with other CNS anomalies and chromosomal and genetic 
syndromes (Klein et al, 2004). Isolated the Dandy–Walker malformation forms have a better 
intellectual prognosis and lower mortality  
Less-pronounced malformations are often termed Dandy-Walker varianta.  
The Dandy–Walker variant has a very similar appearance but there is a lesser degree of 
hypoplasia of the cerebellar vermis. The foramen of Magendie is, however, patent. The 
fourth ventricle is less dilated. The Dandy–Walker variant is a mild form of the Dandy–
Walker malformation or represents a generalized form of cerebellar hypoplasia. However, 
the demarcation between classic Dandy-Walker malformation and Dandy-Walker variant is 
vague, and thus the term Dandy-Walker continuum is more appropriate. To further simplify 
these lesions, the definition of Dandy-Walker malformation has been modified and Blake’s 
pouch cyst has been included in the “Dandy-Walker continuum”. 
12. Vein of Galen aneurysm 
The vein of Galen is part off the venous sinus complex which drains blood from brain. 
Aneurysm of the vein of Galen is a complex arteriovenous malformation consisting of 
multiple communications between the system of the vein of Galen and the cerebral arteries 
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(carotid and/or vertebrobasiliar systems). These vessels are located in the brain deeply and 
posteriorly above the pineal gland, in the subarachnoid space called "cistern of the great 
cerebral vein of Galen". There three types described: arteriovenous fistula, arteriovenous 
malformation with ectasia of the vein of Galen and varix of the vein of Galen (Raybaud et al, 
1989). The vein of Galen malformation is a form of embryonic arteriovenous shunt. Other 
venous anomalies, such as anomalous dural sinuses and sinus stenosis, are commonly 
present in association with vein of Galen malformation. 
Incidence of aneurysm the vein of Galen is rare. It represents 1% of all vascular brain 
malformations. It is more common in males than females. It is often associated with other 
more extensive cerebral abnormalities. It may be associated with secondary hydrocephalus 
due to compression of the aqueduct and with high-output heart failure and non-immune 
hydrops due to the arteriovenous fistula (Brunelle, 1997). Severe high-output cardiac failure 
is caused by a marked increase of cardiac preload from venous return of the brain due to the 
‘steal’ phenomenon. The ‘steal’ phenomenon, with diversion of blood from the parenchyma 
to the aneurysm, may further result in brain infarcts and periventricular white matter 
lesions.  
Ultrasound examination reveals a large echo-free supratentorial cystic structure with high 
velocity flow on Doppler examination (Figure 19.). This lies posterior to the third ventricle, 
and may extend asymmetrically across the midline. Size of this cystic structure depends on 
volume of shunt. The sagittal sinus is reported as dilated in most cases. The feeding arteries 
are difficult to analyze, but a tortuous network of dilated arteries is usually visible in the 
region of the malformation. Demonstration of blood flow in the cystic structure enables the 
diagnosis of an aneurysm of the vein of Galen to be made, as opposed to that of an 
abnormality of other intracranial midline structures, for example arachnoid or 
porencephalic cyst, Dandy–Walker malformation or intracerebral hematoma. However, 
when a clot has formed, it may be iso-or even hyperechoic (Vijayarghavan et al, 2006). 
  
a b 
Fig. 19. Coronal scan (A) and sagittal scan (B) show the typical features of the vein of Galen 
malformation.  
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Prognosis of aneurysm the vein of Galen is poor when cardiac failure and hydrops is 
present. Risk of intrauterine or early neonatal death due to congestive heart failure, requires 
agressive postnatal care. Although the vein of Galen aneurysms may become symptomatic 
in the elderly, they are more typically diagnosed in the neonatal period. The common 
clinical features in the neonate are cardiomegaly with congestive heart failure and increased 
intracranial pressure with hydrocephaly or cranial bruit. Focal neurological deficit, seizures 
and hemorrhages are less common findings. If possible, method of treatment is emergency 
embolization or surgery. However, there are some reports of spontaneous thrombosis and 
calcification of aneurysm of the vein of Galen (Nikas et al, 1999; Chapman & Hockley, 1989). 
13. Neural tube defects  
Neural tube defects are the most frequent CNS malformations and amount to about 1–2 
cases per 1000 births. There have been many reported remarkable reductions in the 
prevalence of neural tube defects after the use of folic acid supplementation and 
fortification, although some have reported no decline in the anencephaly rate. Neural tube 
defects includes different anomalies deriving from failed closure of the neural tube between 
the 3rd and the 4th week of development, the best known being anencephaly, cefalocele, 
and spina bifida. 
13.1 Anencephaly 
Anencephaly results from failure of anterior neural tube closure and occurs before 24 days 
of gestation. Anencephaly is a lethal anomaly characterized by the absence of cerebral 
hemispheres and cranial vault. Most of the cranial vault is absent. It is the most common 
CNS malformation. Its incidence is 0.1 in 1000 births. In neonates, the anomaly is more 
frequent in females than in males. The incidence of anencephaly in abortion material has 
been found to be five times greater than that observed at birth. The risk of recurrence of 
anencephaly is 5% to 13%. Anencephaly is associated with myelomeningocele, microcephaly 
and amniotic band syndrome. Extra-cranial abnormalities occur in some cases and included 
omphaloceles and clubfoot. 
Anencephaly has a multifactorial etiology. Genetic factors seem important because of 
familial incidence, whereas geographic variation suggests an environmental cause. An 
increased incidence of anencephaly and other neural tube defects occur in women who have 
diabetes during pregnancy. Also, women who take valproic acid for a seizure disorder are 
at increased risk for anencephaly if their medication has been consumed prior to conception 
or during the first trimester of pregnancy. The most widely accepted theory is that in most 
cases, because of a failure of development of the cranial vault bones, the encephalic 
structures, covered only by the meninges, are in time subject to extensive destruction, with 
consequent transformation of the encephalon into a mass of soft tissue adhering to the base 
of the cranium (cerebral–vascular area).  
On ultrasound, the anencephalic foetus have a typical froglike appearance (bulging eyes, 
cleft lip or palate, a large tongue, and a very short neck) (Chatzipapas & Whitlow, 1999). 
This anomaly is incompatible with life. Approximately 75% of these neonates are stillborn, 
and the remainder die within the first hours or days of life. Anencephalic infants are a 
potential source of organs for transplantation (Trugg & Fletcher, 1989). 
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13.2 Cephalocele  
Cephalocele is usually considered to be a restricted disorder of anterior neural tube closure. 
It occurs before 26 days of gestation. Cephalocele is characterized by protrusion of 
intracranial structures through a cranial bone defect. The herniated anatomic structures can 
consist of meninges only (meningocephalocele) or meninges plus cerebral tissue 
(encephalomeningocele). Cephaloceles are defined anatomically according to their location 
(frontal, parietal, occipital, frontoethmoidal, etc.). Neural tissue (most often from the 
occipital lobe) in the encephalocele usually displays a normal gyration and underlying 
white matter and is connected to the brain through a narrow neck. The most common 
location is occipital in Europe and the USA, although frontal cephaloceles are more frequent 
in South-East Asia. 
This is relatively high percent (14–18%) of chromosomal anomalies (e.g., trisomy 13 and 18). 
The syndromes possibly associated with cephalocele are Meckel–Gruber syndrome, 
amniotic band syndrome, frontonasal dysplasia and Walker–Warburg syndrome. 
Associated anomalies occur in up to 70–80% of cases and included agenesis of the corpus 
callosum, ventriculomegaly, holoprosencephaly, spina bifida and microcephaly. Among 
extracerebral anomalies, the most frequently associated are cardiac anomalies and skeletal 
dysplasias. 
According to the most widely accepted theory, cephalocele is caused by a lack of fusion of 
the neural tube in its specific closing sites, although some authors claim that postneurulation 
events with anomalies of the mesenchymal induction phases of the nervous tissue are 
responsible for the lesion.  
Ultrasound diagnosis is based on the recognition of a cystic (meningocephalocele) or 
complex (meningoencephalocele) formation of variable size protruding through a skull 
defect, often localized in the occipital region (Figure 20.). In cases where the cephalocele is 
located in the lower occipital region or upper cervical area, cerebellum is usually present in 
the encephalocele and often associated with type III Chiari malformation. Chiari III 
malformation is a high cervical encephalomeningocele in which the medulla, fourth 
ventricle, and virtually the entire cerebellum reside. 
 
Fig. 20. Axial scan shows the typical features of occipital cephalocele.  
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Prognosis is depending on the dimensions and the location of the lesion, on the presence of 
cerebral tissue in the herniated sack, and on any association with hydrocephaly or 
microcephaly or other extracranial anomalies. The postnatal mortality rate varies from 30% 
to 50%, depending on the above-mentioned parameters. Very large lesions have an 
unfavorable prognosis, while small cephaloceles can be corrected surgically. 
13.3 Spina bifida 
The term ‘spina bifida’ is still commonly used as a synonym for spinal dysraphism, 
although it properly refers to defective fusion of posterior spinal bony elements. The terms 
spina bifida aperta or cystica and spina bifida occulta were once used to refer to open spinal 
dysraphism and closed spinal dysraphism, respectively but have been progressively 
discarded. Spina bifida encompasses a broad spectrum of abnormalities. Lesions are 
commonly subdivides into ventral and dorsal defects. Ventral defects are extremely rare and 
are characterized by the splitting of the vertebral body and the occurrence of a cyst that is 
neuroenteric in origin. This lesion is generally seen in the lower cervical or upper thoracic 
vertebrae. Dorsal defects are the most common. Closed spinal dysraphisms represents 
approximately 15% of the cases and is characterized by a small defect completely covered by 
skin. Closed spinal dysraphisms are considered to be disorders of caudal neural tube 
formation (secondary neurulation) and include distortion of the spinal cord or roots by 
fibrous bands and adhesions, intraspinal lipomas, epidermoid cysts, fibrolipomas, tethered 
cord (the most common condition), and diastematomyelia. In many cases, this condition is 
completely asymptomatic and is diagnosed only incidentally at radiographic examination of 
the spine. In other instances, there is an area of hypertrichosis, pigmented or dimpled skin, 
or the presence of subcutaneous lipomas. Closed spinal defects are extremely difficult to 
diagnose. Open spinal dysraphism is the most frequent lesion. The neural canal may be 
exposed, or the defect may be covered by a thin meningeal membrane. More often, the 
lesion appears as a cystic tumor (spina bifida cystica). If the tumor contains purely 
meninges, the lesion is referred to us a meningocele. More frequently, neural tissue is part of 
the mass, and the name myelomeningocele is used. The skin and muscles above the defect 
are absent. Approximately 75% of myelomeningoceles have a lumbar localization. 
The incidence varies according to many factors, such as geographical area, ethnic 
differences, and seasonal variation. Spinal defects are more frequent in Caucasians than in 
Orientals or blacks. Spina bifida has a multifactorial etiology. The vast majority of cases are 
thought to be due to an interaction of genetic factors (chromosomal abnormalities and in 
single-gene disorders) with environmental factors (such as valproate exposure or maternal 
diabetes mellitus). Risk of chromosomal anomalies (trisomy 13, trisomy 18 and triploidy) is 
8–16%. The syndromes possibly associated with spina bifida are Meckel syndrome, HARDE 
syndrome, Marfans syndrome and Ehlers–Danlos syndromes. 
Cranial ultrasound should always be performed in neonates with spinal dysraphisms, as 
there may be associated a variety of intracranial abnormalities, including ventriculomegaly 
and hypoplasia of the posterior fossa structures. All infants with spina bifida have some 
degree of Arnold-Chiari type II malformation (D’Addario et al, 2001). Arnold-Chiari type II 
malformation is complex congenital anomaly of the hindbrain characterized by 
displacement of cerebellar tonsils, parts of the cerebellum, fourth ventricle, pons, and 
medulla oblongata through the foramen magnum into the spinal canal. In 95% of the cases it 
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is accompanied by hydrocephalus and myelomeningocele. Clubfoot may develop in a 
significant percentage of cases. Neonates with lumbal spinal dysraphisms should have a 
hydronephrosis and renal ultrasound should also be perfomed. 
A larger bone and cartilage-free portals may be present at the site of the lesion on a spinal 
ultrasonography. A meningocele contains only CSF and no neural elements (Figure 21.a). 
The sac is clearly cystic and occasionally communicates directly with the extra-axial space. 
Myelomeningocele may be unilocular or multi-locular sacs but always contain hyperechoic 
nerve roots. Ultrasonography should not be performed on open lesions. Both 
myelomeningoceles and meningoceles are associated with a tethered low-lying spinal cord 
and diastematomyelia or syringomyelia. Tethering of the spinal cord occurs in 70%–90% of 
these neonates. If spinal cord lies posteriorly and appears fixed then tethering should be 
suspected. In cases in which there is a low tethered cord, the conus is low and the spinal 
cord is displaced dorsally. There is lack of normal cord pulsatility, and the filum terminale is 
thickened to over 2 mm. The thickened filum terminale may be fibrous or lipomatous. 
Lipomas are highly echogenic and are easily identified on sonograms. Hydromyelia or 
syringomyelia occurs in 40-80% of these neonates. These conditions result from disturbance 
of cerebrospinal fluid circulation. Hydromyelia and syringomyelia always occur cranial to 
the placode and may be focal or involve the entire spinal cord and spinal US shows 
dilatation of the central canal of the spinal cord (Figure 21.b). 
  
a b 
Fig. 21. Longitudinal scan shows the typical features of meningocele (A) and syringomyelia (B). 
There is high association with ventriculomegaly and Arnold-Chiari type II malformation. 
Ultrasound diagnosis of the Arnold-Chiari type II malformation is based on the recognition 
of: ventriculomegaly, banana sign (abnormal anterior curvature of the cerebellar 
hemispheres), caudal displacement of fastigium of fourth ventrcle and cerebellar 
hemispheres, obliteration of the cisterna magna (< 2 mm), and a hypoplastic cerebellar 
hemispheres (Figure 22.).  
Spina bifida is a serious congenital anomaly. Prognosis depend on the location and extent of 
the lesion (cervical and high thoracic lesions are frequently fatal), kyphoscoliosis and other 
major structural abnormalities. The presence of severe hydrocephaly has always been 
considered a poor prognostic sign. The stillbirth rate is estimated as 25%. The untreated 
infants die within the first few months of life. Survival rate of those treated in the immediate 
neonatal period approaches 40% at seven years. Clinical symptoms are variable (absent, 
minimal, moderate, or severe) according to the degree of neural tissue involvement. Varying 
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degree of paresis (often severe) of the legs and sphincter dysfunction are the major clinical 
signs. Intellectual and psychological disturbances are also frequently associated. 
 
Fig. 22. Axial scan shows the tipical features of the Arnold-Chiari type II malformation.  
14. Conclusions  
Congenital brain anomalies are some of the most common of all congenital abnormalities 
These abnormalities are often evident of birth, but some brain malformations may not be 
immediately obvious. The neonates with dysmorphic features or abnormal neurologic 
behaviour may suggest cerebral malformation, and various imaging techniques are essential 
for fether clarification. In the neonatal period cranial US can be used as the initial modality 
to exclude a major structural malformation. Cranial US is non-invasive highly sensitive, 
safe, easily repeatable and cost effective for detecting congenital anomalies of the brain in 
both preterm and full-term neonates. It may provide important information regarding the 
anatomic location, size, and shape of congenital brain anomalies as well as their mass effect 
on adjacent structures. Cranial US are correlated with anatomical and pathological findings 
and clinical outcomes. Familiarity with the US features of congenital brain anomalies is 
therefore an extremely valuable tool, as it facilitates an accurate diagnosis and treatment 
when necessary.  
15. References 
Altman N, Naidich TP, Brafmann BH. (1992). Posterior fossa malformations. AJNR, Vol. 13, 
No. 2, (March 1992), pp. 691-724. 
Atlas S, Shkolinik A, Naidich T. (1985). Sonographic recognition of agenesis of the corpus 
callosum. AJR, Vol. 145, No.1, (July 1985), pp. 167-173. 
Barkovich AJ. (Ed).(2005). Pediatric neuroimaging. 4rd ed.Lippincott Williams & Wilkins 
Publishers, lSBN 0-7817-5766-5, New York, USA. 
Barkovich AJ, Kjos BO, Norman D, Edwards MS. (1989). Revised classification of posterior 
fossa cyst and cystlike malformations based on the results of multiplanar MR 
imaging. AJR, Vol.153 , No.6, (December 1989), pp. 1289–1300. 
 
Congenital Anomalies − Case Studies and Mechanisms 
 
104 
is accompanied by hydrocephalus and myelomeningocele. Clubfoot may develop in a 
significant percentage of cases. Neonates with lumbal spinal dysraphisms should have a 
hydronephrosis and renal ultrasound should also be perfomed. 
A larger bone and cartilage-free portals may be present at the site of the lesion on a spinal 
ultrasonography. A meningocele contains only CSF and no neural elements (Figure 21.a). 
The sac is clearly cystic and occasionally communicates directly with the extra-axial space. 
Myelomeningocele may be unilocular or multi-locular sacs but always contain hyperechoic 
nerve roots. Ultrasonography should not be performed on open lesions. Both 
myelomeningoceles and meningoceles are associated with a tethered low-lying spinal cord 
and diastematomyelia or syringomyelia. Tethering of the spinal cord occurs in 70%–90% of 
these neonates. If spinal cord lies posteriorly and appears fixed then tethering should be 
suspected. In cases in which there is a low tethered cord, the conus is low and the spinal 
cord is displaced dorsally. There is lack of normal cord pulsatility, and the filum terminale is 
thickened to over 2 mm. The thickened filum terminale may be fibrous or lipomatous. 
Lipomas are highly echogenic and are easily identified on sonograms. Hydromyelia or 
syringomyelia occurs in 40-80% of these neonates. These conditions result from disturbance 
of cerebrospinal fluid circulation. Hydromyelia and syringomyelia always occur cranial to 
the placode and may be focal or involve the entire spinal cord and spinal US shows 
dilatation of the central canal of the spinal cord (Figure 21.b). 
  
a b 
Fig. 21. Longitudinal scan shows the typical features of meningocele (A) and syringomyelia (B). 
There is high association with ventriculomegaly and Arnold-Chiari type II malformation. 
Ultrasound diagnosis of the Arnold-Chiari type II malformation is based on the recognition 
of: ventriculomegaly, banana sign (abnormal anterior curvature of the cerebellar 
hemispheres), caudal displacement of fastigium of fourth ventrcle and cerebellar 
hemispheres, obliteration of the cisterna magna (< 2 mm), and a hypoplastic cerebellar 
hemispheres (Figure 22.).  
Spina bifida is a serious congenital anomaly. Prognosis depend on the location and extent of 
the lesion (cervical and high thoracic lesions are frequently fatal), kyphoscoliosis and other 
major structural abnormalities. The presence of severe hydrocephaly has always been 
considered a poor prognostic sign. The stillbirth rate is estimated as 25%. The untreated 
infants die within the first few months of life. Survival rate of those treated in the immediate 
neonatal period approaches 40% at seven years. Clinical symptoms are variable (absent, 
minimal, moderate, or severe) according to the degree of neural tissue involvement. Varying 
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degree of paresis (often severe) of the legs and sphincter dysfunction are the major clinical 
signs. Intellectual and psychological disturbances are also frequently associated. 
 
Fig. 22. Axial scan shows the tipical features of the Arnold-Chiari type II malformation.  
14. Conclusions  
Congenital brain anomalies are some of the most common of all congenital abnormalities 
These abnormalities are often evident of birth, but some brain malformations may not be 
immediately obvious. The neonates with dysmorphic features or abnormal neurologic 
behaviour may suggest cerebral malformation, and various imaging techniques are essential 
for fether clarification. In the neonatal period cranial US can be used as the initial modality 
to exclude a major structural malformation. Cranial US is non-invasive highly sensitive, 
safe, easily repeatable and cost effective for detecting congenital anomalies of the brain in 
both preterm and full-term neonates. It may provide important information regarding the 
anatomic location, size, and shape of congenital brain anomalies as well as their mass effect 
on adjacent structures. Cranial US are correlated with anatomical and pathological findings 
and clinical outcomes. Familiarity with the US features of congenital brain anomalies is 
therefore an extremely valuable tool, as it facilitates an accurate diagnosis and treatment 
when necessary.  
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1. Introduction 
Congenital pulmonary lymphangiectasis (CPL) is a rare and poorly documented disease of 
neonates, and is characterized by prominent and diffuse microcystic lymphatic dilation in 
the septal, subpleural and peribronchial tissue throughout both lungs. Although an accurate 
incidence of CPL is elusive, a previous autopsy study has suggested that approximately 1% 
of all infants stillborn or dead in the neonatal period have CPL (Laurence KM, 1955), and at 
least 30 and 130 cases of CPL have been reported in Japan and in the world, respectively. 
According to previous CPL reports, males are affected more than females, and there is no 
familial predisposition in most cases. However, a few cases have described an association 
with genetic disorders, such as Noonan, Down, Turner, and Fryns syndromes (Fryns JP & 
Moerman P, 1993; Jacquemont S et al., 2000). CPL is generally divided into two groups: 
primary (congenital) and secondary. In addition, Noonan classified CPL into three groups 
(Noonan JA et al., 1970): group 1 is characterized by generalized lymphangiectasis 
(lymphedema with intestinal lymphangiectasis) (Bellini C et al., 2001; Maclean JE et al, 
2002); in group 2, CPL is caused by pulmonary venous hypertention or obstruction 
associated with surgery, radiation, infection, tumor, or cardiovascular anomalies including 
anomalous pulmonary venous drainage or cor triatriatum (Gilewski MK et al., 1996; Verlaat 
CWM et al., 1994); group 3 is due to a primary developmental defect of the pulmonary 
lymphatics (Huber A et al., 1991; Moerman P et al., 1993). Therefore, groups 1 and 3 of CPL 
are primary (congenital), and group 2 is secondary. In particular, group 3 CPL is 
characterized by severely disturbed pulmonary gas exchange and a poor prognosis (Hoehn 
T et al., 2006), and some reports have shown that neonates with group 3 CPL have 
lymphatic dilation in the lungs and multiple other organs, and pursue an adverse clinical 
course (Frank J et al., 1955; Hirano H et al., 2004; Mckendry JBJ et al., 1957). Because of the 
clinicopathological similarities between group 3 CPL and pulmonary interstitial emphysema 
(PIE), CPL tends to be misdiagnosed as PIE (Finder J & Steinfeld J, 2004; Xiao ZY et al., 
2009). Although a conclusive diagnosis of CPL can only be made pathologically or by 
autopsy, CPL should be distinguished from PIE because of their distinct treatments and 
prognoses (Laurence KM, 1955; Finder J & Steinfeld J, 2004; Xiao ZY et al., 2009). 
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2. Case report 
An autopsy case of CPL group 3 is described with a special reference to distinction from PIE.  
2.1 Clinical summary 
A male Japanese neonate was born at 34 weeks of gestation after the pregestational 
treatment for infertility and medication for mild amniorrhexis, and was the second child 
born to non-consanguineous parents. The parents’ first baby weighed 3,276 g and was born 
at 40 weeks of spontaneous gestation 5 years before this case. The patient weighed about 
2,300 g at birth, and his Apgar scores were 7 and 8 at 1 and 5 minutes, respectively. The 
amniotic fluid was clear, and the amount was approximately 400 mL. The placenta, 
weighing 460 g, had no remarkable features. However, he developed a severe moaning 
sound and dyspnea about 10 minutes after birth, in spite of artificial oxygenation. A chest X-
ray film showed bilateral frosted glass-like infiltrates with an air bronchogram and an air 
leak (arrows) around the cardiac shadow, suggesting pneumomediastinum (Fig. 1). 
 
Fig. 1. Plain chest X-ray. 
Despite artificial ventilation after intubation and surfactant substitution therapy, he died of 
hypoxemic respiratory failure 13 hours after birth due to persistent pneumomediastinum 
and bilateral pneumothorax, which were resistant to the puncture by thoracostomy tubes 
and the intravenous administration of dopamine and bicarbonate. The blood cell counts and 
values of blood biochemistry were within normal limits, except for a venous blood sample 
when breathing at 30% oxygen concentration in the incubator showing elevated partial 
pressure of carbon dioxide (PaCO2) (70.7 mmHg), and decreased base excess (–7.4 mEq/L) 
and pH (7.145), indicating marked respiratory acidosis. An autopsy was performed 
approximately 3 hours after death. 
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2.2 Gross findings 
At autopsy, the baby measured 45cm in height and weighed 2,328 g. An external 
examination showed no detectable anomalies or abnormalities except for several needle 
marks on the chest wall and the extremities. In an internal examination of the thoracic cavity 
(Fig. 2) there was a bilateral clear yellow pleural fluid (20 mL; 20 mL) without hemorrhage 
or chylothorax, and one cystic lesion was noted in the anterior mediastinum.  
 
Fig. 2. An internal examination of the thoracic cavity. 
In addition to the visceral pleura, both lungs demonstrated a network of dilated cystic 
spaces. The left and right lungs weighed 21 g and 23 g, respectively, and were firm in 
consistency. The cut surfaces of the congestive lungs also showed numerous cystic spaces 
ranging from about 1 to 2 mm in size in the surface visceral pleura as well as in the 
thickened interlobular septum and hilum, although the cystic changes were inconspicuous 
after formalin fixation. These findings were well recognized in a hematoxylin-eosin-stained 
scanning magnification of the lungs (Fig. 3).  
The heart, weighing 18 g, showed no gross abnormalities. No specific findings were 
identified in the other internal organs or the brain, except for a clear yellow peritoneal fluid 
(150 mL).  
2.3 Pathological findings 
A histological examination of the lungs showed diffuse and marked lymphatic dilation in 
the peribronchial (Fig. 4A), subpleural, interlobular (Fig. 4B) and hilar areas.  
The dilated lymphatic channels were invariably lined with flattened endothelium, which 
was immunohistochemically positive for D2-40 (Nichirei Bioscience Co., Tokyo, Japan, 1:1) 
(Fig. 5), CD31 (Dako Cytomation Co., Kyoto, Japan, 1:20) and CD34 (IMMUNOTECH, 
Marseille, France, 1:50).  
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2. Case report 
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leak (arrows) around the cardiac shadow, suggesting pneumomediastinum (Fig. 1). 
 
Fig. 1. Plain chest X-ray. 
Despite artificial ventilation after intubation and surfactant substitution therapy, he died of 
hypoxemic respiratory failure 13 hours after birth due to persistent pneumomediastinum 
and bilateral pneumothorax, which were resistant to the puncture by thoracostomy tubes 
and the intravenous administration of dopamine and bicarbonate. The blood cell counts and 
values of blood biochemistry were within normal limits, except for a venous blood sample 
when breathing at 30% oxygen concentration in the incubator showing elevated partial 
pressure of carbon dioxide (PaCO2) (70.7 mmHg), and decreased base excess (–7.4 mEq/L) 
and pH (7.145), indicating marked respiratory acidosis. An autopsy was performed 
approximately 3 hours after death. 
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2.2 Gross findings 
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Fig. 2. An internal examination of the thoracic cavity. 
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ranging from about 1 to 2 mm in size in the surface visceral pleura as well as in the 
thickened interlobular septum and hilum, although the cystic changes were inconspicuous 
after formalin fixation. These findings were well recognized in a hematoxylin-eosin-stained 
scanning magnification of the lungs (Fig. 3).  
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identified in the other internal organs or the brain, except for a clear yellow peritoneal fluid 
(150 mL).  
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Fig. 3. Scanning magnification of the lung, right lower lobe. 
 
Fig. 4A. Histological finding of CPL (peribronchial). 
No CD68-positive (Dako, 1:100) foreign-body type histiocytes were seen in these cystically-
dilated lesions. Most of the mature-looking alveolar spaces were collapsed, and the alveolar 
walls were close to each other with frequent deposits of hyaline membrane along the 
bronchioli or alveolar ducts, accompanied by accumulated basophilic amorphous materials 
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(Fig. 6), which were negative for Kossa staining and probably derived from the necrotic 
bronchioloalveolar epithelium (Wigglesworth JS, eds., 1984). 
 
Fig. 4B. Histological finding of CPL (subpleural and interlobular). 
 
Fig. 5. Immunohistochemical finding of the dilated lymphatic channels. 
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Additionally, mild lymphangiectasis was found around the mediastinum including the 
thymus and the intra-abdominal organs such as the adrenal gland, kidney, pancreas, spleen, 
sigmoid colon, and abdominal aorta, all of which also lacked any foreign-body reaction. 
Pseudofollicular cysts were present in the definitive adrenal cortex (Fig. 7).  
 
Fig. 6. Histological finding of the bronchioli to alveolar spaces. 
 
Fig. 7. Histological finding of the adrenal gland. 
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The diagnosis of CPL, a primary form, Noonan Group 3, was established based on these 
features.  
2.4 Discussion 
Congenital pulmonary lymphangiectasis (CPL) was first described by Virchow (Virchow R, 
1856), demonstrating clinical manifestations of aggressive dyspnea after birth, cyanosis and 
death. The lungs of CPL show grossly dilated lymph channels beneath the pleura and in the 
variably thickened interlobular septa, and these dilated lymph vessels are also recognized in 
the subpleura, interlobular septa, and peribronchial tissue throughout both lungs 
microscopically. The mortality rate of neonatal CPL was considered to be nearly 100% more 
than 30 years ago. However, because neonatal care has advanced significantly since then, 
the outcome of the patients has improved, especially for those who present the symptoms 
after the neonatal period or for those belonging to Noonan classification group 1 or 2 
(Hirano H et al., 2004; Moerman P et al., 1993). Nevertheless, Noonan group 3 CPL is 
usually associated with an adverse clinical course and high mortality. It is well known that 
group 3 CPL is due to a developmental error, probably resulting from a failure of 
pulmonary interstitial connective tissue to regress and leading to the dilation of pulmonary 
lymphatic vessels (Xiao ZY et al., 2009). This usually occurs after the 16th week of fetal life 
(Faul JL et al., 2000; Laurence KM, 1995), followed by insufficient dilatation of alveolar 
structures. These pathological changes might result in severe pulmonary symptoms (Janett 
SN et al., 1963), probably including those due to respiratory distress syndrome (RDS). 
CPL is often difficult to differentiate from pulmonary interstitial emphysema (PIE) because 
of the clinicopathological similarities between these two diseases (Laurence KM, 1955; 
Finder J & Steinfeld J, 2004; Xiao ZY et al., 2009). PIE in the newborn is a frequent 
complication of RDS or hyaline membrane disease. The typical chest X-ray findings of PIE 
include multiple large cysts (0.8-3.0 cm) in a background of smaller cysts (0.2-0.4 cm) with 
uniform minute reticulogranular densities and abnormal airbronchograms caused by RDS 
(Stocker JT & Madewell JE, 1977). The X-ray in the current case showed bilateral frosted 
glass-like or cotton-like infiltrates with an air bronchogram and an air leak around the 
cardiac shadow due to RDS and pneumomediastinum, partly resembling the findings of PIE 
complicated by pneumomediastinum. Moreover, the patient suffered an uncontrollable 
bilateral pneumothorax after artificial ventilation was started. Therefore, a clinical 
distinction between these entities is not straightforward, and a definitive diagnosis of CPL 
can be made only by pathological examinations (Laurence KM, 1955; Finder J & Steinfeld J, 
2004; Xiao ZY et al., 2009). The small cysts of PIE are invariably lined by mono- and 
multinucleated giant histiocytes displaying a foreign-body type reaction (Keeling JW, eds., 
1993). In contrast, cysts in CPL are lined with flattened endothelium without evidence of 
aggregated histiocytes. Although this case demonstrated pneumothorax and 
pneumomediastinum, their etiological mechanisms are not easy to explain. However, the 
bilateral pneumothorax might have been caused by the artificial ventilation, which often 
results in air leak to the extra-airspaces, rather than by RDS itself. As to the 
pneumomediastinum prior to the ventilation and pneumothorax, a dilated lymphatic vessel 
might have been misunderstood as air leakage forming the persistent cystic lesion in the 
anterior mediastinum, in which, not only the immunohistochemical result of D2-40 showed 
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positive-stainings, but also no giant cell reaction was identified. Furthermore, it is certain 
that RDS is sometimes accompanied by pulmonary lymphangiectasis, which might or might 
not lead to mediastinal lymphangiectasis, to a degree that renders its distinction from CPL 
difficult (Keeling JW, eds., 1993). However, in RDS, distended lymphatics are primarily 
interlobular in location, while in CPL they are also found in the subpleural and 
peribronchial areas and are wider in size, as in the present case. From these viewpoints, it is 
suggested that this pulmonary to mediastinal lymphangiectasis is caused by not only CPL, 
but also by RDS, although to a lesser degree. 
Besides PIE, CPL should be distinguished from diffuse pulmonary lymphangiomatosis 
(DPL) (Hirano H et al., 2004; Bush JK et al., 1969; Brown M et al., 1999), because of  
their similar clinical manifestations and histological features. In addition, an 
immunohistochemical approach cannot differentiate between CPL and DPL, both of which 
share positive stainings for vimentin, CD31, CD34, factor VIII-related antigen, and D2-40. 
Histologically, DPL is characterized by an increased number of complex anastomosing 
lymphatic channels, in which variable dilation or expansion is a secondary phenomenon 
within the lungs and mediastinum, whereas in CPL the lymphatics are not increased in 
number and are relatively more regular in size and shape (Bush JK et al., 1969; Brown M et 
al., 1999; Hirano H et al., 2004; Moerman P et al., 1993). Based on these features, DPL could 
also be excluded in our case. 
3. Conclusion 
Herein was reported a neonate case of group 3 CPL with pathological findings of 
lymphangiectasis in or around multiple organs, including both lungs, the mediastinum, and 
those in the intra-abdominal cavity. Although PIE was considered an important differential 
diagnosis because of the overlapping clinicopathological features, a giant cell reaction 
surrounding the interstitial cystic lesions, a histological hallmark of PIE, was absent in the 
present case. 
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1. Introduction
Assisted reproductive technology (ART) encompasses all medical intervention used to assist
people becoming parents, mainly but not solely as a result of infertility. In vitro fertilisation
(IVF) is the cornerstone of ART. It involves stimulating the ovaries, retrieving and culturing
oocytes which are then inseminated with capacitated spermatozoa. The embryo is cultured
and transferred into the uterus. The first successful IVF pregnancy came to term in 1978. Since
then numbers have rapidly increased and it now accounts for nearly 2% of births in the UK
and more than 4 million worldwide (Human Fertilisation and Embryology Authority, 2011;
ICMART, 2008).
There has always been concern about the possibility of an increased rate of congenital
malformations in children conceived using ART. Analysis of early longitudinal data from
Australia showed a higher rate of transposition of the great arteries and spina bifida in
individuals conceived by IVF than expected (Lancaster, 1987). In IVF, sperm and eggs
are removed from their normal environment and subject to altered hormones, handling
and culture media. Newer techniques such as Intracytoplasmic sperm injection (ICSI) and
preimplantation genetic diagnosis (PGD) are even more invasive, potentially leaving the
developing embryo at greater risk of malformation. Major malformations are usually defined
as those which generally cause functional impairment, other conditions are considered to be
minor anomalies (Holmes, 1976).
Studying ART outcomes has proved difficult. Initial studies were small and there was a
confounding high incidence of multiple births. Methodological pitfalls included difficulty
finding adequate control groups as the ART population differs from the general population.
The underlying cause of infertility might itself lead to pregnancy loss and congenital
malformation and surveillance is often more rigorous following ART pregnancies (Simpson,
1996).
As more babies are born as a result of these techniques, there is more data available regarding
the outcomes, and increasing evidence that there is a slightly higher risk of congenital
malformations than following spontaneous conception. This chapter begins with an overview
of ART and then moves on to discuss associated malformations and potential mechanisms. It
was produced following a Medline search using the MeSH terms ‘fertilisation in vitro’ AND
‘congenital malformation’. References from articles selected were reviewed to find additional
articles.
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2. Assisted reproductive technology
The term assisted reproductive technology (ART) covers a range of techniques to enable
people to have children who wouldn’t otherwise be able to. It can be used to assist fertilisation
in vivo with ovulation induction, intra uterine insemination and gamete intrafallopian
transfer (GIFT). When in vivo fertilisation is not possible in-vitro fertilisation (IVF) is described
above.
Intracytoplasmic sperm injection (ICSI) was initially used where sperm are unable to fertilise
the egg. A single sperm is selected based on morphological characteristics and injected into
the oocyte cytoplasm. It was first used in 1992 (Palermo et al., 1992) and its high success
rate has led it to be used in many centres for all cause infertility. If sperm can not be produced
without medical intervention it can be collected directly from the epididymis by percutaneous
epididymal sperm aspiration (PESA) or from the testicles, by testicular sperm aspiration
(TESA). It is also possible to remove tiny quantities of testicular tissue from which sperm
can be extracted using testicular sperm extraction (TESE). As only small numbers of sperm
are produced by these methods, ICSI is then used to achieve fertilisation.Âă
Preimplantation genetic screening or diagnosis (PGS/PGD) is used in families known to
have a genetic disease or with previous recurrent miscarriages. It is used to select either
embryos without disease or âĂŸsaviour siblingsâĂŹ where HLA matched cells could be used
as treatment for an already affected individual (Rubio, 2010). Embryos are produced by IVF or
ICSI and then one or two cells are taken from the embryo by a trained embryologist at day two
or three and tested for the features required. Acceptable embryos are transferred to the uterus
to allow them to develop and suitable remaining unaffected embryos can be cryopreserved
for later use. Embryos which are affected by the condition are allowed to perish.
Eggs, ovarian tissue, sperm and embryos can be cryopreserved for use in the future.
Embryos are usually from IVF cycles, gametes are stored to preserve fertility for example
while undergoing treatment for cancer. With an increase in single embryo transfer, more
embryos are being frozen and this can be done at several stages with potential for differing
outcomes. Egg cryopreservation is the most recent possibility as it has been difficult to
develop techniques to prevent eggs bursting.
3. Adverse perinatal outcomes
Initial longitudinal studies of IVF in England (MRC Working Party on Children Conceived
by In Vitro Fertilisation, 1990) and Australia (Australian in vitro fertilisation collaborative
group, 1985) showed poor outcomes for IVF infants with significant low birth weight
and prematurity. These risks have subsequently been confirmed by multiple studies and
systematic reviews (Hansen et al., 2005; 2002; Helmerhorst et al., 2004; Jackson et al., 2004;
Schieve et al., 2007; 2002).
The most well documented risk of ART is multiple births. Assisted conception accounts for
1.7% of all births but 21% of multiple births in the UK (Human Fertilisation and Embryology
Authority, 2011). Higher order births are more likely to be born preterm, have a lower birth
weight and have congenital malformations. Single embryo transfer is now promoted which
has reduced these complications. Despite this ART children still have a higher perinatal
morbidity and mortality than matched controls (Al-Fifi et al., 2009; Helmerhorst et al., 2004).
A systematic review found that for singletons the relative risk of a very preterm birth (<32
weeks) was 3.27 (95% CI 2.03 -5.28) after assisted conception (Helmerhorst et al., 2004).
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4. Congenital malformations
A large number of studies have been conducted looking at malformations in ART conceived
children. Couples using ART differ from the general population in several ways and results
have been particularly complicated by difficulty finding adequate control groups. Typically
they are older, have a higher socioeconomic status and are infertile. The underlying cause
of infertility might itself lead to malformation and it is difficult to find appropriate infertile
controls who have spontaneously conceived. It may be that couples are less likely to terminate
pregnancies conceived by IVF thus increasing the rate of children born with congenital
malformations. In early studies ART offspring were rigorously examined and malformation
rates then compared to the general population who may have only undergone superficial
examination and malformations may not have been recorded appropriately. Many studies
only examined children for abnormalities at birth when fewer congenital anomalies can
be identified compared to at 6 months of age. Birth defects should be assessed without
knowledge of conception status but it has been shown that paediatricians are relatively
good at determining this from other cues (Ludwig, Katalinic, Entenmann, Thyen, Sutcliffe,
Diedrich & Ludwig, 2009). There are few studies looking at ART outcomes in people using
the techniques for reasons other than infertility.
It is possible that ART may predispose to only certain types of malformations. The initial
Australian study suggested a link with cardiac and neural tube defects (Lancaster, 1987). An
early study of all infants born in Sweden after IVF, 1982âĂŞ1997 (n = 9111) found a 3-fold
excess risk of neural tube defects, alimentary atresia and omphalocele (Ericson & Källén, 2001).
It found an increased risk for hypospadias after ICSI but not after standard IVF. In a follow
up study this group continued to find an increased risk of neural tube defects, choanal atresia
and alimentary tract atresia in this population (?). Further work in Australia found a specific
association between ART and ‘blastogenesis birth defects’ arising in the first 4 weeks of
pregnancy such as abdominal wall defects, vertebral segmentation defects, tracheoesophageal
fistula, diaphragmatic defects, neural tube defects, anal atresia and renal agenesis. They were
present in 1 in 160 ART pregnancies compared with 1 in 400 controls (Halliday et al., 2010).
A recent study from Paris found cases of congenital heart disease were more likely to have
been conceived using ART (Tararbit et al., 2011). ART was specifically associated with
significant increases in the odds of malformations of the outflow tracts and ventriculoarterial
connections (adjusted OR 1.7, 95% CI 1.2âĂŞ2.4) and of cardiac neural crest defects and double
outlet right ventricle (adjusted OR 1.7, 95% CI 1.1âĂŞ2.7) (Tararbit et al., 2011). A retrospective
cohort study again found a higher rate of cardiovascular malformations in infants conceived
by ART than controls (Wen et al., 2010). An American study of infants with birth defects
found more infants had been conceived by ART and a specific association with septal heart
defects (Reefhuis et al., 2009). Fetal echocardiography did not find an increase of congenital
heart defects above the general population but it did find higher rates in twin pregnancies
compared to singletons which may contribute to earlier findings (Bahtiyar et al., 2010).
Several studies have found an increased rate of cerebral palsy in children born following IVF
(Hvidtjørn et al., 2010; 2006; Lidegaard et al., 2005; Zhu et al., 2010). In some cases this has been
accounted for by the high rate of multiple births and preterm delivery (Hvidtjørn et al., 2010;
2006). Some have found the risk remains increased when accounting for these confounders
(Lidegaard et al., 2005; Zhu et al., 2010; ?).
Looking at malformations overall Rimm et al. performed a meta-analysis of 19 controlled
studies comparing major malformation rates in IVF and ICSI children with spontaneously
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conceived children (Rimm et al., 2004). They found an odds ratio for major malformations of
1.29 (95%CI 1.01-1.67) in children conceived by IVF/ICSI. There was no significant difference
in malformation rates in individuals conceived by IVF compared to ICSI. There was a lot of
variation in major malformation rates between studies. The odds ratio for malformations
was higher in singletons compared to multiple births, probably because of the increase in
monozygotic twins with a higher rate of malformations after spontaneous conception. There
were many problems identified with the studies used in this meta- analysis. Most used
inappropriate groups of healthy controls which often did not control for the older age and
fertility problems of parents using ART. There was no distinguishing if cryopreservation had
been used.
Overall, meta-analysis has shown a 40-50% increased rate of major malformations following
ART (Hansen et al., 2005; Lie et al., 2005; Rimm et al., 2004). A recent update (Rimm et al., 2011)
included an augmented calculation of the contribution of infertility (Zhu et al., 2006). This
found ART does not increase the risk of major malformations as much as previously reported
when subfertile couples are used as controls suggesting a proportion of the increased risk of
congenital malformations following IVF is due to the underlying subfertility rather than ART
per se.
5. Mechanisms leading to congenital malformations in ART children
5.1 Point mutations
In very rare cases a mutation can be found which has shown variable expression, causing
infertility in the parent and a more apparent congenital malformation in the offspring.
5.1.1 IHH and SOX2 mutations
A mother with idiopathic hypogonadotrophic hypogonadism had given birth to two children
following ovulation induction. One had anopthalmia and one had unilateral micropthalmia
(Stark et al., 2011). All three were subsequently found to be carriers of a SOX2 mutation.
Studies appeared to show the mother carried a lower level of DNA with this mutation but
they were unable to determine if she was a mosaic.
5.1.2 Cystic fibrosis
Previous studies have shown CFTR mutations in a significant proportions in azoospermic
(31%) and oligospermic (22%) men (Gallati et al., 2009). If the mother is also heterozygous for
a CFTR mutation the offspring may have more manifestations of cystic fibrosis.
5.2 Chromosomal abnormalities
Chromosomal abnormalities are an uncommon cause of malformations following ART. About
4.6% of infertile men with with oligospermia and 13.7% with aspermia and have a coexistent
chromosome abnormality which is most frequently a deletion in the long arm of the Y
chromosome (Foresta & Ferlin, 2001; Vicdan et al., 2004). A recent study found 4.3% (5/115)
azoospermic men had a karyotype abnormality, 80% of these were Kleinfelters syndrome
(Koşar et al., 2010). Most centres now perform a karyotype as part of a basic infertility screen.
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5.2.1 Ring Y
A case has been reported of an infant conceived by ICSI with ambiguous genitalia (Spinner
et al., 2008). The father had presented with infertility and oligospermia. The child’s karyotype
was 47,XXr(Y)[10]/46,XX[40]. The ring Y chromosome was inherited from the father. A
simillar case from an oligospermic father following ICSI has been reported previously, in a
child with a 45,X/46,Xr(Y) mosaicism (Bofinger et al., 1999).
5.2.2 Aneuploidy
Cases have been reported of an unusual karyotype in association with trisomy 21 in
individuals conceived by IVF with embryo cryopreservation. One report described a mosaic
where one cell line contained an additional copy of chromosome 21 as part of a Robertsonian
translocation and the other cell line contained a ring chromosome 21 (Guran et al., 2010).
An evaluation of products of conception following miscarriage in ART pregnancies or
spontaneous conception in subfertile couples showed an abnormal karyotype in 63.2% cases
after ART and in 71.5% after natural conception in subfertile couples.41 Overall 60% of such
abortuses would be expected to have an abnormal karyotype. Only 10 ICSI-TESE cases were
analysed, and there was a discrepancy between chromosome abnormalities detected in this
group (80%) compared to ICSI (61.5%). 50% showed triploid/tetraploid karyotypes, when
in the other groups polyploidy did not exceed 17.5%. Although numbers are very small
authors hypothesize that the use of immature testicular spermatozoa confers a higher risk
of cytogenetically abnormal conceptions (Bettio et al., 2008).
5.3 Epigenetic abnormalities
Imprinted genes are those where only one allele is normally expressed, according to the parent
of origin (Amor & Halliday, 2008). About 1% of human genes are thought to be imprinted,
typically paternally expressed genes promote growth whereas maternally expressed genes
suppress growth. The signal for this origin specific expression is an epigenetic change in the
form of methylation and histone modification, changing the structure of the DNA rather than
the sequence. With each generation the imprinted signal is erased and re-establised during
gametogenesis.
Several mechanisms can lead to errors of imprinting, some of which cause recognised
syndromes. There may be a mutation in one allele of an imprinted gene which prevents its
expression or a larger deletion encompasing a whole gene or its imprinting control centre.
A child can inherit two copies of a chromosome from one parent, uniparental disomy. An
alternative mechanism is an epigenetic abnormality, for example affecting methylation. For
each of the recognised imprinting syndromes the rates with which each mechanism accounts
for cases differs.
There have been reports of unexpectedly raised rates of imprinting disorders in children
born after assisted conception. Analysis indicates that imprinting defects in these individuals
are largely due to epigenetic defects, specifically aberrant DNA methylation (Bahtiyar et al.,
2010; Odom & Segars, 2010). It is hypothesised that the erasure and reestablishment of the
imprinting signal may be disrupted by some forms of ART. The demands placed on the
embryo by ART may induce adaptations in foetal epigenetic patterns eventually leading to
such imprinting disorders. Indeed, altered epigenetic patterns have been found in assisted
conception embryos, cord blood and placenta (Turan et al., 2010).
12ist d Reproductive Technology and Congenital Malformations
4 Will-be-set-by-IN-TECH
conceived children (Rimm et al., 2004). They found an odds ratio for major malformations of
1.29 (95%CI 1.01-1.67) in children conceived by IVF/ICSI. There was no significant difference
in malformation rates in individuals conceived by IVF compared to ICSI. There was a lot of
variation in major malformation rates between studies. The odds ratio for malformations
was higher in singletons compared to multiple births, probably because of the increase in
monozygotic twins with a higher rate of malformations after spontaneous conception. There
were many problems identified with the studies used in this meta- analysis. Most used
inappropriate groups of healthy controls which often did not control for the older age and
fertility problems of parents using ART. There was no distinguishing if cryopreservation had
been used.
Overall, meta-analysis has shown a 40-50% increased rate of major malformations following
ART (Hansen et al., 2005; Lie et al., 2005; Rimm et al., 2004). A recent update (Rimm et al., 2011)
included an augmented calculation of the contribution of infertility (Zhu et al., 2006). This
found ART does not increase the risk of major malformations as much as previously reported
when subfertile couples are used as controls suggesting a proportion of the increased risk of
congenital malformations following IVF is due to the underlying subfertility rather than ART
per se.
5. Mechanisms leading to congenital malformations in ART children
5.1 Point mutations
In very rare cases a mutation can be found which has shown variable expression, causing
infertility in the parent and a more apparent congenital malformation in the offspring.
5.1.1 IHH and SOX2 mutations
A mother with idiopathic hypogonadotrophic hypogonadism had given birth to two children
following ovulation induction. One had anopthalmia and one had unilateral micropthalmia
(Stark et al., 2011). All three were subsequently found to be carriers of a SOX2 mutation.
Studies appeared to show the mother carried a lower level of DNA with this mutation but
they were unable to determine if she was a mosaic.
5.1.2 Cystic fibrosis
Previous studies have shown CFTR mutations in a significant proportions in azoospermic
(31%) and oligospermic (22%) men (Gallati et al., 2009). If the mother is also heterozygous for
a CFTR mutation the offspring may have more manifestations of cystic fibrosis.
5.2 Chromosomal abnormalities
Chromosomal abnormalities are an uncommon cause of malformations following ART. About
4.6% of infertile men with with oligospermia and 13.7% with aspermia and have a coexistent
chromosome abnormality which is most frequently a deletion in the long arm of the Y
chromosome (Foresta & Ferlin, 2001; Vicdan et al., 2004). A recent study found 4.3% (5/115)
azoospermic men had a karyotype abnormality, 80% of these were Kleinfelters syndrome
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Loss or gain of the epigenetic signal can occur on either the maternal or paternal allele but in
most reported cases affecting ART children the problem is hypomethylation on the maternal
allele (Amor & Halliday, 2008). There is no evidence other mechanisms such as large deletions
or duplications giving an imbalance of the imprinted genes occur at higher incidence due
to ART. This is interesting as ART mothers are typically older so an increased incidence of
uniparental disomy could be expected.
It is difficult to know whether the abnormal methylation causing these imprinting defects is
as a result of one of the many processes encompassed by ART or associated with subfertility.
Studies of superovulated oocytes from infertile women have shown altered methylation (Sato
et al., 2007).
Genomic imprinting may be less complete when immature gametes are used (Tesarik &
Mendoza, 1996). There is currently no evidence of increased numbers of individuals with
imprinting defects conceived by PESA and TESA but numbers are too small to draw any firm
conclusions and further study is required.
Two particular imprinting syndromes which seem to be at higher rates following ART are
Angelman syndrome and Beckwith Weidemann syndrome (BWS).
BWS is an overgrowth syndrome where individuals are affected by neonatal hypoglycaemia,
macroglossia, macrosomia and midline abdominal wall defects (omphalocele, umbilical
hernia, diastasis recti). It is caused by uniparental disomy or imprinting defect affecting
chromosome 11p15 (Shuman et al., 2005). Several studies have found increased rates of BWS
in children born following ART (Halliday et al., 2004; Maher et al., 2003). Studies in the UK,
USA and France have found children with BWS were more likely to have been conceived by
ART (Chang et al., 2005; Gicquel et al., 2003; Maher et al., 2003). These cases were largely
caused by imprinting defects. One case report describes a family where two children have
been born with BWS, one following IVF and one spontaneously conceived (following years
of infertility treatment) suggesting in this case the IVF was not the cause (Strawn et al., 2010).
Interestingly in animals conceived by IVF or nuclear transfer a large offspring syndrome has
been described which shares similarities with BWS (Gicquel et al., 2003).
Angelman syndrome affects âĹij1 in 16 000 children and is characterized by severe intellectual
disability, speech impairment, a happy demeanour, ataxia, seizures and microcephaly. It
is caused by abnormalities affecting the maternal copy of chromosome 15q11-13. Overall
5% of cases are associated with an imprinting defect. Early case reports described cases of
Angelman syndrome conceived using ICSI with AS secondary to loss of methylation. A higher
proportion of cases of AS in children born using ART seem to be as a result of methylation
defects. Interestingly a German cohort found an excess of AS cases again with methylation
defects in children spontaneously conceived by subfertile couples (Lidegaard et al., 2005).
Two case reports have described hypomethylation of the paternally derived H19/IGF2 locus
in infants with Russell-Silver syndrome conceived by ICSI (Chopra et al., 2010; Douzgou
et al., 2008). Several other children born following ART with this syndrome have also been
described. Beyond the classically recognised imprinting syndromes, decreased methylation
has been found in spontaneously conceived individuals with neural tube defects (Wang et al.
2010). Further work is needed to see if this is consistent with the explanation for the possible
increase in ART.
Many of the imprinting syndromes are very rare. Even if ART increases the risk of these
disorders by two or three times it will still be very difficult to detect this increased risk. The
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Danish National IVF cohort study found no cases of imprinting disorders in the 6052 children
born following IVF between 1995 and 2001 (Lidegaard et al., 2005).
6. Association of malformations with different types of ART
Most studies have found few differences in the malformation rates between different types of
ART. It could be hypothesized that the more invasive techniques are likely to carry a higher
risk of malformation but many techniques have not yet been used enough to show definitive
results. It seems likely that techniques allowing in vivo fertilization (eg GIFT) are safer than
those relying on in vitro fertilization. To support this no increase in malformations have been
observed following ovarian stimulation (?).
An early study of 91 infants born following embryo cryopreservation found a relative risk of
a major malformation of 1.4 including cases of Beckwith Weidemann syndrome and Downs
syndrome (Sutcliffe et al., 1995). More recent work has shown an increase in aneuploidys in
embryos following cryopreservation (Guran et al., 2010). Other work has shown no increase
in malformations when using frozen embryos over fresh (Li et al., 2010). A systematic review
found comparable results for IVF using fresh or frozen embryos (Wennerholm et al., 2009).
Some of the most definitive work shows that children conceived by ART are at a higher
risk of reproductive tract anomalies, particularly hypospadius in boys conceived by ICSI
(Funke et al., 2010; Klln et al., 2005b; ?). Prematurity, low birthweight, and multiple
gestation, are indirect risk factors for developing male genital malformations but in infants
with normal birthweight or from singleton pregnancies, ICSI is a specific risk factor for
hypospadias.(Funke et al., 2010) More boys conceived by ICSI were also found to have
undescended testes requiring surgery (Ludwig, Katalinic, Thyen, Sutcliffe, Diedrich &
Ludwig, 2009). In ICSI the sperm has been unable to fertilise the egg and is therefore in
some way abnormal. It is possible that men who are only able to have children by ICSI, in
some cases pass on this defect to their sons. In ICSI using epididimal or testicular sperm
(MESA and TESA) a systematic review (Woldringh et al., 2010) found there is not enough
data to reliably say if this affects the rate of congenital malformations in subsequent offspring
although one study had found a higher rate of polyploidy in abortuses (Mateu et al., 2010).
Early reports from cases series of individuals conceived following preimplantation genetic
diagnosis show no risk of malformations over ICSI but there was an increased perinatal death
rate (Liebaers et al., 2010).
7. Conclusions
There is mounting evidence that infants conceived by these methods are at slightly
higher risk of congenital abnormalities overall with particularly compelling evidence for
imprinting syndromes and urogenital malformations. Some of the increased risk of congenital
malformations following ART appears to be the effect of subfertility rather than ART per se.
This conclusion is echoed by a recent ESHRE position statement which states "Children
from couples who get pregnant after assisted reproduction techniques, like IVF/ICSI, have
a 40-50% increased risk for a birth defect. A similar increased risk has been reported for
subfertile couples who get pregnant spontaneously after a prolonged time period. This
increased risk seems thus mainly be due to parental characteristics from the infertility status
and not to the treatment given."
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8 Will-be-set-by-IN-TECH
It is still early days. Louise Brown, the first person born by IVF is now in her 30s and has
given birth to a spontaneously conceived child. The oldest person born by ICSI is only 20.
There are case reports of people born following ART with a range of syndromes for example
Goldenhar syndrome and Rubinstein-Taybi syndrome conceived by ICSI (Balci et al., 2008).
It is too early to say if this is a chance finding or a genuine association. As the number of
people born following ART increases and they move through their lives It is important they
continue to be monitored particularly as new techniques are developed so people using these
techniques, which overall are relatively safe, can be given an accurate picture of the risks they
face and future children can be monitored appropriately.
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This book is in essence a collection of essays which are state of the art in their 
respective areas of knowledge. They inform  the reader of all sorts of mechanistic 
considerations when developing understanding of  issues  surrounding the origins 
of congenital abnormalities. These chapters are written by world renown authorities 
in this area of science and represent a wide range of expertise from a clinician 
perspective, through to genetic mechanisms. Unlike some books which take a formal 
textual, somewhat plodding way through pathophysiology here instead we have cut 
through chapters in which the student , or scientist or medic is lead to understand just 
how complex the origins can be via examples from different parts of the body. With 
the erudite chapters are relevant tables and other diagrams to help clarify the text . 
These chapters represent a starter text for the stimulus for further knowledge of what 
is an increasingly important area of human health.
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